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SUMMARY OF THESIS
1. A novel technique utilising the microdialysis technique to measure the 
concentrations of chemicals of nitrosation, nitrite, thiocyanate, ascorbic acid 
and total vitamin C in the lumen of the human upper gastrointestinal tract was 
developed and validated in vitro.
2. The recoveries of the chemicals of interest using the microdialysis probes 
were inversely proportional to the rate of perfusion of the microdialysis 
probes except for nitrite which was also dependent on the pH of the solution 
being sampled. We determined the optimal perfusion rate of the microdialysis 
probes as 0.15mL hr'^ This perfusion rate enabled adequate volumes of 
microdialysis product to be obtained for subsequent analysis without reducing 
the recoveries of the chemicals by the microdialysis probe.
3. The microdialysis probe was accurate in sampling the chemicals of interest 
under dynamic conditions which mimicked the reaction of intermittent 
delivery of nitrite in swallowed saliva with gastric juice ascorbic acid under 
both high and low nitrite load.
4. Salivary nitrite in man is derived from the bacterial reduction of dietary nitrate 
which has undergone entero-salivary recirculation. In the human subjects 
without gastro-oesophageal reflux, high concentration of nitrite was detected 
in the saliva and the distal oesophagus following an oral nitrate load.
5. In subjects without gastro-oesophageal reflux, there was an increasing 
concentration gradient for ascorbic acid and total vitamin C at increasingly 
distal sites of the upper gastrointestinal tract whereas there was a decreasing 
concentration gradient for nitrite with virtually no nitrite detectable in the 
distal stomach. In the acidic stomach, the cardia was the site of greatest 
ascorbic acid oxidation and also the site of the lowest ascorbic acid to nitrite 
ratio both before and after an oral nitrate load indicating that the condition for 
the formation of carcinogenic A-nitrosamines was maximal at this anatomical 
site in subjects without gastro-oesophageal reflux.
6. Twenty to thirty percent of the nitrate in the saliva is reduced to nitrite by the 
bacteria within the oral cavity. The nitrate reduction appears to continue 
within the oesophagus leading to a greater recovery of nitrite to that in the
VI
saliva in some subjects. No nitrate reduction was seen within the nasal cavity 
of healthy subjects.
7. In subjects with Barrett’s oesophagus, concentration gradients for ascorbic 
acid, total vitamin C and nitrite showed a similar pattern to that of the subjects 
without gastro-oesophgaeal reflux. However, the ascorbic acid to total vitamin 
C ratio and ascorbic acid to nitrite ratio in the acidic environment were both 
lowest within the Barrett’s segment suggesting that the oxidative stress and 
the nitrosation potential were greatest within this anatomical site during 
periods of acid reflux.
8. Within the Barrett’s segment the nitrite concentrations fell greatly compared 
to that of the squamous oesophagus which was attributed to the conversion of 
acidified nitrite by the gastric juice ascorbic acid to nitric oxide. Using a 
miniturised nitric oxide sensor and measuring the nitric oxide generation in 
real-time we were able to demonstrate nitric oxide generation of up to 50pM 
when saliva came into contact with acidic gastric juice within the Barrett’s 
segment during periods of gastro-oesophageal reflux.
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CHAPTER ONE
ANATOMY
1.1 Anatomy of the oesophagus
The oesophagus is a hollow tubular organ extending from the pharynx to the 
cardiac region of the stomach measuring approximately 25cm in length. The distal 
2cm of its length resides in the abdominal cavity. The oesophagus begins 
proximally where the skeletal muscles, inferior pharyngeal constrictor merges 
with the cricopharyngeus and forms the upper oesophageal sphincter. The body of 
the oesophagus occupies the posterior mediastinum and is composed of inner 
circular and outer longitudinal layers of smooth muscles. The oesophagus passes 
through the hiatus in the diaphrgam formed by the right crus of the diaphragm and 
leaves the thoracic cavity. The distal 2 to 4 centimetres of thickened circular 
smooth muscle forms the lower oesophageal sphincter which sits within the 
diaphragmatic hiatus. The position of the lower oesophageal sphincter is 
maintained within the hiatus by the plirenico-oesophageal ligament, a continuation 
of the transversalis fascia of the diaphragm.
The oesophageal mucosa is formed by non-keratinized stratified squamous 
epithelium consisting of three functionally distinct layers; the stratum corneum, 
the outermost layer of flattened (anucleate) cells connected laterally by tight 
junctions with rich lipid matrix within the intercellular spaces and act as a 
permeability barrier. The middle layer, stratum spinosum contains metabolically 
active cells with numerous intercellular connections through desmosomes which 
give them the characteristic appearance and provides structural integrity of the 
tissue. The stratum geminativum or the basal layer consists of cuboidal cells 
occupying up to 15% of the epithelial thickness and is capable of replication and 
the overlying cellular layers are derived from the basal cells.
The junction between the oesophageal mucosa and that of the stomach is 
readily seen endoscopically as the pale pink mucosa of the oesophagus abruptly 
changes to the salmon pink mucosa of the stomach. The demarcation line is the 
ora serrata, also known as the Z-line and under normal circumstances coincides 
with the proximal extent of the normal gastric mucosa.
Below the epithelium lies the lamina propria which is made up of a loose 
network of connective tissue containing blood vessels. The lamina propria forms a 
digitating invagination into the epithelium to form rete pegs, otherwise known as 
the dermal papillae. The muscularis mucosa is a thin layer of smooth muscle 
which separates the lamina propria from the submucosa. The function of this layer
is unclear. The submucosa is comprised of a dense network of connective tissue. 
Contained within this layer are blood vesels, lymphatic channels, oesophageal 
glands and the Meissner’s plexus.
1.2 Anatomy of the stomach
The stomach is a J-shaped organ that is in continuity with the oesophagus 
proximally and the duodenum distally. The function of the stomach is to act as a 
reservoir for ingested food and to initiate the digestive processes, both physical 
and enzymic, and release the partially digested chyme in aliquots into the 
duodenum.
The stomach is divided into four regions (Fig. 1.1). The cardia is the small, 
ill-defined area just adjacent to the junction with the oesophagus and the most 
fixed portion of the stomach. The cardiac incisure, which is formed by the acute 
angle between the left border of the oesophagus and the stomach, demarcates the 
upper margin. A line drawn horizontally across the stomach from the cardiac 
incisure separates the fundus above from the body below. The greater curvature 
commences at the cardiac incisure and continues along the left border of the 
stomach. The lesser curvature is continuous with the right margin of the 
oesophagus. The incisura angularis is located two-thirds along the lesser 
curvature and is demarcated by a sharp indentation. The incisura indicates the 
junction between the body and the gastric antrum. The antrum, however, is ill- 
defined anatomically along the greater curve. The gastric antrum extends to the 
pylorus which leads to the duodenum.
The outer longitudinal muscle layer is continuous with that of the 
oesophagus and duodenum. The middle layer consists of the circular layer which 
forms a muscular ring at the pylorus, the pyloric sphincter. An incomplete layer of 
oblique fibres form the innermost muscular layers of the stomach, which course 
over the gastric fundus and the anterior and the posterior walls of the stomach.
The surface of the mucosa has numerous small elevations created by 
shallow furrows which are further invaginated to form the gastric pits, or foveolae, 
and is continuous with the gastric glands at their base. The surface epithelium 
covering the stomach, including the foveole is columnar epithelium with basal 
nuclei and cytoplasmic granules containing mucin. There are regional differences 
in the cell populations comprising the gastric glands in the different regions of the
stomach. The mucus secreted by these cells protects the epithelial cells from the 
noxious injury from the acid and enzymes in the gastric secretions.
The cardia glands comprise less than 5% of the total gastric gland. The 
majority of the glands in this region consist mainly of mucous cells with small 
numbers of undifferentiated cells and endocrine cells. The main secretory 
products from the cardia glands are mucin and group II pepsinogen. Oxyntic 
glands comprise 75% of the gastric glands and are located in the fundus and the 
corpus of the stomach. Paiietal, chief, endocrine, mucous neck and 
undifferentiated cells make up the oxyntic gland. The parietal cells secrete 
hydrochloric acid and intrinsic factor which is necessaiy for the absorption of 
vitamin B12. In close association with the parietal cell are the mucous neck cells 
which contain acidic and sulphated mucin which are different from the surface 
mucous cells which secrete neutral mucin. It is thought that the mucous neck cell 
functions as stem cells for surface mucous, chief, parietal and endocrine cells. The 
chief cells, also known as the zymogen cells, secrete pepsinogen. The endocrine, 
or enteroendocrine cells, are scattered among the oxyntic glands and include the D 
cells, which secrete somatostatin and enterochromaffln-like cells which secrete 
histamine and serotonin depending on their silver staining characteristics. The 
pyloric glands comprise the remaining 20% of the gastric glands. The pyloric 
glands are composed of mucous, endocrine and small numbers of parietal cells 
which secrete pepsinogen II. The enteroendocrine cells, G cells which secrete 
gastrin and D cells which secrete somatostatin are also found in these glands.
1.3 Physiological functions of gastric acid.
Gastric acid has several important functions. It is important for activating 
pepsinogen to start the digestion of protein which is also important in releasing 
vitamin Biz complexed to food protein. Gastric acid facilitates absorption of 
inorganic iron absorption in the duodenum. It stimulates pancreatic bicarbonate 
release through the action of secretin but also inhibits antral gastrin secretion by 
negative feedback. Gastric acid also has an antimicrobial effect and achlorhydria 
leads to bacterial overgrowth in the gastric lumen.
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Figure 1.1: Anatomy of the stomach.
The stomach is divided into four anatomical regions: the cardia, 
fundus, body and the antrum.
CHAPTER TWO
EPIDEMIOLOGY OF 
CARDIA AND OESOPHAGEAL 
ADENOCARCINOMA
2.1 Introduction
In contrast to the falling incidence in the more distal gastric cancers, the 
incidences of adenocarcinoma of the oesophagus and cardia have increased 
dramatically in many developed countries in the last two decades.
Cardia cancer forms almost 50% of the gastric cancers diagnosed in white 
American men. The causes for the increases in these cancers are unclear.
In this section an overview of the epidemiology of the cardia and 
oesophageal adenocarcinoma will be presented.
2.2 Incidence of adenocarcinoma of the cardia
Since the late 1970s, the incidence of adenocarcinoma of the gastric cardia 
increased dramatically in the U.S.A. This is in striking contrast to the 
falling incidence of non-cardia gastric cancer in U.S.A. and other countries
In the most recent study of white males in USA, the age-adjusted amiual 
incidence rate of cardia adenocarcinoma increased from 2.1 per 100 000 during 
the period 1974 ~ 1976 to 3.3 per 100 000 during the period 1992 ~ 1994. The 
same trend is also seen for the black males with the annual incidence rising from 
1.0 per 100 000 to 1.9 per 100 000 over the same period of time The annual 
incidence rates for non-cardia gastric cancer has fallen from 5.1 per 100 000 for 
the period 1974 ~ 1976 to 3.7 per 100 000 during 1992 ~ 1994 in American white 
males. In the American blacks there was an initial increase in the incidence of 
non-cardia gastric cancer during the period 1974 ~ 1981 ftom 10.9 per 100 000 to
13.4 per 100 000 and declined again to 10.9 per 100 000 during the period 1992 ~ 
1994(3)
The incidence of eardia cancer in women is lower than that of males but the 
increasing trend seen in the females has been of a similar magnitude. In the study 
reported by Devesa, the incidence of cardia cancer in white women in USA 
increased from 0.3 per 100 000 during 1974 ~ 1976 to 0.6 per 100 000 during 
1992 ~ 1994 (table 2.1). Increasing trends for cardia cancer have been reported 
worldwide including Netherlands Sweden Denmark England 
Scotland and Japan All the above studies, except Powell et al studying the 
period 1962 ~ 1981, reported a falling incidence in the non-cardia gastric cancer.
Not all countries have noted an increase in cardia cancer. Finland ^^^ a^nd Vaud 
in Switzerland have yet to demonstrate a significant increase in cardia cancer. 
Calvados in France have seen a declining trend in the incidence. There is a 
suggestion more recently that the incidence of cardia cancer may have peaked in 
the USA
As a result of the falling incidence in the non-cardia gastric cancer and the 
increasing incidence of cardia cancer, the proportion of cardia cancer contributing 
to the diagnosis of gastric cancer as a whole has increased. Cardia cancer 
currently fonns approximately 13 to almost 50% of the gastric cancer
diagnosed in the western nations.
2,3 Incidence of adenocarcinoma of the oesophagus.
The incidence of the adenocarcinoma of the oesophagus has increased more 
rapidly than that of the cardia (see table 2.2). Among the white males in USA, the 
annual incidence of adenocarcinoma of the oesophagus rose from 0.7 per 100 000 
population during 1974 - 1976 to 3.2 per 100 000 during 1992 - 1994, an increase 
of more than 350 % overtaking squamous carcinoma as the most common 
oesophageal cancer since 1990 The incidence of adenocarcinoma of the 
oesophagus in the white female population also increased from 0.1 per 100 000 to 
0.4 per 100 000 in the same study. Increasing incidences of oesophageal 
adenocarcinoma have also been reported in England and Wales Scotland 
Netherlands Switzerland Norway Denmark and other European 
countries with annual increases in incidence exceeding 20 % in some regions. 
In some countries, oesophageal adenocarcinoma has overtaken squamous 
carcinoma of the oesophagus as the most common cancer affecting the male 
oesophagus
STUDY PERIOD SEX RACE
INCIDENCE per 100 000
(Country) START END % CHANGE
Powell
(W. Midlands, 
UK)
1962-1981 * * 0.75 2.0 +168
Hansson 1970-1985 M
$ 1.9 3.0 +58
(Sweden) F * 0.5 0.8 +60
M
White 2.4 3.2 +33
Blot 1976-1987
Black 1.2 1.7 +42
(USA)
F
White 0.42 0.56 +33
Black 0.45 0.6 +33
Bytzer # 
(Denmark) 1970-1991 * * 1.6 2.9 +81
Dodaran 
(England & 
Wales)
1971-1993
M * 2.4 6.0 +147
F * 0.6 1.6 +151
M
White 2.1 3.3 +57
Devesa 1974-1994
Black 1.0 1.9 +90
(USA)
F
White 0.3 0.6 +100
Black NA N A NA
Kocher f 1960-1996
M * 1.3 2.4 +85
(England) F * 0.3 0.5 +75
Sihvo 1976-1995
M * 2.1 2.1 0
(Finland) F * 0.6 0.47 -22
Brewster 1977-1996
M * 3.1 5.2 +68
(Scotland) F $ 1.0 1.4 +40
Levi('') 1976-1997
M * 3.1 3.2 +3
(Swiss) F * 0.5 0.1 -80
Table 2.1; Incidence of cardia adenocarcinoma (per 100 000 of population). 
Key: Start: beginning of study period. End: end of study period.
# includes fundus
t  age-standardised incidence rate per 100 000 world population
STUDY
(country) PERIOD SEX RACE
- —...... .... . '
INCIDENCE per 100 000
START END % CHANGE
Powell
(W. Midlands, 
UK)
1962-1981 * * 0.14 0.63 +350
Bytzer
(Denmark) 1970-1991 * * 0.3 2.3 +666
Hansen t  
(Norway) 1958-1992
M * 0.1 0.8 +700
F * 0.0 0.1 >100
Dodaran 
(England & 
Wales)
1971-1993
M $ 1.5 5.2 +252
F 0.4 1.1 +167
Devesa
(USA) 1974-1994
M White 0.7 3.2 +357
Black 0.4 0.6 +50
F White 0.1 0.4 +300
Black NA NA NA
Brewster
(Scotland) 1977-1996
M * 3.9 8.0 +105
F $ 1.2 2.3 +92
Wijnhoven
(Netherlands) 1978-1996
M * 0.5 2.2 +340
F * 0.1 0.6 +514
Levi
(Swiss) 1976-1998
M * 0.5 1.9 +280
F * 0.1 0.2 +100
Table 2.2: Incidence of adenocarcinoma of the oesophagus (per 100000 of 
the population).
Key: Start: beginning of study period. End: end of study period, 
f  adjusted according to world standard population, not age- 
adjusted
# age and sex adjusted
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2,4 Sex distribution of non-cardia gastric cancer, 
adenocarcinoma of the cardia and oesophagus.
Gastric cancer has a typical male to female ratio of 2:1 Cardia
cancer has a male to female ratio of more than 3:1 Some studies
have reported even greater male preponderance, particularly in the younger 
population. For example, Hansson noted the male to female ratio of 7:1 in those 
who were aged less than 50 Similar finding was noted by Levi where the male 
to female ratio was also higher in the younger age groups with subjects 50 -  59 
years had a ratio of 11.9 compared to 7.2 for 60 -  69 years and 7 for 70 -  79 years 
and 3.4 for 80 + years
The sex ratio of adenocarcinoma of the oesophagus, like that of the cardia 
cancer, is male predominant with a typical ratio of 3:1 or more 5,7,8, ii, is, i9)
2.5 Race and adenocarcinoma of the cardia and oesophagus.
Cardia and oesophageal adenocarcinoma are diseases which afflict 
predominantly the white population. In the U.S.A., adenocarcinoma of the cardia 
is approximately twice as common in the white men as in the black men; 
oesophageal adenocarcinoma is five times more common in the whites than in the 
blacks In contrast, squamous carcinoma of the oesophagus and non-car dia 
gastric cancer were more common in the blacks being approximately six times 
and three times more common in the blacks respectively
In Singapore, the Chinese males have a higher cumulative rate of cardia and 
oesophageal adenocarcinoma than the Indian or the Malay males. Oesophageal 
adenocarcinoma was twice as common in Chinese males in Hong Kong compared 
to Chinese males in Singapore. Jews born in USA or Europe were more likely to 
be afflicted with cardia cancer than Jews born in Israel These studies 
suggested that the genetic predisposition for developing cardia and oesophageal 
adenocarcinoma differed between racial groups and that the risk of developing 
these cancers was modified by environmental factors.
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2.6 Socioeconomic status and cancers of the upper gastro­
intestinal tract.
Socioeconomic status appeal's to have an influence upon the risk for the 
different cancers of the upper gastrointestinal tract. Both squamous oesophageal 
carcinoma and non-cardia gastric cancers are more common in those of the lower 
socioeconomic status. There is an inverse association between income, education, 
and social deprivation for both these tumors Part of the
inverse association between social class and non-cardia gastric cancer can be 
explained by Helicobacter pylori {H. pylori) infection which is more prevalent in 
the lower social class Adverse socioeconomic conditions including past 
domestic overcrowding at home during childhood have been associated with 
an increased risk of gastric cancer mortality rates and has been associated with a 
higher H  pylori infection rate in such population
There is less socioeconomic divide in adenocarcinoma of the cardia. Some 
studies have suggested an increased risk for cardia cancer in people in higher 
social class. In a study in U.S.A., cardia adenocai'cinoma was non-significantly 
greater in young men who had some college education by 30% compared to those 
who did not receive any high school education A more recent study showed 
that 81 % of gastric cardia cases had at least high school education compared to 
58 % in distal gastric cancer cases A study in West Midlands suggested that in 
males there were 16% more cardia cancer cases and 27% less antral carcinoma 
than expected from the distributions of cancer affecting all sites in social class 1 
and 2. Conversely, in social class 4 and 5 there were 10% less cardia and 8% more 
antral cancer than expected. Both differences were highly statistically significant 
(p<0.001) A Scottish study also suggested that men who were most deprived 
also had lower incidence rates for cardia cancer but this was not seen for women 
Other studies have shown a non-significant reduction in risk in high income 
earners and those who had better education
Oesophageal adenocarcinoma, like adenocarcinoma of the cardia, does not 
have a clear association between socioeconomic status. No association between 
level of education and oesophageal adenocarcinoma has been noted 
Studies between social class and oesophageal adenocarcinoma are also 
inconclusive. Powell noted a higher incidence of oesophageal adenocarcinoma in
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men who were social class 1 or 2 A study of women in Scotland showed an 
increasing trend in those who were in the lower social class but was not 
significant statistically A further study in Scotland found no association 
between deprivation category and oesophageal adenocarcinoma in both men and 
women There were two studies in USA which suggested a reduced risk in 
those who were high income earners
A study conducted in Maryland, U.S.A., showed an increased mortality 
from gastric cardia and cardio-oesophageal cancer in administrative jobs 
(Women: OR (95% Cl) 3.9 (1.5 -  9.8); Men: OR 1.4 (1.1 -  1.9)) and in health 
professionals (Women: OR 1.8 (0.6 -  5.3); Men 2.4 (1.3 -  4.6))
In summary, there is ample evidence to suggest that squamous carcinoma of 
the oesophagus and non-cai'dia gastric carcinoma occur more commonly in the 
less privileged whereas adenocarcinoma of the oesophagus and gastric cardia 
appear to show no such trend and there are some suggestions that the two cancers 
affect the upper middle class, white population.
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CHAPTER THREE
AETIOLOGY OF ADENOCARCINOMA
OF THE 
CARDIA AND OESOPHAGUS
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3.1 Introduction
The causative factors for the development of adenocarcinoma of the cardia 
and oesophagus are unknown. There are a several factors which have been 
reported to be of aetiological importance in cardia and oesophageal 
adenocarcinoma. Socioeconomic status was discussed in the previous chapter. 
Others include smoking, body habitus, gastro-oesophageal reflux, Helicobacter 
pylori, Barrett’s oesophagus and diet. The following sections discuss each of these 
factors in turn and their relevance in the aetiology of the cardia and oesophageal 
adenocarcinomas.
3.2 Smoking.
Smoking as a major risk factor for the development of squamous carcinoma 
of the oesophagus has been well established The risk for developing 
squamous oeosophageal carcinoma being elevated several fold compared to non- 
smokers and both dose and duration of smoking increases the risk for developing 
squamous oesophageal carcinoma.
Smoking does not appear to be a strong risk factor in non-cardia gastric 
cancer. Some studies have shown a significant association between smoking 
others have shown only a weak association with less than a two-fold risk 
48,49) association at all o^, 5i) contrast, the risk for both adenocarcinoma 
of the cardia and the oesophagus is at least two-fold in smokers compared to non- 
smokers and both duration and amount of cigarettes smoked increases the risk 
36,38,44,46,49,52) increased risk of oesophageal adenocarcinoma in smokers
may only be applicable to men as some authors have shown that smoking does not 
appear to be an important risk factor for developing adenocarcinoma of the 
oesophagus and cardia in women
Thus, the association with smoking is strongest in squamous carcinoma of 
the oesophagus with the risk being increased several-fold, followed by 
adenocarcinoma of the cardia and oesophagus, with at least a two-fold increase in 
risk and finally distal gastric cancer which appears to have only a weak 
association with smoking.
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3.3 Body Size.
Body mass is a major risk factor for adenocarcinoma of the oesophagus with 
numerous studies indicating increased risk for adenocarcinoma of the oesophagus 
in individuals with higher body mass index (BMI) with up to several-fold increase 
in risk compared to those who are lean Even when the body mass
size was studied many years prior to the diagnosis of cancer the positive 
association was still present For example, in a well-conducted Swedish
population-based case-control study, those classified as obese (BMI > 30kg/m^)
20 years before the diagnosis of cancer had a 16-fold increase in risk for 
developing oesophageal adenocarcinoma compared to those with a BMI of less 
than 22, A clear dose-response increase in risk was seen with increasing BMI 
Obesity appears to be a greater risk factor for oesophageal adenocarcinoma in 
those diagnosed younger than 50 years as well as in non-smokers
The association between body mass index and cardia adenocarcinoma is 
weaker than that for oesophageal adenocarcinoma. Increasing BMI increases the 
risk for developing cardia adenocarcinoma up to four-fold If we take
the example of the Lagergren study, the multivariate-adjusted odds ratio for obese 
patients (BMI >30 kg/m^, 20 years prior to interview) the odds ratio was four-fold 
for cardia adenocarcinoma compared to the 16-fold increase for oesophageal 
adenocarcinoma. BMI also appears to be a greater risk factor for younger subjects 
than older subjects for cardia adenocarcinoma
In contrast to both adenocarcinoma of the oesophagus and cardia, body size 
appears have no clear association for both squamous oesophageal carcinoma and 
distal gastric cancer with some studies showing inverse associations with BMI or 
no association at all
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3.4 Gastro-oesophageal reflux.
Gastro-oesophageal reflux is a common symptom with almost 40 % of the 
American population suffering from reflux symptoms with more than 13 % of the 
population reporting heartburn at least once a week
A study from U.S.A. indicated that the risk of developing cardia and 
oeosophageal adenocarcinoma was increased by two-fold in the presence of 
symptoms This study however did not differentiate between the two tumors. 
A Swedish study indicated that those who had reflux symptoms at least once a 
week, excluding symptoms which developed within five years of the diagnosis of 
cancer to exclude reverse causality, had almost an 8-fold increase in risk of 
developing oesophageal adenocarcinoma, a two-fold increase in risk for cardia 
adenocarcinoma and no association between reflux symptoms and squamous 
oesophageal carcinoma. For those individuals with more frequent, more severe 
and longer duration of symptoms the risk for oesophageal adenocarcinoma 
increased to 43-fold and only to just over four-fold for cardia adenocarcinoma 
which indicated that gastro-oesophageal reflux was an important risk factor for 
oesophageal adenocarcinoma but much less important for cardia adenocarcinoma
(59)
The presence of Barrett’s oesophagus predisposes to the development of 
adenocarcinoma of the oesophagus. Barrett’s metaplasia is a consequence of 
severe acid reflux into the oesophagus. This entity will be discussed in a separate 
chapter.
3.5 Helicobacter pylori and cancers of the upper gastrointestinal 
tract.
The association between H. pylori and gastric cancer is well known. It is 
classified as a class I carcinogen by the World Health Organisation. Individuals 
positive for K  pylori IgG more than 10 years prior to the diagnosis of cancer 
have approximately a six-fold increase for developing gasti'ic cancer The risk 
increases to 21-fold when cytotoxin associated antigen A (CagA) antibodies are 
used to identify those infected with H. pylori by identifying those who are false 
negative on H. pylori IgG
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For many years, however, non-cardia gastric cancer incidence has been falling 
worldwide and this is true even in countries with high incidence of non-cardia 
gastric cancer This decline in incidence has been largely attributed to the fall 
in the prevalence of H. pylori infection and the resultant fall in chronic
gastritis and atrophy
In contrast to the inereased risk for developing non-cardia gastric cancer, an 
inverse association of H. pylori infection, in particular those with the Cag A 
positive H. pylori, and oesophageal and cardia adenocarcinoma have been 
reported, A case-control study in Norway demonstrated a negative association 
between K  pylori infection and cardia cancer with an odds ratio of 0.4 for cardia 
cancer in subjects positive for H  pylori IgG In contrast, a Swedish and an 
American study suggested that there was no association between K  pylori 
antibody status and cardia cancer with an odds ratio between cases and controls of 
0.92 and 0.94 in the respective studies However, in both studies odds ratio 
of H. pylori infection in patients with cardia cancer was significantly lower than in 
non-cardia gastric cancer consistent with other studies In a recent study, a 
non-significant risk reduction was seen in both cardia and oesophageal adeno­
carcinoma in those were positive for H. pylori IgG (OR 0.7, 95 % Cl 0.4-1.1) but 
when analysed by Cag A status, the risk for cardia or oesophageal 
adenocarcinoma was significantly lower than population-based controls (OR 0.4, 
95 % Cl 0.2-0.8)
In a prospective study, Weston demonstrated that the prevalence of H. 
pylori in patients with Barrett’s oesophagus with high-grade dysplasia (14.3 %) 
and or adenocarcinoma (15 %) were significantly lower compared to those with 
Barrett’s oesophagus with low-grade dysplasia (36.2 %), Barrett’s oesophagus 
without dysplasia (35.1 %) or those with gasro-oeosphageal reflux disease 
(44.2 %) Another study observed that the H. pylori infection was just as 
common in control population undergoing gastroscopy for symptoms other than 
gastro-oesophageal reflux (42 %) compared to Barrett’s patients without dysplasia 
(24 %), Barrett’s patients with dysplasia or adenocarcinoma (37 %) and cardia 
adenocarcinoma (21 %) (p = non-significant for each compared to control). When 
analysed according to Cag A status, 53 % of the controls were infected with Cag 
A strains compared to 10% in patients with Banett’s oesophagus with or without 
dysplasia / adenocarcinoma (p = 0.005). Thirty three percent of those with cardia
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adenocarcinoma had Cag A strains but because of the small number of cardia 
cancer cases infected with H, pylori (n = 3) there was no statistical significance 
between this group and controls
These studies suggest that H. pylori infection appears to be protective for 
gastro-oesophageal junction cancers in particular those with Cag A seropositivity. 
The mechanism for this protective effect is unclear although greater inflammation 
and gastric atrophy being more common in those with Cag A strain infection led 
to the speculation that perhaps reduced acid secretion may protect against cancers 
which are associated with gastro-oesophageal reflux However, a recent 
study using pepsinogen I as a marker for gastric atrophy suggested that there was 
no association between gastric atrophy and oesophageal adenocarcinoma but for 
adenocarcinoma of the cardia both atrophy and elevated pepsinogen I levels were 
associated with increased risks (OR of 4.5 and 2.9 respectively) Re-analysing 
the data by subdividing cardia tumors, an increased risk for tumors above or on 
the gastro-oesophageal junction was noted for those with elevated pepsinogen I 
level, which was associated with gastro-oesophageal reflux. Tumors below the 
junction demonstrated an increased risk in those who had a low pepsinogen I level 
consistent with atrophy The latter tumor is likely to be positively associated 
with H. pylori atrophic gastritis; the former tumor being similar to oesophageal 
adenocarcinoma, is negatively associated with H. pylori and likely to be positively 
associated with gastro-oesophageal reflux
3.6 Diet and adenocarcinoma of the upper gastrointestinal tract.
Diet has been long viewed as being important in the aetiology of many 
cancers including cancers of the upper alimentary tract as nutrients ingested first 
come into contact with this anatomical region and the process of digestion begins. 
The topic of diet and upper gastrointestinal tract cancer is beyond the scope of this 
thesis. An overview of the literature relevant to this thesis will be discussed.
One of the most consistent findings about diet and non-cardia gastric cancer 
is the negative association with intake of vegetables and fi'uits. Consumption of 
raw vegetables and fruit reduces the relative risk for non-cardia gastric cancer by 
up to 70%
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For cardia cancer, the protection offered by vegetables and fruit are less 
convincing than that for non-cardia gastric cancer. Some studies have 
demonstrated a protective effect of fresh vegetables for cardia cancer (OR 0.4 - 
0.6) whereas others did not find a protective effect of vegetables for
cardia cancer The protective effect of fruit for cardia cancer was demonstrated
in some studies (OR 0.2 - 0.5) whereas others have shown no significant 
protective effect Vegetables (OR 0.45 -  0.6) and fruit (OR 0.2 -
0.5) both appear to protect from oesophageal adenocarcinoma. Consumption 
of dietary fibre has also been associated with a significantly reduced risk for non- 
cardia gastric cancer, oesophageal and cardia adenocarcinoma
Protein and fat intake have been positively associated with non-cardia 
cancer cardia and oesophageal adenocarcinoma The risk of cancer
varies depending on the source of the protein and fat; animal protein or fat have 
been shown to increase risk whereas that of plant origin appear to have little effect 
or even a protective effect
Consumption of ascorbic acid (vitamin C) has been consistently shown to 
reduce the risk for non-cardia gastric cancer by up to 67%
Ascorbic acid reduced the risk from cardia and oesophageal adenocarcinoma by 
up to 70% and 60% respectively others have shown no such protective
effect for both these tumors
Beta-carotene reduces the risk for non-cai'dia gastric cancer by up to 67%
8 0 ,8 3 , 8 4 , 8 7 )  j ^ Q w e v e r  when adjusted for ascorbic acid, a-tocopherol and nitrates, 
the protective effect of p-carotene was lost Beta-carotene was protective from 
cardia cancer in only one of four studies Beta-carotene appeal's to be
protective for oesophageal adenocarcinoma perhaps only in those with reflux 
symptoms
Alpha-tocopherol reduced the risk for non-cardia gastric cancer by up to 
48% when unadjusted for other antioxidants When adjusted for
ascorbic acid, p-carotene and nitrate, the protective effect of a-tocopherol was lost 
Interestingly when a-tocopherol intake was examined in relation to ascorbic 
acid intake, the protective effect a-tocopherol could only be seen in those with 
middle and the highest tertile of ascorbic acid intake suggesting that ascorbic 
acid is important as a co-factor for a-tocopherol to exert its antioxidant effect in
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preventing non-cardia gastric cancer. Alpha-tocopherol does not appear to protect 
from either cardia or oesophageal adenocarcinoma
Nitrate was a source of great interest in the 1970s and 1980s as a potential 
precarcinogen in gastric carcinogenesis. The major source of nitrate in man is 
derived from the ingestion of vegetables; cured meat and some water supplies are 
also known sources of nitrate but contain significantly less than vegetables
A number of studies have suggested some association between high nitrate 
concentrations in the drinking water and gastric cancer 
The study in Columbia demonstrated that intestinal metaplasia and clironic 
atrophic gastritis were more common in the inhabitants of areas with high gastric 
cancer risk than in low risk areas. However, in the high risk areas more subjects 
consuming surface water had intestinal metaplasia and chronic atrophic gastritis 
compared to well users (in which nitrate content was much higher) which 
suggested that higher nitrate consumption may be associated with gastric cancer 
but that nitrate itself was not responsible for these precursor lesions Others 
have shown no association between nitrate in the drinking water and gastric 
cancer but the levels of nitrate found in the drinking water were low in both these 
studies
As for dietary nitrate and gastrie cancer, Forman and colleagues reported 
that the salivary nitrate and nitrite concentrations in areas of low gastric cancer 
incidence were significantly higher than those of areas with high gastric cancer 
incidence which reflected nitrate intake A number of studies reported an 
inverse association between gastric cancer and dietary nitrate More
recent studies showed that dietary nitrate ingestion 20 years prior to the diagnosis 
of gastric cancer was associated with a significantly reduced risk (OR 0.55) but 
multivariate analysis showed that only vitamin C intake showed a significant 
protective effect suggesting a confounding effect of other dietary constituents 
Others have shown no association between dietary nitrate and gastric cancer
95)
There appears to be little published evidence regarding nitrite ingestion and 
the risk of gastric cancer. Risch and Mayne in separate studies reported a 
significantly increased risk for gastric cancer with an adjusted OR of 2.6 and 1.6 
respectively Other studies have shown no statistically significant 
association between nitrite ingestion and gastric cancer An
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increased risk of gastric cancer with increasing nitrite ingestion for a given level 
of protein intake (low, medium and high) has been reported
Nitrate and nitrite do not appear to be associated with an increased risk for 
cardia cancer in two published studies and a single study suggested that 
nitrite alone was not a risk factor for oesophageal adenocarcinoma However, 
the study by Mayne showed that low vitamin C intake in combination with a high 
nitrite intake had a 2-fold and 3-fold increase in risk for cardia and oesophageal 
adenocarcinoma respectively compared to those with high vitamin C and low 
nitrite intake Such finding may be in keeping with nitrosamine formation 
within the acidic environment of the stomach in those with low vitamin C and 
high nitrite intake.
3.6.1 Summary of diet and upper GI cancer.
There are important limitations to consider when interpreting dietary studies. 
Firstly, many studies have assessed recent dietary habits and used this data to 
calculate the association between nutrients and cancer. The accepted time interval 
between exposure and carcinogenesis is said to be around 20 years and therefore 
recent dietary habits may not necessarily reflect intake 20 years previously. 
Second, the dietary recall for many years previously is unlikely to be precise and 
may distort the result. Thirdly, preference of a certain food group is associated 
with a reduced intake of another food group e.g. high meat intake is associated 
with a low vegetable and fruit intake Therefore a positive association between 
meat and cancer may be a marker of poor vegetable and fruit intake rather than 
meat being positively associated with cancer ‘per se’. Fourthly, many different 
nutrients are found in a single food item and it may be difficult to ascribe an 
association between cancer and the nutrient in question as other nutrients may 
confound the effect of a single nutrient which may mask or magnify its effect. For 
example we have seen that nitrate appears to be protective taken at face value but 
since majority of dietary nitrate is derived h'om vegetables, nutrients such as 
ascorbic acid is also found which is also protective from cancer and in fact when 
nitrate is adjusted for ascorbic acid the protective effect disappears. This suggests 
that the apparent protective effect of nitrate is due to the concomitant presence of 
ascorbic acid and other micronutrients. Many of the studies have not made
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adjustments for the myriad of nutrients that may be present together which may 
have therefore incorrectly ascribed the nutrient in question being positively or 
negatively associated with cancer.
With the above limitations borne in mind some general conclusions can be 
made. Fibre, ascorbic acid, a-tocopherol and p-carotene appear to be consistently 
shown to protect from non-cardia gastric cancer and in turn these nutrients are 
found in abundance in fruits and vegetables and hence these food groups also 
consistently shown to be inversely associated with the risk for non-cardia gastric 
cancer. Data on cardia and oesophageal adenocarcinoma are still limited but 
ascorbic acid and vitamin E may lack the protective effect seen in distal gastric 
adenocarcinoma according to the available evidence but more data are required 
before firm conclusions can be made. Evidence for nitrates suggests that it is 
protective for non-cardia gastric adenocarcinoma. As mentioned earlier, this is 
likely to be due to the confounding effects of other micronutrients found in 
vegetables and nitrate on its own is unlikely to be protective and may prove to be 
harmful as detailed later in the thesis. As for nitrites, its major source is from the 
reduction of dietary nitrate which has undergone enterosalivary recirculation. A 
study suggested that increased nitrite consumption for a fixed protein intake was 
associated with a significant risk for distal gastric cancer Another study 
suggested a low vitamin C intake coupled to a high nitrite intake was associated 
with an increased risk for oesophageal, cardia and non-cardia adenocarcinoma 
These studies hint at the potential role of A-nitrosamines in the aetiopathogenesis 
of adenocai'cinomas of the upper gastrointestinal tract.
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CHAPTER FOUR
BARRETT’S OESOPHAGUS
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4.1 Definition.
Barrett’s oesophagus is defined as the presence of columnar metaplasia in 
the distal oesophagus. Description of Barrett’s metaplasia includes distal 
oesophageal mucosa containing fundic mucosa, junctional mucosa and mucosa 
with intestinal metaplasia. Only the latter entity predisposes to the development of 
adenocarcinoma of the oesophagus.
4.2 Epidemiology.
Barrett’s oesophagus is predominantly a disease of middle-aged men with a 
male to female ratio of 2 to 1 Approximately 6 - 1 2 %  of the patients 
undergoing endoscopy for gastro-oesophageal reflux symptoms are noted to have 
Barrett’s oeosphagus and is dependent on the criteria used to define Barrett’s 
oesophagus. A population-based study in Olmstead demonstrated that Barrett’s 
oesophagus is found in approximately 1% of unselected autopsies (7 of 733) of 
whom only two patients were diagnosed before death Those using the older
definition of columnar mucosa > 3 cm report lower prevalence compared to those 
who include those with < 3cm of intestinal metaplasia The prevalence of
Barrett’s oesophagus in asymptomatic, predominantly male veterans over the age 
of 50 was noted to be 25% Up to a third of the patients with Barrett’s 
metaplasia either have no or minimal reflux symptoms These findings
explain why the majority of the patients with Barrett’s oesophagus remain 
undiagnosed.
In some families Barrett’s oesophagus and oesophageal adenocarcinoma 
appears to be inherited as an autosomal dominant characteristic This
may be related to the fact that there may be a genetic predisposition to the 
development of reflux in families of patients with Barrett’s oesophagus and 
oesophageal adenocarcinoma
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4.3 Histological Features.
Barrett’s mucosa can be recognised endoscopicaily from the normal pale 
pink squamous mucosa by its velvety, salmon- pink appearance extending above 
the gastro-oesophageal junction. Microscopically, Barrett’s oesophagus is 
diagnosed by identifying ‘specialised’ columnar epithelium which replaces the 
native squamous epithelium of the oesophagus.
Ultra-structurally the Barrett’s metaplastic epithelium is made up of a 
mixture of cell types. These include cells resembling gastric cells, small intestinal 
cells and cells with variable microvilli appearance. Goblet cells which secrete acid 
mucins are found in association with the latter two cell types and not with the 
gastric-like cells Intestinal metaplasia has been subdivided into complete and 
incomplete depending on the maturity of the enterocytes. Complete intestinal 
metaplasia is characterised by the presence of mature absorptive cells and do not 
secrete mucin and is termed type I. Incomplete intestinal metaplasia consist of few 
or absent absorptive cells, goblet cells and columnar cells that secrete mucin and 
depending on the type of mucin secreted it is designated type II A, which secrete 
neutral mucins, (now designated as type II) and IIB, which secrete sulphomucins 
(now designated type III) Intestinal metaplasia in Barrett’s oesophagus is 
associated with all types but type II predominate and type I is rare or absent
Previous study suggested an association between gastric cancer and intestinal 
metaplasia that was associated with sulphomucins This finding has been 
extrapolated to Barrett’s oesophagus and it has been suggested that the presence 
of type IIB/III intestinal metaplasia predisposed to the development of 
oesophageal adenocarcinoma
Barrett’s oesophagus was previously only diagnosed when at least 3cm of 
columnar mucosa was visible above the proximal gastric fold. This arbitrary 
distance was adopted as it can be difficult for an endoscopist to determine the end 
of the tubular oesophagus and the beginning of the hiatus hernia, which is almost 
always found in Barrett’s oesophagus. To add to the difficulty, it was suggested 
that even the “normal oesophagus” could be lined by 2cm of columnar epithelium 
and therefore biopsy of this region will provide a false positive diagnosis of 
Barrett’s oesophagus
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More recently, it has been recognised that Barrett’s oesophagus can be 
shorter than 3 cm and can be detected by the proximal extension of the columnar- 
lined mucosa from the gastro-oesophageal junction, confirmed histologically by 
the presence of intestinal metaplasia and Barrett’s oesophagus is now defined as 
the presence of intestinal metaplasia anywhere within the oesophagus 
Another related entity is intestinal metaplasia of the cardia which is defined as the 
presence of intestinal metaplasia at a normal-appearing gastro-oesophageal 
junction The metaplastic mucosa of varying lengths termed long-segment 
Barrett’s, short-segment Barrett’s and intestinal metaplasia of the cardia 
depending on the extent of the metaplasia likely represent a continuum of a single 
disease process with a common aetiological agent, although intestinal metaplasia 
at the cardia appears to have another aetiology as we shall discuss later.
4.4 Malignant transformation in Barrett’s oesophagus.
Malignant transformation of the Barrett’s mucosa appears to be restricted to 
the intestinal-type mucosa The majority of oesophageal adenocarcinomas
are surrounded by or adjacent to the metaplastic mucosa f  although in some 
resection specimens of oesophageal adenocarcinoma, intestinal metaplasia is 
absent and the likely explanation is that the tumor has overgrown the area of 
metaplastic mucosa obliterating the evidence
The incidence of adenocarcinoma developing in Barrett’s oesophagus 
quoted in the literature is between one case in 441 patient-years to one case in 52 
person-years (table 4.1). The reason for the wide discrepancy between the quoted 
figures may be attributable to a number of potential factors. Some institutions 
which specialise in managing Barrett’s oesophagus will undoubtedly be referred 
patients with dysplasia who are more likely to develop adenocarcinoma i.e. there 
is a refenal bias. Some studies have included subjects with high-grade dysplasia 
at the initial endoscopy which will bias towards higher incidence of 
adenocarcinoma Some studies looking at screening have included patients
without intestinal metaplasia in the Barrett’s segment which inevitably will 
include those who are not destined to develop adenocarcinoma reducing the 
estimation for developing malignant lesion Some studies will be biased due 
to the patient characteristics, for example studies conducted in the Veterans
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Administration in the U.S.A. will be over-represented by the male population and 
this will increase the chance for identifying oesophageal adenocarcinoma since 
these malignancies are much more common in the male population (see chapter 2). 
Studies that have incorporated short segment BaiTett’s oesophagus, defined as 
Barrett’s mucosa of less than 3cm, have lower incidence of detecting 
adenocarcinoma Overall, the individual studies are small in number and
even one or two additional cases of oesophageal adenocarcinoma will greatly 
affect the estimate. It can be seen from the table 4.1 that the higher estimates are 
in those studies with patient number <100.
4.5 Dysplasia in Barrett’s oesophagus.
Pathological specimens of oesophageal adenocarcinoma frequently have 
ai'eas of dysplasia in Ban etf s epithelium which are remote from the tumor itself 
(119,125)^  Dysplasia is defined as an unequivocal neoplastic alteration of the 
epithelium and categorised as negative, indefinite, low grade and high grade 
dysplasia. Dysplastic cells are distinguished by histological changes exceeding 
that of repaiative process and cytologic abnormalities: cellular and nuclear 
pleomorphism, nuclear hypercliromatism, loss of nuclear polarity and marked 
stratification of nuclei It is believed that the metapalstic Barrett’s epithelium 
progresses from non-dysplastic through low and high-grade dysplasia and 
eventually carcinoma although it is well documented that some
patients progress from no dysplasia to frank adenocarcinoma during surveillance 
endscopies which are aimed at the early detection of adenocarcinoma 
Miros’s study showed that only those with dysplasia progressed to 
adenocarcinoma and therefore the absence of dysplasia prior to the diagnosis 
of adenocarcinoma most likely reflects sampling interval and or sampling error.
The natural history of low-grade dysplasia is becoming clearer. During a 
three-year follow up of 102 patients with Barrett’s oesophagus 8% of those free of 
dysplasia developed low or high-grade dysplasia. Those with low grade dysplasia 
at any time during surveillance endoscopy 12% developed high-grade dysplasia or 
adenocarcinoma and two patients out of five who had high grade dysplasia at any 
time developed adenocarcinoma
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Reports have suggested that adenocarcinoma is found in up to 73 % of 
oesophagi resected for high-grade dysplasia (see table 4.2). Such high proportions 
are likely to reflect the small number of patients studied, the lack of intensive 
biopsy protocols to detect the tumor present (sampling error) and inclusion of 
patients with mucosal abnormalities suggestive of neoplasia and those with 
proven adenocarcinoma on pre-operative biopsy specimens (selection bias). 
Malignant degeneration of high-grade dysplasia is not inevitable. Intensive biopsy 
sampling can accurately classify high-grade dysplasia and adenocarcinoma and 
may obviate the need for oesophagectomy in those with high-grade dysplasia 
without evidence of carcinoma A study by Levine using intensive biopsy 
protocols in 70 patients with high-grade dysplasia suggested 17% had prevalent 
adenocarcinoma, 26% developed adenocarcinoma during a mean follow up of 27 
months with surveillance endoscopy More recent data by the same group 
demonstrated that out of 76 patients with high-grade dysplasia 59% developed 
adenocarcinoma during a mean follow up over a 5-year period. In those subjects 
who had aneuploidy or 4N (tetraploid) fractions on flow cytometry 61% 
developed adencocarcinoma compared to 42% in those without flow cytometric 
abnormalities over a three-year period Schnell followed 79 patients with 
high-grade dysplasia and found that 11% developed adenocarcinoma in the first 
year of diagnosis of high-grade dysplasia and 20% during an average of 7 years’ 
follow up The risk of malignant degeneration also depends on the extent of 
high-grade dysplasia. Buttar followed 100 patients and found cancer in 38% at 1 
year and 56% at 3 years in those patients with diffuse-high grade dysplasia and 
7% and 14% at 1 and 3 years in those with focal high-grade dysplasia In 
reality, difficulty in differentiating between intramucosal carcinoma and high- 
grade dysplasia means that many clinicians will continue to advocate 
oesophagectomy in those who are found to have high-grade dysplasia and are fit 
enough for surgery
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Author Patient Number Adenocarcinoma (%)
Lee 1985^ 2 1(50)
Hamilton 198?'' 3 1(30)
Altorki 1991* 7 2 (2 9 )
Pera 1992 18 9 (5 0 )
Rice 1993 16 6 (38)
Peters 1994 9 5 (5 6 )
Edwards 1996 11 8 (7 3 )
Heitmiller 1996 30 13 (43)
Cameron 1997 19 2 (1 0 )
O’Connor 1999
........................... ......... - ......
2 0 (0)
Table 4.2: Prevalence of oesophageal adenocarcinoma in oesophag- 
ectomies performed for high grade dysplasia.
t  The author presented four patients with high-grade dysplasia 
(HGD) but two patients had cancer diagnosed before operation and are 
excluded in this analysis.
# The author presented 5 patients with HGD. One had exophytic 
tumor with only dysplasia diagnosed as invasive carcinoma after 
oesophagectomy; another case had invasive cancer on repeated biopsy 
for HGD 3 weeks later which were not included in the above analysis.
* The author presented 9 cases of HGD. Two out of 4 patients who 
were found to have carcinoma had malignant cells on prior cytology 
brushings therefore are not included in this analysis.
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4.6 Pathogenesis of Barrett’s oesophagus.
The precise pathological process leading to the development of Barrett’s 
oesophagus is unknown. The most important factor for the development of 
Barrett’s metaplasia is gastro-oesophageal reflux. It is unclear which constituents 
of refluxed material is the most important. Acid and pepsin does not appear to be 
the only damaging constituents since Barrett’s oesophagus has developed after 
total gastrectomy with oesophagojejunostomy This would suggest that 
contents of the small intestine which include pancreatic and biliary secretions may 
be important in the development of this condition.
4.6.1 Gastro-oesophageal reflux and Barrett’s oesophagus.
Gastro-oesophageal reflux is instrumental in the development of Barrett’s 
oesophagus. However, it is unclear why some people with gastro-oesophageal 
reflux develop Barrett’s whilst others do not. Compared to those with gastro- 
oesophageal reflux disease without Barrett’s oesophagus, subjects with Barrett’s 
oesophagus typically have a lower resting lower oesophageal sphincter pressure - 
in particular those with longer Barrett’s segment a greater degree of
oesophageal acid exposure and impaired acid clearance, particularly in the supine 
position - as measured by 24-hour pH monitoring, which would suggest that any 
acid reflux that occurred in the Barrett’s oesophagus will be present in the 
oesophagus for a longer duration than those with reflux oesophagitis 
One study, however, noted that the manometric findings and the 24-hour pH 
measurement in subjects with severe circumferential oesophagitis were similar to 
subjects with Barrett’s oesophagus The degree of oesophageal acid exposure 
as measured in both the upright and supine position in patients with Ban'ett’s 
oesophagus is related to the length of Barrett’s metaplasitic mucosa In
other words the longer the BaiTett’s segment, the greater is the degree of gastro- 
oesophageal reflux.
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4.6.2 Hiatus hernia.
Sliding hiatus hernia appears to play an important role in the pathogenesis 
of gastro-oesophageal reflux disease. Patients with reflux oesophagitis are more 
likely to have hiatus hernia than those without oesophagitis and gastro- 
oesophageal reflux occurs to a greater degree than those without hiatus hernia 
Hiatus hernia is demonstrated in 60 - 94 % of patients with oesophagitis 
161, 162,163) severity of oesophagitis correlates with the presence and the
size of the hernia In patients with Barrett’s oesophagus, a subgroup of
refluxers with the greatest oesophageal acid exposure, greater than 90% of the 
patients have demonstrable hiatus hernia
The mechanisms by which hiatus hernia predispose to gastro-oesophageal 
reflux appears to be through its effect on the lower oesophageal sphincter pressure 
and impairing oesophageal acid clearance. Patients with hiatus hernia 
demonstrated reduced lower oesophageal sphincter pressures compared to those 
without a hernia shorter sphincter length and reduced /absent intra­
abdominal length of sphincter Maneuvers which abruptly raise the
intraabdominal pressure are more likely to result in reflux in subjects with hiatal 
heranias The presence of a non- reducing hiatal hernia is associated with an 
impaired diaphragmatic pressure augmentation during inspiration The spatial 
separation of the lower oesophageal sphincter and the diaphragmatic high pressure 
zone reduces the effective pressure exerted at the level of the lower oesophageal 
sphincter Clearance of the refluxed gastric content is impaired in the 
presence of a hiatus hernia and as a result there is increased oesophageal acid 
exposure and reflux of the contents of the hernia back into the
oesophagus has been demonstrated using barium and radio-isotope scanning
170)
In summary, it can be seen that hiatus hernia predisposes to gastro- 
oesophageal reflux by impairing the sphincter mechanisms of the lower 
oesophagus by a number of mechanisms and prolongs the exposure of the 
oesophagus to the noxious effect of the refluxed gastric contents.
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4.6.3 Acid, pepsin and bile reflux.
Animal studies have established the importance of acid and pepsin in 
producing peptic oesophagitis. Redo demonstrated that hydrochloric acid alone at 
pH<2 did not cause erosions or ulcerations of the oesophagus whereas 2% 
solutions of pepsin at pH<2 caused ulcerations. Addition of bile to gastric juice 
attenuated the mucosal injury caused by gastric juice at acid pH In a feline 
model high acidity was required (pH<1.3) for producing oesophagitis when only 
hydrochloric acid was employed whereas oesophagitis was produced when pepsin 
was present with hydrochloric acid even under conditions of pH>l .3 and the 
damage was prevented by the presence of a pepsin inhibitor Furthermore,
hydrochloric acid alone at pH 2 did not cause oesophagitis or increase mucosal 
permeability in the rabbit oesophagus whereas addition of pepsin at pH 2 caused 
both macroscopic damage and increased mucosal permeability to various ions 
including H^ ions Taurodeoxycholate, a conjugated bile acid at pH 2 
increased mucosal permeability but did not cause macroscopic change and trypsin 
did not alter gross appearance or the permeability This would indicate that 
pepsin and acid are the key components leading to oesophagitis in patients with 
peptic oesophagitis.
Acid reflux is clearly important in the pathogenesis of Barrett’s oesophagus 
as noted previously. However, animal and human studies of Barrett’s oesophagus 
suggest an important role of refluxing duodenal contents, which include 
pancreatic juice, in the pathogenesis of intestinal metaplasia of the distal 
oesophagus. A thiee-month study on dogs suggested that surgically damaged 
oesophageal mucosa exposed to gastric contents heals by columnar metaplasia but 
without the goblet cells This suggested that in the presence of epithelial 
disruption, continued reflux of acidic gastric contents leads to regeneration with 
columnar epithelium. Either gastric juice was inadequate stimulus to produce 
columnar metaplasia with goblet cells or the duration of the study was too short 
for its development. Rats surgically treated to produce reflux of duodenal contents 
with or without gastric acid and fed standard rat chow, developed intestinal 
metaplasia and adenocarcinoma of the oesophagus. Only 2 out of the 16 animals 
subjected to only reflux of gastric contents developed columnar-lined oesophagus 
and none developed any malignant lesions 50 weeks after the surgical procedure
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This suggests that bile reflux is an important component in the pathogenesis 
of Barrett’s oesophagus and adenocarcinoma in this animal model.
In man, bile reflux also appears to be important in the pathogenesis of 
Barrett’s oesophagus. In patients with Barrett’s oesophagus bile reflux, as 
measured by bilirubin absorbance, is higher than in those with uncomplicated 
gastro-oesophageal reflux and bile salt concentrations in gastric and
oesophageal aspirates of patients with Barrett’s oesophagus are higher in 
individuals with Barrett’s compared to those with uncomplicated reflux 
Bile salts aspirated from the fasted stomach were found to be greater in those with 
increasing severity of gastro-oesophageal reflux and in particular those with 
complicated Barrett’s oesophagus Vaezi showed that the combination of 
acid and bile reflux in humans who have previously undergone partial 
gastrectomy led to the development of oesophagitis whereas patients with bile 
reflux alone did not demonstrate oesophagitis The majority of patients with 
intact stomach and gastro-oesophageal reflux, especially those with Barrett’s 
oesophagus, have simultaneous reflux of both acid and bile although
Barrett’s metaplasia developing following gastrectomy has also been described
(152)^
The mechanism by which bile acids induce oesophageal injmy appears to be 
related to the dissociation constant (pKa) of the bile acids and the pH of the 
prevailing environment. Conjugated bile acids at concentrations found in gastric 
juice produced ultrastructural damage to oesophageal epithelium at pH 1 but not 
at pH 7 whereas unconjugated bile acids produced damage at pH 7 An in vivo 
study of bile salt injury to the gastric mucosa in mice demonstrated that 
taurocholate with a pKa of 1.8 only produced damage at pH 1 whereas 
glychochenodeoxycholate with a pKa of 4.2 produced damage at pH 1 and pH 3
(183)
The cellular damage produced by the bile salts in acid appears to be related 
to the increased epithelial permeability to the lumenal H^ ions. Conjugated bile 
salt in hydrochloric acid cause back diffusion of H"^  ions into human stomach 
and the oesophagus in animal experiments Taurine-conjugated bile acids
was shown to cause back diffusion of H^ ions into the oesophageal epithelium 
from the lumen in rabbits at pH 2 whereas unconjugated bile acids caused back 
diffusion of H^ ions at pH 7 but not at pH 2 The pH dependent effect of the
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different bile acid is due to the ionisation status of the particular bile acid at 
different pH. Below the pKa the bile acid is predominantly non-ionized and is 
permeable to the epithelial membrane whereas ionized species are less permeable. 
Additionally, unconjugated bile salts precipitate out in acid rendering them 
harmless. Epithelial barrier disruption by bile salts appears to be due to the 
accumulation of bile salts in the epithelium rather than the solubilization of 
mucosal lipid layer by bile acids Bile acids also appear to be mitochondrial 
toxins leading to the failure of oxidative phosphorylation and subsequently cell 
rupture However, the epithelial disruption and cytotoxicity of the bile salts 
does not explain how they may contribute to the carcinogenic process in Barrett’s 
oesophagus.
More recent studies have focussed on the effect of acid and bile acids on 
cellular proliferation which may have an important role in the development of 
neoplasia in Barrett’s oesophagus. In an ex-vivo organ culture model of Barrett’s 
oesophagus, Fitzgerald showed that cellular proliferation was increased and 
differentiation decreased in Barrett’s mucosa exposed to pulses of acid at pH 3.5 
compared to those tissues which had either continuous exposur e to acid or 
maintained at physiological pH Subsequent study by the same group in 
patients with Barrett’s oesophagus demonstrated that patients who had complete 
suppression of acid reflux compared to those with incomplete suppression on 
proton pump inhibitor therapy, cellular proliferation was reduced and villin 
expression, a marker of epithelial maturation for this type of mucosa, was 
increased six months later whereas those with inadequate suppression showed no 
change from baseline These studies suggest intermittent exposure of Barrett’s 
mucosa to acid increases cellular proliferation and reduced differentiation. Souza 
demonstrated an increase in cellular survival and proliferation in oesophageal 
adenocarcinoma cell line by reducing apoptosis and increase in cells entering G2 
phase of the cell cycle after exposm*e to a brief pulse of acid mediated through the 
effects of mitogen activated protein kinases
Induction of cyclooxegenase-2 (COX-2) expression in the Barrett’s 
epithelium by acid and bile has been noted. Bile acids have been shown to 
stimulate COX-2 expression via the epidermal growth factor receptor in 
cholangiocarcinoma cell line Increasing COX-2 protein expression is seen 
progressing from normal oesophageal mucosa to Barrett’s mucosa, Ban'ett’s
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mucosa with dysplasia and adenocarcinoma of the oesophagus. Exposure of the 
Barrett’s oesophagus to acid and bile salts increased COX-2 expression, 
particularly by acid or bile acid individually and appears to be mediated by 
protein kinase C COX-2 may contribute to carcinogenesis by promoting 
cellular proliferation, inhibiting apoptosis and supporting angiogenesis Buttar
demonstrated in an animal model of oesophageal adenocarcinoma that COX-2 
protein was expressed, without a significant increase in COX-1 protein, and PGE2 
levels were increased in the oesophageal tissue. Tumor incidence was reduced in 
animals treated with Sulindac and a COX-2 specific inhibitor, both of which 
reduced the level of PGE2 in the oesophageal tissue compared to controls It
remains to be seen if COX-2 inhibitors may be a useful chemopreventative agent 
in patients with Barrett’s oesophagus in man.
Although acid and duodenal contents including bile acids appear to be 
important in the pathogenesis of the Barrett’s metaplasia and malignant 
degeneration, they may not be the mutagen leading ultimately to adenocarcinoma. 
The implication of the above studies is that acid and duodenal contents lead to 
epithelial disruption in the normal squamous oesophageal mucosa and lead to the 
development of Barrett’s metapalsia. The same factors increase the cellular 
proliferation of Barrett’s epithelium, for example by up-regulating COX-2 
expression, and increase the susceptibility of the epithelium to mutagenic 
compounds. The mutagen(s) for the malignant degeneration in Barrett’s mucosa is 
currently unknown. The present thesis will later discuss the potential mechanisms 
which lead to the mutagenic process in BaiTett’s epithelium.
4.7 Intestinal metaplasia of the cardia and carditis.
Barrett’s oesophagus was previously defined arbitrarily as metaplastic 
epithelium > 3cm above the gastro-oesophageal junction. Recent studies have 
subdivided the Barrett’s oesophagus in to those > 3cm as classical Barrett’s or 
long-segment Barrett’s and < 3cm as short-segment BaiTett’s oesophagus (see 
above). More recently, it was noted that intestinal metaplasia can be frequently 
detected at the cardia in patients with gastro-oesophageal junction with apparently 
normal appeaiances with prevalence ranging between 6 % to 25 %
The precise pathogenesis of intestinal metaplasia at the cardia is unclear.
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Intestinal metaplasia is thought to arise as a result of chronic inflammation 
and can be induced by carcinogenic nitrosocompounds
There has been a debate as to the relative importance of H, pylori infection 
and gastroesophageal reflux in causing inflammation and intestinal metaplasia of 
the cardia. Helicobacter pylori has been implicated in having a causative role in 
carditis and intestinal metaplasia of the cardia Chen demonstrated a
higher prevalence of H. pylori infection at the cardia and other gastric sites in 
individuals with increasing severity of caidia inflammation whereas reflux 
symptoms showed a statistically non-significant inverse trend in relation to the 
severity of caiditls. In addition those without carditis did not have H  pylori 
infection. However, overall only 27% of patients were positive for H  pylori on 
biopsy in the presence of carditis in that study Eradication of H. pylori has 
been shown to dramatically improve cardia inflammation whereas in those with 
persistent infection no improvement was seen Others have implicated gastro- 
oesophageal reflux as the cause of carditis and intestinal metaplasia at this site 
Oberg and colleagues suggested that the so-called cardiac mucosa does not 
normally exist and is due to metaplasia secondary to some noxious insult of the 
native mucosa at this site. They showed that individuals with cardiac-type mucosa 
had more objective evidence of gastro-oesophageal reflux. Virtually all patients 
who demonstrated cardiac mucosa had “carditis” which was associated with less 
antral H  pylori infection than those without cardiac mucosa and when the 
organism was found in cardia biopsy specimens it had no association with the 
presence or absence of carditis. In subjects with intestinal metaplasia of the cardia 
more subjects had oesophagitis and hiatal hernia compared to those with cardiac 
mucosa without intestinal metaplasia. Only 17% of the subjects with intestinal 
metaplasia of the cardia had antral H. pylori infection
The real answer appears to lie somewhere in between and that some cases of 
intestinal metaplasia are due to H. pylori and the others gastric acid related
Carditis secondary to H. pylori infection has evidence of gastritis elsewhere in 
the stomach; those with a normal stomach, carditis is associated with gastro- 
oesophageal reflux Using cytokeratin 7 and 20 staining pattern, Balaji
showed that patients with intestinal metaplasia of the cardia and objective 
evidence of gastro-oesophageal reflux, negative for H. pylori, had incomplete type 
of metaplasia and in 90% of these patients cytokeratin staining pattern was the
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same as that of Barrett’s oesophagus. In contrast those who had cardia intestinal 
metaplasia who were positive for K  pylori with or without reflux, 50% and 41% 
respectively stained positive for Barrett’s cytokeratin pattern Interestingly 
Balaji’s study also highlighted patients who had cardia intestinal metaplasia with 
cytokeratin staining pattern of Barrett’s metaplasia but had no objective evidence 
of gastro-oesophageal reflux or of H. pylori infection. The latter finding can be 
explained by the fact that at the cardia the pH is already acidic and individuals do 
not have to have reflux for the cardia to be subjected to the effects of gastric acid 
Helicobacter pylori infection, particularly the Cag A strain, is associated with 
a reduced risk for cardia and oesophageal adenocarcinoma and the above
studies suggest that the risk for developing cardia adenocarcinoma in patients with 
cardia intestinal metaplasia will be dependent on the aetiology of the metaplasia.
A recent study suggested H. pylori may be both protective and predispose to 
cardia adenocarcinoma. Cardia cancer was negatively associated with H. pylori 
infection but was over-represented by H  pylori associated gastric atrophy 
compared to controls suggesting a dual aetiology for this type of cancer
The above studies suggest that carditis and intestinal metaplasia at the cardia 
have dual aetiologies - H  pylori and gastro-oesophageal reflux. It is likely that 
intestinal metaplasia of the cardia unrelated to H. pylori, short-segment Barrett’s 
and long-segment Barrett’s form a continuum and the so-called Barrett’s 
oesophagus encompasses a vaiiable length of intestinal metaplasia extending 
proximally from the gastro-oesophageal junction and is better termed intestinal 
metaplasia of the distal oesophagus. The risk for developing cardia 
adenocarcinoma from cardia intestinal metaplasia related solely to reflux/acid 
exposure is unknown whereas for long-segment Barrett’s and short-segment 
Barrett’s oesophagus are 1 in 150 ‘ and perhaps in exess
of 1 in 200 patient -  years respectively.
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CHAPTER FIVE
NITROSAMINES IN CANCER
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5.1 Introduction.
In the late 1960’s through to the early 1980’s there was a considerable 
interest in iV-nitroso compounds as a potential carcinogen in human gastric cancer, 
many of which were potent carcinogens in animals. V-nitroso compounds could 
be synthesized in vitro from amines and nitrite under acidic conditions and there 
was considerable interest regarding the formation of V-nitroso compounds in the 
acidic environment of the stomach. However, this did not reflect the clinical 
practice where non-cardia gastric cancer developed in association with gastric 
atrophy and hypo-Zachlorhydric stomach. Correa proposed a hypothesis where the 
stomach underwent a series of changes from gastritis to atrophic mucosa 
eventually developing hypo-Zachlorhydria which then became colonised by 
bacteria capable of nitrosating amines in the presence of nitrite to generate 
carcinogenic V-nitrosamines which could potentially lead to mutagenesis and 
carcinogenesis in the gastric epithelium
The subsequent sections will deal with V-nitroso compounds, describe the 
nitrosation chemistry, including bacterial nitrosation in more detail, and their 
potential relevance in cardia and oesophageal adenocarcinoma which form the 
basis of this thesis.
5.2 Nitroso compounds. What are they?
V-nitroso compounds are a diverse group of chemicals encompassing N- 
nitroso derivatives of primary, secondary and aromatic amines, amides guanidines 
and ureas. They have been extensively studied for their carcinogenic effects. N- 
nitroso compounds are found in the environment and are known to be widely 
distributed for example tobacco smoke, food, by-products of industrial processes 
to name but a few. This has been reviewed extensively and will not be the 
subject of further discussion in this thesis.
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iV-nitroso compounds have a general structure 
Ri
' " n - n=o/R2
They can be divided into two classes with different chemical properties:
(1) Nitrosamines where Ri and R% are alkyl or aryl groups.
(2) Nitrosamides where Ri is an alkyl or aryl group, and R2 
is an acyl group.
Nitrosamines are generally stable compounds and require metabolic activation by 
mammalian enzymes prior to DNA alkylation (fig 5.1).
In contrast, nitrosamides (and related nitrosoureas and nitrosoguanidines) are 
unstable in neutral or alkaline aqueous solutions and do not require metabolic 
activation before they react and alkylate DNA.
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Fig 5.1: Bioactivation of A-nitroso compounds.
A-nitrosoureas and related compounds such as nitrosamides, nitroso­
guanidines decompose at physiological pH to form electrophilic 
alkylating agents. A-nitrosamines are stable at physiological pH and 
require activation by cytochrome P450-dependent hydroxylation at the 
carbon atom adjacent to the V-nitroso group which is the critical step in 
the biotransformation.
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5.3 Nitrosamines in animal models of oesophageal
adenocarcinoma.
Several studies have used V-nitroso compounds to produce adenocarcinoma 
of the oesophagus in conjunction with surgical procedures to produce reflux of 
duodenal contents into the oesophagus (217, 218, 219, 220, 221) operated to produce 
gastroduodeno-oesophageal reflux developed adenocarcinoma (some were 
adenosquamous) of the oesophagus when treated with nitrosamines whereas those 
treated with nitrosamines alone developed only squamous oesophageal carcinoma 
suggesting that bile reflux modifies the carcinogenic property of the nitrosamines 
(218,219) another similar study, rats operated to produce gastroduodeno- 
oesophageal reflux and administered nitrosamine developed columnar-lined 
mucosa in addition to oesophageal adenocarcinoma. A high fat diet increased the 
number of animals developing oesophageal adenocarcinoma and squamous 
oesophageal carcinoma In some studies surgical procedure which produced 
gastro-duodeno-oesophageal reflux alone was sufficient to produce both columnar 
mucosa resembling Barrett’s oesophagus and oesophageal adenocarcinoma 
The study by Miwa showed that normal duodenal secretions were important 
in the generation of columnar-lined mucosa and oesophageal adenocarcinoma 
The development of oesophageal adenocarcinoma by different methods in these 
animal models appears to be related to the different rat strains used in different 
studies: Sprague-Dawley rats did not develop adenocarcinoma in the absence of 
nitrosamine administration (although glandular metaplasia with mucus-secreting 
cells developed) Wistar rats on the other hand developed Barrett’s 
oesophagus and oesophageal adenocarcinoma without any carcinogen (^ 25.221) 
These studies suggest that duodenal secretions, which include bile and pancreatic 
secretions, can produce Barrett’s oesophagus and oesophageal adenocarcinoma 
but such susceptibility is determined by the strain of the rat. The studies also 
suggest that the duodenal secretions modify the cellular differentiation of the 
carcinoma that subsequently develops in the rats exposed to nitrosamine.
Although the animal models provide an insight into the importance of the 
reflux of duodenal contents in producing Barrett’s oesophagus and oesophageal 
adenocarcinoma, it must be borne in mind that in all animal models of 
gastroduodeno-oesophageal reflux, the normal anatomical relationship of the
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oesophagus, stomach and duodenum have been altered and as such it does not 
precisely mirror the sequence of events which leads to duodeno-gastro- 
oesophageal reflux where the duodenal secretions enter the stomach and then 
reflux into the distal oesophagus. Developing an animal model which reflects the 
normal physiological process of duodenogastro-oesophageal reflux should be the 
logical next step.
5.4 A-Nitroso compounds and human cancer.
Direct evidence linking V-nitroso compounds to car cinogenesis in human is 
lacking and is based on substantial circumstantial evidence. jV-nitroso compounds 
are carcinogenic in many animal species and produce cancer in numerous organs 
(222)^  Over 80% of nitrosamines and over 90% of nitrosamides are carcinogenic in 
many animal species including primates and it is unlikely that humans will be 
immune to the carcinogenic effect of nitroso compounds Nitrosoureas used in 
cancer chemotherapy, which are alkylating agents, are implicated in second 
neoplasms developing in treated individuals Human liver metabolises
nitrosodimethylamine (NDMA) like rat liver and liver fractions from humans 
can convert NDMA to chemicals mutagenic to bacteria Human liver
and oesophagus can metabolize A-nitroso compounds into chemicals which can 
bind to DNA Acute toxicity of A-nitrosodimethylamine in man
produce hepatic necrosis with lesions resembling those seen in rodents and 7 - 
methylguanine and O'^-methylguanine which aie DNA adducts generated by 
nitroso compounds were found in the liver of a victim of NDMA poisoning 
In Linxian, China, where there is a high incidence of oesophageal carcinoma, 
DNA adducts are elevated in oesophageal tissues unaffected by tumor in those 
who underwent oesophagectomy compared to samples from European patients 
In addition urinary excretion of A-nitroso compounds is elevated in such 
patients compared to subjects from a low-risk region These reports provide 
evidences that A-ntiroso compounds are likely to be carcinogenic in humans.
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5.5 Nitrosation chemistry.
A-nitrosation involves the replacement of hydrogen which is attached to 
nitrogen by the nitroso group.
Ri R i \X -N O  + ^ N - H  ----------------- ► H - X  + N -N O
R2' '
5.5.1 Acid-catalysed nitrosation.
Nitrous acid generated from the addition of nitrite to acid is the oldest 
method of preparing a nitrosating agent. Nitrous acid has a pAa of 3.4 (at pH 3.4, 
50% of the acid is dissocaited into H  ^and NO2') and therefore nitrosation by 
acidified nitrite is acid catalysed. Neither nitrous acid nor nitrite is able to 
nitrosate directly but nitrous acid generates a cocktail of chemicals including a 
number of nitrosating agents as shown below (indicated in bold print).
NO2' + H ^-> HNO2 (1)
2H N 0 2 ^ N 203 + H 20 (2)
2N 203+ 02^2N 204  (3)
HN02+H'"<->H2N02'' (4)
H2N02‘" NO"- + H2O (5)
The nature of the nitrosating species depends on the prevailing pH. For example, 
at pH <2, nitrous acid becomes protonated and generates nitrosating species in 
equations (4) and (5) whereas in weaker acids, pH -  3, N2O3 appears to be the 
major nitrosating species
Nitrosamine formation from secondary amines, the most widely studied 
reaction, follows the rate equation:
Rate = k [R2NH] [nitrite]^
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The optimal pH for nitrosation of secondary amines which have a pAa > 5 is pH -  
3.4, the pAa of nitrous acid The optimal pH for nitrosation is due to the 
balance between the formation of nitrosating species at lower pH, which increases 
the rate of nitrosamine formation, and the reduction in rate due to the formation of 
protonated amines at the lower pH which do not react with the nitrosating agent. 
The reaction is catalysed by the presence of halide anions and thiocyanate anions 
(237,238) presence of thiocyanate, the optimum pH for nitrosation is pH -  2.5
In this situation, the nitrosation species is formed as follows:
HN02+H'"<->H2N02'" (4)
H2NO2'' NO+ + H2O (5)
NO+ + SCN' NOSCN (6 )
The rate equation for nitrosation of secondary amines follows:
Rate = k [amine][HN0 2 ][SCN‘]
Since the concentration of SCN" is far greater concentration of nitrite/HN0 2  at 
gastric pH (< 2), rate of nitrosation is greater than in the absence of SON" where 
the rate is proportional to [nitrite]^.
For the nitrosation of amides and related compounds, the rate equation follows:
Rate = k [amide] [HNO2] [H ]^
5.5.2 Bacterially catalysed nitrosation.
Bacteria can caiTy out A-nitrosation at neutral pH. This may be relevant in 
the achlorhydric stomach where bacterial overgrowth has been documented 
and in other sites of the body where conditions favour both bacterial catalysation 
and nitrate reductase activity The nitrosating ability of the different bacterial 
species depends on whether the organism is capable of denitrification. 
Denitrifying bacteria appear to catalyse the formation of A-nitrosamine from 
nitrate and amines more effectively than non-denitrifying bacteria The 
proposed mechanisms for bacterial nitrosation include:
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1. The bacteria reducing nitrate to nitrite concurrently lowering the pH of the 
culture medium promoting acid-catalysed nitrosation
2. The bacteria providing a physical medium in which nitrosation is promoted 
for example the provision of a lipid phase by the bacterial membranes
3. The favoured theory is that bacterial enzymes catalyse the nitrosation 
reaction
The ability of bacteria to catalyse the nitrosation is dependent on the generation of 
nitric oxide or NO^-like species In the case of E. coU, a non-denitrifying
bacteria, the nitrosation reaction is catalysed by the respiratory nitrate reductase 
(248) Yv^ hich is induced under anaerobic conditions In the case of denitrifying 
bacteria such as Pseudomonas aeruginosa and Neisseria mucosae, cdj nitrite 
reductase induced during anaerobic growth condition appears to be responsible for 
the nitrosation reaction
5.5.3 Nitrosation by macrophages and netrophils: the role of 
nitric oxide.
Macrophages stimulated by bacterial lipopolysaccharides and/or interferon y 
nitrosates secondary amines at physiological pH (250-25i)^  L-arginine is the souice 
of the nitrosyl group of the nitrosamine generated by activated macrophages 
and involves the generation of nitric oxide as inhibitors of nitric oxide synthase 
and oxyhaemoglobin, a nitric oxide trapping agent inhibited nitrosation 
Extravasated neutrophils also nitrosate amines by the same mechanism The 
fact that the nitrosation of amines by macrophages required the presence of 
oxygen suggests that the nitrosation process involved the generation of N2O3 or 
N2O4 similarly, nitric oxide in aerobic solution nitrosates morpholine at 
physiological pH, most likely due to the formation of N2O3 Interestingly, 
activated macrophages and neutrophils simultaneously generate superoxide 
radicals with nitric oxide, which it consumes, and reduces nitrosation of amines. 
Superoxide dismutase increases the nitrosating potential of activated macrophages 
and neutrophils whereas superoxide generating system (xanthine
oxidase and hypoxanthine) attenuated nitrosation Catalase had no such effect
(256)
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5.6 Ascorbic acid as an inhibitor of nitrosation.
5.6.1 Ascorbic acid inhibits acid-catalysed nitrosation.
Nitrosation reaction can be inliibited by a number of chemicals, including 
ascorbic acid. Ascorbic acid has been demonstrated to effectively inhibit acid- 
catalysed nitrosation reaction of secondary amines and amides under the 
conditions where A-nitroso compounds were generated in the absence of ascorbic 
acid Ascorbic acid reacts with the nitrosating species in anaerobic conditions 
to yield nitric oxide and dehydroascorbic acid as follows:
CHaOH
HOCH
O
H
O
H
CH2OH
HOCH
O O
ASCORBIC DEHYDROASCORBIC
ACID ACID
" Nitrosating species: 2 HN0 2  ^  N2 0 3  + H2 0
HNO2 + HX NOX + H2O, where X = SCN', Cl' (and
other halide ions)
In anaerobic conditions, Imole of ascorbic acid reacts with 2 moles of nitrite 
Under aerobic conditions the ascorbic acid becomes less efficient as a 
scavenger for nitrosating species and the 2 : 1  stoichiometric ratio for the reaction
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between nitrite and ascorbic acid is reduced This is due to the recycling of 
the nitric oxide in the presence of oxygen to N2O3
2NO + 0 2 -^  2 NO2 
NO2 + NO ^  N2O3
5.6.2 Ascorbic acid inhibits bacteria-catalysed nitrosation.
Ascorbic acid in human gastric juice is considerably lower where 
histological abnormality such as chronic gastritis or intestinal metaplasia is 
present compared to the normal stomach Little or no ascorbic acid is
present in hypo/achlorhydric gastric juice (^ 64,265)^  Acid suppressing medications 
such as omeprazole produce the same effect Bacterial overgrowth has been 
documented in the naturally or drug-induced achlorhydric stomach and
potentially catalyse the foimation of A-nitrosamines in such conditions. Ascorbic 
acid has been shown to inhibit bacteria-catalysed nitrosation at neutral pH in vitro 
and is likely to be effective in inhibiting bacteria-catalysed nitrosation in vivo.
5.6.3 Ascorbic acid inhibits N-nitrosation by activated 
macrophages and neutrophils.
Ascorbic acid has been shown to inhibit nitrosation by activated 
macrophages in vitro. However, ascorbic acid concentrations less than 50faM 
paradoxically increased the yield of nitrate and nitrosamine When ascorbic 
acid-deficient rats stimulated by lipopolysaccharlde were fed ascorbic acid, 
excretion of 7V-nitrosothioproline was significantly reduced which suggests that 
ascorbic acid can inhibit nitrosation by activated macrophages in vivo 
Ascorbic acid also inhibits A-nitrosation of amines by extravasated polymorphs
(254)
50
5.7 Acid-catalysed nitrosation in the human stomach.
5.7.1 Introduction
Acid-catalysed nitrosation is potentially relevant in the acid-secreting 
human stomach. All the substrates relevant to the nitrosation reaction are present 
in the upper gastrointestinal tract. Nitrite is present in the saliva and is derived 
from the bacterial reduction of diet-derived nitrate in the oral cavity (see 5.7.2). 
The nitrite is swallowed and forms nitrous acid with acidic gastric juice to form 
nitrous acid and the nitrosating species which can react with nitrosatable amines 
to produce A-nitrosamines. The process is catalysed by thiocyanate anions, which 
are secreted in the saliva and present in gastric juice via the formation of
the nitrosationg species nitrosothiocyanate (NOSCN) (see 5.5.1).Thiocyanate in 
human is derived ifom foods, in particular those of the Brassica species (e.g 
broccoli, cabbage) and also from inhaling cyanide in tobacco smoke as well as 
ingestion of cyanide in the diet which is subsequently converted to thiocyanate by 
the enzyme rhodanese Ascorbic acid is a potent inhibitor of the A-nitrosation 
reaction. The healthy human stomach actively secretes ascorbic acid into the 
gastric juice and the concentrations in the gastric juice is higher than that of 
plasma Ascorbic acid rapidly reduces the nitrosating species to nitric
oxide and is itself oxidised to dehydroascorbic acid This
removal of intragastric nitrite by the ascorbic acid in gastric juice is probably the 
major mechanism preventing the generation of A-nitroso compounds within the 
lumen of the stomach. Thus the major determinant of A-nitrosation within the 
lumen of acid secreting stomach is the relative availability of nitrite and ascorbic 
acid. When the supply of nitrite exceeds that of ascorbic acid then nitrosation will 
occur, when ascorbic acid supply exceeds that of nitrite then nitrosation will be 
prevented.
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5.7.2 Enterosalivary circulation of nitrate and the formation of 
salivary nitrite.
The major source of nitrite ingested by man is derived from enterosalivary 
recirculation of dietary nitrate. The average intake of nitrate in UK in 1985 was 54 
mg/day and tap water contributed 1 0 -2 0 mg/day assuming a daily intake of 1 litre; 
nitrite intake was calculated to be 4.2 mg/day Most of the nitrate ingested in 
our diet comes from vegetable sources which contributes 75 -  80% of the intake 
(90,279) Y qjj  little nitrite is found in vegetables with concentrations rarely 
exceeding 2 mg/kg Both nitrate and nitrite salts are used as curing agents in 
meat to develop and act as antioxidants. Nitrite, through the formation of nitric 
oxide, combines with myoglobin to stabilize the pink colour in cured meats 
Sodium nitrite is an antimicrobial agent that inhibits growth of Clostridium 
botulinum by delaying outgrowth of their spores
The majority of nitrate ingested is absorbed from the proximal small 
intestine. Sixty percent is excreted in the urine Approximately 25% is
taken up by the salivary glands where it is concentrated and secreted into the 
buccal cavity (Fig 5.2). Man synthesizes approximately 1 mmol/day of nitrate 
(282,284) j s  l i k e l y  t o  b g  derived from nitric oxide Twenty to 30% of the 
nitrate secreted into the buccal cavity is reduced to nitrite by bacterial
enzymes on the dorsum of the tongue during anaerobic respiration 
Approximately 5% of the ingested nitrate is thus converted to nitrite. The nitrite in 
saliva is swallowed and becomes acidified on entering the acidic gastric juice to 
form nitrous acid. Nitrous acid subsequently forms various nitrosating species in 
solution which is reduced to nitric oxide by the ascorbic acid secreted by the 
healthy huaman stomach and in the process ascorbic acid is oxidized to 
dehydroascorbic acid
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Fig 5.2: Enterosalivary recirculation of dietary nitrate in man.
Dietary nitrate is swallowed in the saliva and absorbed in the in the 
proximal small intestine. 25% is taken up and concentrated in the 
salivary glands and secreted into the oral cavity. Bacteria on the 
dorsum of the tongue reduce 20 - 30% of the nitrate to nitrite 
which is then swallowed in the saliva. The nitrite on contact with the 
gastric juice becomes acidified and rapidly reacts with ascorbic acid 
in gastric Juice and generates nitric oxide in the process.
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5.7.3 Ascorbic acid secretion in the human stomach.
Ascorbic acid is actively secreted into the gastric lumen as the concentration 
of ascorbic acid in gastric juice of histologically normal stomach is much higher 
than the concentrations of ascorbic acid found in the plasma In
histologically normal stomach, virtually all of the ascorbic acid is in the reduced 
form (range 83 -  100%) Ascorbic acid concentration in gastric juice is higher
in histologically normal stomach than in stomachs with chronic H. pylori gastritis 
or atrophic gastritis Rokkas and colleagues have demonstarted that the
Cag A(+) strain M pylori, which produce greater gastric inflammation, have lower 
total vitamin C in the gastric juice compared to subjects infected by the Cag A(-) 
strain Gastric juice ascorbic acid concentration was shown to be inversely 
correlated with the degree of corpus inflammation Eradication of H.
pylori restores the gastric juice ascorbic acid towards normal levels
In addition to the H. pylori gastritis, the ascorbic acid concentration is 
reduced in subjects with gastric juice pH > 4, including subjects who become 
hypo/achlorhydric during treatment with a proton pump inhibitor, when the 
predominant form of ascorbic acid is in the oxidized foim of dehydroascorbic acid 
(264, 265, 266, 274)^  Ttie rcduccd form of ascorbic acid is unstable in neutral pH and the 
presence of oxidants in neutral/achlorhydric gastric juice may explain the low 
ascorbic acid concentrations in achlorhydric gastric juice
5.8 Evidence for intragastric nitrosation in the acid-secreting
human stomach.
In vitro experiments have demonstrated the formation of nitrosamines in 
gastric juice collected from humans when incubated with sodium nitrite and 
secondary amines Although large quantities of nitrite and amines were
used, these experiments showed the potential for acid-catalysed nitrosation in 
human gastric juice. Subsequently it was shown that feeding nitrate to human 
subjects followed by proline led to increased urinary excretion of A-nitrosoproline 
indicating endogenous synthesis Using 3.5 mmol [^^ N] nitrate and 4.3 mmol 
L-proline Wagner demonstrated [^^ N] A-nitrosoproline excretion of up to 187 
nmol/24hour again indicating endogenous nitrosation occuring in the stomach
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Simultaneous ingestion of normal food high in nitrates (e.g. spinach) and amines 
(e.g. cod) results in increased urinary excretion of jV-nitrosamines Such 
studies clearly indicate that human stomach is an important site for acid-catalysed 
nitrosation and that normal dietary constituents may lead to the intragastric 
synthesis of 7V-nitroso compounds. Furthermore, ascorbic acid has been shown to 
inhibit endogenous nitrosamine formation in man. Concomitant ingestion of 
ascorbic acid with proline in subjects living in a high-risk region for oesophageal 
cancer in China significantly reduced the urinary excretion of fV-nitrosamino acids 
including nitrosoproline Using [^^ N] nitrate, it was shown that pre-loading 
subjects with ascorbic acid in addition to administering ascorbic acid with nitrate 
and proline reduced incorporation of [^^ N] nitrate into nitrosoproline by 81% 
These studies clearly show that there is the potential for intragastric 
nitrosation to occur in human subjects ingesting nitrate in the presence of 
nitrosatable chemicals in the diet and ascorbic acid can inhibit intragastric 
nitrosation.
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6.1 Nitrate utilisation.
Since the Second World War, nitrogenous fertilizer use has increased 
considerably as a result of intensive farming methods (Fig 6.1). Both the increase 
in the nitrate content of ground water and the increase in the nitrate content of 
some vegetables during 1960s to 1970s have been attributed to the increased use 
of nitrogenous fertilizers In the United Kingdom the majority of public water 
supplies have less than the acceptable level of nitrate (<50 mg L'*) as legislated 
by the European Community. However in 1985, just over 1 % of the tap water 
samples in the UK exceeded 50 mg L'* of nitrate and <0.01 % received water 
exceeding 80 mg L'  ^ A study in Oxford and SB Thames region demonstrated 
that drinking water contributed to approximately 2 0  % of nitrate intake 
suggesting that the water supply may be an important additional source of nitrate. 
Nitrates and nitrites are used curing agents for meat and both nitrate and nitrite 
concentrations in meat have declined since 1960 In the United Kingdom, 
dietary estimates from the Total Diet Study show that average dietary nitrate 
intake in 1979 was approximately 61 mg per day and approxiamtely 53 mg 
per day in 1997 with the vegetarians consuming 93 mg per day
6.2 Social Class and salivary nitrate/nitrite: a possible link
between cardio-oesophageal adenocarcinoma.
Forman compared the salivary nitrate and nitrite concentrations in areas of 
low gastric cancer incidence (Oxford, Canterbury and Eastbourne) to areas of high 
gastric cancer incidence (Hartlepool, Sunderland, Bangor and Llandudno). Both 
the salivary nitrate and nitrite concentrations were higher in the more affluent 
regions (with lower incidence), compared to the less affluent regions (with high 
incidence) in both the male and female population. They also noted a significantly 
higher salivary nitrate and nitrite concentrations in the higher social class 
compared to the lower social classes within the region of low gastric cancer 
incidence Unlike distal gastric cancer which is a disease of the lower social 
class, adenocarcinoma of the cardia and oesophagus have no such distinctions and
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some studies point to an increased risk of these cancers in higher social standings 
(see 2 . 6  above).
The rise in incidence of the oesopahgeal and cardia adenocarcinoma is 
apparent 20 to 30 years after the increased utilisation of nitrogenous fertilisers 
which is the accepted time scale between exposure to a carcinogen and 
development of cancer (Fig 6.1). The findings of non-cardia gastric cancer 
occuring more commonly in the lower social class whereas cardia and 
oesophageal adenocarcinoma may be occuring more often in the middle class 
subjects hint at the potential role of dietary nitrate in the pathogenesis of cardia 
and oesophageal adenocarcinomas.
6.3 The pathophysiological process leading to adenocarcinoma 
of the oesophagus and cardia occurs in the lumen of the 
distal oesophagus and the cardia.
The cardia is a unique site where the environment changes from the neutal 
pH of the oesophageal lumen to an acid pH of approxiamtely 2.5 This is also 
the site where salivary nitrite, derived from the entero salivary recirculation of 
dietary nitrate, first meets acidic gastric juice. On contact with the acidic gastric 
juice, nitrite in saliva becomes protonated to nitrous acid which forms nitrosating 
species such as N2O3 and NO^ which can react with nitrosatable amines to 
generate fV-nitrosamines (Fig 6.2). This acid-dependent nitrosation is 
catalysed by the thiocyanate anion (SCN‘), present in the human saliva and gastric 
juice, by forming the nitrosating species, NOSCN. The major inhibitor of the 
nitrosation reaction in the human stomach is ascorbic acid which is actively 
secreted into gastric juice. The nitrosating species are rapidly reduced to nitric 
oxide by the ascorbic acid which itself is oxidised to dehydroascorbic acid in the 
process. When nitrite is present in excess of ascorbic acid, nitrosating agents can 
react with nitrosatable substances to form Wnitroso compounds. In subjects 
without gastro-oesophageal reflux, the cardia is presented with the greatest nitrite 
load and ascorbic acid will be the most depleted in this region, a condition likely 
to favour the formation of the carcinogenic Wnitroso compounds which may 
possibly lead to the development of adenocarcinoma of the cardia.
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In subjects with Barrett’s oesophagus, reflux of the gastric juice into the 
distal oesophagus will shift the nitrosative chemistry proximally into the Barrett’s 
segment and the formation of W-nitroso compounds will potentially occur in the 
lumen of the distal oesophagus which may lead to the development of 
oesophageal adenocarcinoma.
In addition to the generation of intraluminal Wnitroso compounds, nitric 
oxide is generated at the cardia from the reaction between gastric juice ascorbic 
acid and salivary nitrite in subjects without reflux In subjects with Barrett’s 
oesophagus the process is likely to occur more proximally in the distal 
oesophagus during periods of acid reflux. Nitric oxide formed locally may then 
diffuse into the surrounding epithelium and shift the nitrosative stress 
intracellularly where in the presence of oxygen, it can form the nitrosating agent 
N2O3 and generate A-nitrosamines intracellularly and subsequent DNA
alkylation. Furthermore nitric oxide inhibits key DNA repair enzymes 
which may lead to mutagenesis and carcinogenesis at the cardia and the distal 
oesophagus.
6.4 Aims of the thesis.
The aims of this thesis were:
1. To study the nitrosation chemistry at the cardia in asymptomatic subjects 
without gastro-oesophageal reflux to test the hypothesis that in subjects 
without reflux the cardia is the site with optimal conditions for the formation 
of W-nitroso compounds.
2. To study the nitrosation chemistry in patients with Barrett’s oesophagus and 
test the hypothesis that the optimal conditions for W-nitroso compound 
formation will be in the Barrett’s segment during gastro-oesophageal reflux.
3. To study nitric oxide production in patients with Barrett’s oesophagus during 
acid reflux.
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Fig 6.2: Nitrosation chemistry in the upper gastrointestinal tract.
Nitrite in saliva is swallowed and enters the gastric juice where it forms nitrous 
acid (HNO2) and nitrosating species (* above). Thiocyanate (SCN"), present in 
saliva and gastric juice, catalyses the acid nitrosation. Ascorbic acid (AA), in 
gastric juice competes with the secondary amines for the nitrosating species which 
it reduces to nitric oxide and the AA is oxidised to dehydroascorbic acid. When 
AA is depleted, this enables the nitrosating species to react with secondary amines 
to generate A-nitrosamines. The nitrosamines can diffuse into the cell and alkylate 
DNA. The nitric oxide formed intraluminally may diffuse into the surrounding 
epithelium and can cause DNA damage through DNA deamination, DNA 
alkylation and inhibiting DNA repair enzymes.
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7.1 Introduction.
The experiments for this thesis required apparatus that had the capability of 
measuring chemicals in the lumen of the human upper gastrointestinal tract at 
several different levels simultaneously. The equipment needed to be small in order 
to provide reasonable comfort for the study subjects. The microdialysis probes 
provided all the prerequisite conditions for the experiments. The following 
sections outline the micodialysis probe, its principle and some of its applications 
and technical considerations when utilising the microdialysis probe for sampling 
chemicals of interest.
All chemicals used in the studies were obtained from Sigma-Aldrich 
Company Ltd., Gillingham, Dorset, UK.
7.2 Microdialysis.
The principal use of the microdialysis prohe is for sampling the extracellular 
chemicals. Analysis of the extracellular environment of the dog brain was first 
performed in the 1960s where a ‘push-pulT technique in which fluid was infused 
and withdravm simultaneuosly through two separate cannulae Hollow fiber 
microdialysis probe was first developed by Ungerstedt and with further 
development it has become possible to implant the probe into tissues such as the 
brain, subcutaneous tissue and muscles amongst other applications 
Microdialysis probes have been used to measure luminal concentrations of 
chemicals in the rat uterus chemicals in the blood stream and the
intestinal lumen
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7.2.1 Microdialysis Probes.
There are a number of different types of microdialysis probes All work 
on the principle of dialysing chemicals across a semipermeable membrane. 
Chemicals with low molecular mass diffuse into or out of the probe depending on 
the concentration gradient between the surrounding medium and the fluid used to 
perfuse the probes.
The probes we utilised for the experiments were the concentric type CMA 
flexible microdialysis probes (MAB 7.8.10, Biotech Instruments Ltd, Herts, UK) 
(figs 7.1 and 7.2). The overall length of the probe is 2.2 cm with a maximum 
diameter of 2 mm. The dialysing membrane is 10mm with a 15 kD molecular 
weight cut-off made of polyether-sulphone. The dead space of the inlet and outlet 
tubing is 25 pL. The probe has a fine 1 metre-long inlet (afferent) tube leading to 
the microdialysis chamber and a similar outlet (efferent) tube returning from this 
chamber. The inlet tube is attached to a microdialysis pump (Univentor 864 
microdialysis syringe pump, Biotech Instruments Ltd., UK) capable of driving 6  
syringes simultaneously at a pre-selected rate (fig 7.3). The microdialysis probes 
are perfused with distilled water degassed with helium through the afferent tubing. 
Due to the equilibration across the semipermeable membrane, the concentration of 
solutes in the sample obtained from the efferent tubing provides a measure of their 
concentration in the test solution. There is a lag time which is depending on the 
rate of perfusion of the microdialysis probe for the perfusate to return from the 
microdialysis chamber to the end of the efferent tube.
7.2.2 Terminology.
The solution into which the microdialysis probe was immersed will be 
termed the test solution (or gastric juice). The fluid used to perfuse the 
microdialysis probes will be termed the perfusate. The samples collected from the 
efferent tube following microdialysis sampling will be termed the microdialysis 
product (also known as the dialysate). The concentrations of the chemicals 
recovered in the microdialysis product relative to the concentrations of the 
chemicals in the test solution will be termed the relative recovery (or recovery) 
and is given as a percentage of the concentrations in the test solution.
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7.2.3 Sampling parameter considerations.
There are a number of technical factors that need to be considered when 
sampling with a microdialysis probe. The microdialysis sampling is rarely 
performed under conditions of equilibrium and the final sample represents a 
fraction of the actual concentration in the medium sampled. This is known as the 
relative recovery usually expressed as a percentage of the original sample 
concentration. For a given set of conditions the relative recovery of the chemical 
of interest will be constant and is determined by its concentration gradient. In turn 
the relative recovery is determined by a number of factors which include the 
following
1. The rate of perfusion: The flow rate utilised usually ranges between 0.5 -
5 pL min'^ The slower the perfusion rate the greater the relative recovery 
of the analyte of interest as the process is diffusion dependent. A higher flow 
rate may increase the hydrostatic pressure sufficiently inside the probe, which 
is affected by the probe cross-sectional area, resulting in net extravasation of 
fluid out of the probe reducing the diffusion of analyte into the probe.
However the limitation of the slower perfusion rate is the smaller volume of 
dialysate available for analysis which requires highly sensitive analytical 
methods. Provided that the temporal resolution is not critical then the 
collection interval can be increased to increase the yield.
2. The surface area of the semipermeable membrane: The greater the surface 
area the greater the relative recovery and this can compensate for selecting a 
higher perfusion rate.
3. The membrane and analyte properties: In addition to the physical size of the 
chemical of interest (analyte) and the pore size of the membrane, properties of 
both the membrane and the analyte may lead to physical or chemical 
interactions. The membrane is usually hydrophilic therefore the pores are filled 
with aqueous solution and lipophilic substances show lower relative 
recoveries than chemicals that are non-lipophilic. Electrostatic or adsorption 
interactions can also occur between the membrane and the analyte.
4. The composition and temperature of the perfusate may alter the recovery of 
the analyte: For example, using hypotonic and isotonic perfusates at both 24°C
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and 38°C the recovery of paracetamol from rat cerebral cortex was lower in 
both the hypotonic perfusates particularly at 38°C compared to isotonic 
perfusates with similar recoveries at 24°C and 38°C Generally, higher 
temperature increases recovery due to greater diffusion.
5, Physiological processes such as diffusion of the analyte in the medium, 
transport, uptake, release, binding and metabolism: Under certain 
experimental conditions, alterations in the extracellular environment by 
removal/addition of the chemicals of interest may alter the physiological 
process.
7.2.4 Setting up the microdialysis probe.
In order to perfuse the microdialysis probes with dialysing fluid, it is 
necessary to connect the inlet tubing to a syringe with an adapter. The adapter was 
made by sawing off the tip of a 21 gauge hypodermic needle (Becton Dickinson 
UK Ltd) to 1cm length, making sure that the bore was circular and not 
compressed as this will affect the perfusion pressure of the probes. The 
connection tubing on the inlet tube supplied with the microdialysis probes was 
attached to the adapter.
A 5 mL plastic syringe (Beckton Dickinson UK Ltd, Roborough, Plymouth, 
UK) was filled with double-distilled, deionised water degassed with helium and 
gently tapped until all gas bubbles were eliminated from the syringe. The syringe 
was then connected to the modified needle adapter. The syringes with the 
microdialysis probes attached were then mounted on the microdialysis pump and 
perfused at a preset rate. The probes are ready to use when droplets of fluid, the 
dialysate appears from the outlet tube.
The microdialysis membrane is fragile and must be handled very carefully. 
If the tip is bent as a result of handling mishap then the probe should be discarded.
6 6
Fig 7.1: The flexible CMA microdialysis probe.
The microdialysis probe is of a concentric design (see fig 7.2). 
The white semipermeable tip is made of polyethersulphone with a 
molecular cut-off of 15k Dalton.
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Fig 7.2: The concentric microdialysis probe tip.
The perfusate (blue arrow) enters the probe tip via the inner tube and 
washes out the chemicals small enough to diffuse through the 
semipermeable membrane via the outer tube thus maintaining the 
diffusion gradient.
6 8
Fig 7.3: Univentor 864 microdialysis syringe pump 
(Biotech Instruments Ltd., UK)
The syringe drive is capable of driving 6 syringes simultaneously at a 
low flow rate. The figure also illustrates the 21G hypodermic needle 
adapted for attaching the microdialysis afferent tubing.
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7.2.5 Collecting the microdialysis products.
The dialysate was collected in a 300 pL glass chromatography vial (03- 
CVG, Chromacol Ltd., Herts, UK). For nitrite and thiocyanate analysis, the 
microdialysis product was collected in a chromatography vial containing 20 pL of 
1 M NaOH. This prevented the loss of nitrite which occurs at highly acidic pH 
leading to an underestimate of the nitrite concentration. For ascorbic acid and total 
vitamin C analysis, the microdialysis product was collected in 20 pL of equal 
volume (1:1) 2% m/v metaphosphoric acid / 0.5 % m/v sulphamic acid (M/S) 
which acted as a stabilising solution. One half of the product was then added to an 
equal volume of M/S further diluting the product by a factor of 2. This sample 
measured the ascorbic acid. The other half of the product was added to an equal 
volume of M/S plus 12 mg mL"' dithiothieitol (DTT) (see 7.3.1). The DTT 
reduces oxidised ascorbic acid back to its reduced form and enables the estimation 
of the total vitamin C (which represents oxidised + reduced ascorbic acid).
7.3 Analysis of samples collected by microdialysis.
The microdialysis experiments are limited by the small volumes of dialysis 
products produced in a given experiment and thereby limited by the sensitivity of 
the assay method. Such methods must be able to handle small sample volumes 
often in the nano to microlitre ranges with concentrations as low as pico to 
nanomoles.
High performance liquid chromatography (HPLC) combined with various 
detectors is well-suited to the analysis of samples obtained from microdialysis 
experiments. We used the HPLC coupled to an electrochemical detector to 
measure the ascorbic acid and the total vitamin C concentrations.
Nitrite and thiocyanate concentrations were determined using colorimetric 
methods as the concentrations of theses chemicals found in the human upper 
gastrointestinal tract are easily detectable by the methods described below.
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7.3,1 Determination of ascorbic acid and total vitamin C by 
high performance liquid chromatography.
The ascorbic acid and total vitamin C levels were measured by high 
performance liquid chromatography employing an electrochemical detector as 
described by Schorah and colleagues The instruments comprised of an 
automated sample injector (Shimadzu SIL-IOAD, Shimadzu Corporation, Japan) 
with a 50 pL loop, a pump (Shimadzu LC-IOAT VP), an electrochemical detector 
(Shimadzu L-ECD-6 A) set at 350 mV and 0.2 pA and an integrator (Shimadzu C- 
R3 A Cliromatopac). Ascorbic acid was separated using the reverse-phase, ion-pair 
chromatography on Phenomenex 5 pm C l8  Luna 150 x 4.6 mm analytical column 
(Phenomenex, Macclesfield, Cheshire, UK) protected by a guard column 20x3  
mm (Anachem, Luton, Bedfordshire, UK) hand-packed with Lichroprep RP-18 
(25-40 pm, BDH-Merck Ltd., Poole, Dorset, UK). A precolumn (Phenomenex 
Security guard CIS ODS Octadecyl filters 4 x 3  mm (i.d.)) was also used. The 
mobile phase consisted of 0.1 M sodium acetate containing 0.1 M octylamine and 
15 % acetonitrile with a final pH of 4,3, adjusted with glacial acetic acid. The 
flow rate was 0.8 mL min'' and the retention time of ascorbic acid was 
approximately 3 minutes.
An aqueous stock standard solution (1 mg mL"') was prepared by adding 
5ml of ascorbic acid stock solution to 5 mL of DTT (3.5 mg mL"'). Working 
standards of 5 and 10 pg mL"' were prepared by diluting appropriate volumes of 
the stock solution on the day of analysis.
The autosampler was programmed to inject 25 pL of standards, quality 
control and samples. The first injection was a DTT solution (3.5 mg mL"') to 
remove oxidising sites on the column. Subsequent standards and samples were 
procesessed with standards and quality controls occuring every tenth sample, A 
blank sample of 1:1 metaphosphoric acid: sulfamic acid (M/S) diluted 1 in 2 using 
double-distilled water was also processed for each run and subtracted from the 
measured ascorbic acid of the samples as the M/S solution had a positive ascorbic 
acid reading when analysed. No more than 80 samples were analysed in a single 
run to ensure that ascorbic acid degradation was minimal as standard ascorbic acid 
samples were stable under the laboratory conditions over this time period.
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The coefficient of variation for ascorbic acid concentrations between 3,5 pM to 57 
pM using this method was < 2.2 %.
i) Metaphosphoric acid/sulphamic acid 1:1 solution (M/S)
Metaphosphoric acid 5.6 g was dissolved in distilled water to make up a 
total volume of 100 mL. Sulphamic acid 0.5 g was dissolved in distilled water to 
make up a total volume of 100 mL. Equal volumes of metaphosphoric acid and 
sulphamic acid were mixed to make up the 1:1 M/S solution.
ii) Metaphosphoric acid/sulphamic acid 1:1 solution plus dithiothreitol (M/S + 
DTT)
Dithiothreitol (DTT) is a reducing agent and allows the estimation of the 
total vitamin C in a given specimen by reducing dehydroascrobic acid (oxidised 
ascorbic acid) back to ascorbic acid. Total vitamin C measured by HPLC is the 
sum of reduced ascorbic acid + dehydroascorbic acid. Thirty milligram DTT was 
added to 2.5 mL M/S solution to make up the M/S + DTT solution (12mg mL"' 
DTT in M/S).
7.3,2 Determination of nitrite.
The nitrite (NO2') concentration was determined colorimetrically using the 
modified Greiss reaction
i) Greiss Reagent
The modified Greiss reagent was synthesized from the following chemicals: 
10 g sulphanilamide, 250 mg A-1 -naphthylethylene diamine hydrochloride, 60 
mL concentrated hydrochloric acid and 475 mL distilled water (0.019 g mL"' 
sulphanilamide and 0.47 g mL"' A-1-naphthylethylene diamine hydrochloride).
ii) Sodium nitrate standards
A stock solution of 100 mM sodium nitrite (NaN0 2 ) was made up by 
dissolving 3.45 g NaN0 2  in 500 mL of distilled water. The stock NaN0 2  solution
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was diluted to 1 mM using phosphate buffered saline (PBS). The 1 mM NaNOz in 
PBS was further diluted using PBS to make the following concentrations of 
‘standards’ 10, 25, 50, 75 and 100 pM.
in) Colorimetric determination o f nitrite
A  96-well plate was used to plate the samples for determination of the nitrite 
concentration.
1 2 3 4 5 6 7 8 9 10 11 12
A DistilledH2 O lOiaMNOj' 25hMN02’ 50iaM NOy 75|.iMN02’ lOOnMNOf
B
C
D
E
F
G
H
The first row of the plate was used for nitrite standards as indicated in the diagram, 
distilled water heing equivalent to 0 pM NaNOz. The remainder of the wells were 
used for plating samples for nitrite determination. Using a pipette 60 pL of 
standards and samples were plated into each well. Sixty microlitres of Greiss 
reagent was added to each well followed by 60 pL of distilled water to each well. 
The plate was left to develop at room temperature for 20 minutes. Colorimetric 
analysis was performed using a 540 mn filter. The concentration of nitrite (NO2') 
can be deduced from the NO2' standard curve (fig. 7.4).
The co-efficient of variation for the colorimetric determination of the nitrite 
concentrations up to 100 pM was < 3.5%.
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7,3.3 Determination of thiocyanate.
The thiocyanate (SCN") concentration was determined colorimetrically 
using ferric nitrate known as the Bowler method
i) Ferric nitrate in nitric acid solution
Two-molar nitric acid was prepared in a fume cupboard by diluting 31.5 mL 
concentrated nitric acid with distilled water to make up a 250 mL solution. Eighty 
grams of ferric nitrate was dissolved in the 250 mL 2 M nitric acid solution. The 
solution was further diluted with distilled water to a total volume of 500 mL and 
then filtered using a filter paper. The reagent was kept in a brown bottle at 4°C 
until use when an aliquot was warmed to room temperature.
ii) Thiocyanate Standards
A  stock solution of 1 M sodium thiocyanate (NaSCN) was made by 
dissolving 8.12 g NaSCN in lOOmL of distilled water. Standard NaSCN solutions 
of 50,100, 200, 500 and 1000 pM were prepared by diluting a stock solution of 1 
M NaSCN using distilled water.
75
in) Colorimetric determination of thiocyanate
A  96-well plate was used to plate the samples for determination of the 
thiocyanate (SCN") concentration.
1 2 3 4 5 6 7 8 9 10 11 12
A Distilled H2 O 50pM SCN' lOOgMSCN'
200|aM
SCN'
500pM
SCN' ImM SCN'
B
C
D
E
F
G
H
The first row of the plate was used for SCN" standards as indicated in the diagram, 
distilled water being equivqlent to 0 pM SCN". Using a pipette, 100 pL of 
standards and samples were plated into each well. One hundred pL of ferric 
nitrate in nitric acid solution prepared as described previously was added to the 
wells containing the standards and samples. Colorimetric analysis was performed 
immediately after adding the ferric nitrate reagent using a 450 nm filter. The 
concentration of SCN" can be deduced fiom the SCN" standard curve.
The coefficient of variation for the colorimetric determination of the 
thiocyanate concentration up to 1000 pM was < 4%.
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7.3.4 Determination of nitrate.
Serum nitrate (NO3") was determined using the Aspergillus niger nitrate 
reductase to reduce the nitrate to nitrite and analysed colorimetrically using the 
Greiss reagent as outlined above.
i) Nitrate standards
A stock solution of 100 mM sodium nitrate (NaNOs) was made up by 
dissolving 4.25 g NaNOs in 500 mL of distilled water. This stock soultion was 
kept in a stoppered brown glass bottle and kept at 4°C. The stock NaNOa solution 
was diluted to 1 mM using phosphate buffered saline (PBS). The 1 mM NaNOa in 
PBS was further diluted using PBS to make the following concentrations of 
‘standards’ 10, 25, 50, 75 and 100 pM.
ii) Nitrate reductase reaction buffer
The reaction buffer was made up from the following chemicals:
a) P-Nicotinamide dinucleotide phosphate (NADPH)
Ten millilitres of distilled water was added to 50 mg NADPH. Eight 
hundred microlitre aliquots were pipetted into Bppendorf tubes to give 4 mg in 
800 pL. Unused NADPH was stored at -20°C until subsequent use.
b) Flavin adenine dinucleotide (FAD)
Six millilitres of distilled water was added to 250 mg FAD. Eight hundred 
microlitre aliquots were pipetted into Eppendorf tubes to give 33.2 mg in 800 pL. 
Unused FAD was stored at -20°C until subsequent use.
c) Nitrate reductase
Foui* hundred and fifty microlitres of distilled water was added to 10 Units of 
Aspergillus niger nitrate reductase and mixed gently. Eighty microlitre aliquots 
were pipetted into Eppendorf tubes. Unused nitrate reductase was stored at -20 
until subsequent use.
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e) Distilled water
The reaction buffer was made up after plating the samples and immediately before 
use. Eight hundred micro litres each of NADPH, FAD and PBS and 1520 pL of 
distilled water were mixed with 80 pL nitrate reductase at room temperature.
Hi) Colorimetric determination of nitrate
The standards and samples were plated in two separate 96-well plates as 
shown below.
PLATE I: Total (Nitrate + Nitrite) Concentrations
1 2 3 4 5 6 7 8 9 10 11 12
A Distilled H 2 O lO^M NOz" 25hMN02' 50|aM NO 2 ' 75nM  NOz" lOO^iMNOz'
B Distilled H2 O lOnMNOg' 25pM  NOs" 50nM  NO 3 ' 75 i^ MN03" lOOnMNOs'
C
D
E
F
G
H
The first row of the plate was plated with nitrite (NO2') standards and the second 
row with nitrate (NO3') standards. Distilled water was equivalent to OpM NO2’ 
and NO3'.
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PLATEII:Nitrite Concentration
1 2 3 4 5 6 7 8 9 10 11 12
A Distilled H2 O 10|^M N O 2 ' 25hM N 02 ‘ 50pM  N o y 75|xM NO 2 ' lOOiiM NOa"
B
C
D
E
F
G
H
The first row of the plate was used for nitrite standards as indicated in the diagram,
distilled water being equivalent to 0 pM NaNÛ2. The remainder of the wells were
used for plating samples for nitrite determination.
The following steps were followed:
1) Add 60 pL of standards and samples as shown in the diagrams for plate I and II.
2) Add 30 pL of reaction buffer to each well of plate I.
3) Add 30 pL of distilled water to each well of plate II.
4) Both plates were incubated at 25°C in the dark for 2 hours.
5) Add 60 pL of Greiss reagent to each well of both plates.
6 ) Add 30 pL of distilled water to each well of both plates.
7) Leave at room temperature for 20 minutes.
8 ) Read plates I and II using a colorimeter with a 540 nm filter.
9) The nitrate concentration can be calculated from nitrite concentration in plate 
I (nitrite measured = nitrite + reduced nitrate) minus nitrite concentration in 
plate II (only nitrite). This calculated nitrate is then compared to the nitrate 
standard curve to obtain the actual concentration correcting for the efficiency 
of the nitrate to nitrite reduction by the nitrate reductase (reduction efficiency 
= NO3' standard / NO2' standard in plate I).
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CHAPTER EIGHT
IN-VITRO STUDIES: 
VALIDATION 
OF
MICRODIALYSIS PROBES
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8.1 Introduction
Before using the microdialysis probes in humans it was necessary to 
validate and construct the equipment for measuring the chemicals involved in 
nitrosation reaction in the lumen simultaneously at different levels of the human 
upper gastrointestinal tract. The initial experiments were performed using 
individual probes and later experiments were performed using multiple 
microdialysis probes assembled in a nasogastric tube which was used in the 
human subjects.
8.2 Effect of perfusion rate on recoveries of nitrite, thiocyanate, 
ascorbic acid and total vitamin C.
8.2.1 Methods.
The experiments were performed with the microdialysis probe suspended in 
a beaker, containing the chemical of interest, which was placed in a water bath set 
at 37®C. The beaker samples were stirred continuously with a magnetic stirrer.
The microdialysis probe was placed in individual solutions, pH adjusted at 37°C:
•  200 pM NaNOz adjusted to pH 9 with NaOH
•  500 pM NaSCN in pH 1.5 HCl
•  200 pM ascorbic acid in pH2.5 HCl.
In the nitrite experiment, the microdialysis probe was perfused with distilled water 
adjusted to pH 9 with NaOH. In the thiocyanate experiment the microdialysis 
probe was perfused with distilled water. In the ascorbic acid experiments, the 
microdialysis probe was perfused with pH 2.5 HCl,
The concentration of the microdialysis product was compared to the average 
concentration of the chemicals in the samples taken from the beaker at 0  minutes 
and 40 minutes, corresponding to the beginning and the end of the experiment.
The time of commencing and completing the collection of the microdialysis 
product was delayed according to the lag-time for the dialysate to travel the length 
of the outlet tubing. This was 15, 10, 7.5, 5, 3.75 and 2.5 minutes for 0.1, 0.15, 
0.2, 0.3, 0,4 and 0.6 mL h r '\ The dialysate was collected in a 300 pL glass
8 2
chromatography vial (03-CVG, Clnomacol Ltd., Herts, UK) containing 20 pL of 
IM NaOH for nitrite and thiocyanate samples and 20pL of M/S for ascorbic acid 
and total vitamin C samples.
8.2.2 Data Analysis.
The results are given as percentage recovery -  also known as the relative 
recovery compared to the original test solution. This was calculated as follows:
[X] in microdialysis product FXIo beaker + [XLo beaker X 1 0 0 %
where [X] is the concentration of the chemical of interest, X; [X]o beaker is the 
concentration of X at 0 minutes; [X]4o beaker is the concentration of X at 40 
minutes.
8.2.3 Results.
The concentration of each compound in the test solution remained stable 
during the study. The recoveries for nitrite were 100, 92, 89, 74, 6 8 , 50 %; for 
thiocyanate 97, 95, 95, 84, 8 8  and 79 %; for ascorbic acid 83, 74, 67, 53, 46 and 
32 % and for total vitamin C 85, 78, 6 6 , 56, 53 and 39 % at the respective 
perfusion rates of 0.1, 0.15, 0.2, 0.3, 0.4 and 0.6 mL hi'"^  (fig. 8.1)
8.2.4 Conclusion.
The experiment demonstrated that the relative recovery of a chemical was 
inversely proportional to the rate of perfusion of the microdialysis probe.
Recovery of thiocyanate appears to be affected to a lesser degree than the 
recovery of nitrite, ascorbic acid and total vitamin C. The molecular weight of 
NaSCN is approximately 81 whereas NaNOz is 69 and that of ascorbic acid is 176. 
The possible explanations for the greater recovery of NaSCN, with a higher 
molecular weight than NaNOz, include the differences in pH under which the 
experiments were conducted or the concentrations of the analyte used in the 
experiments, the fonner being the most likely explanation (see 8.6.3).
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8.3 Effect of pH of the test solution being examined on the pH of
the dialysate.
Gastric juice is highly acidic with its pH varying between 1 and 4. We 
therefore investigated the effect the pH of the test solution had on the pH of 
microdialysis product sample. The pH of the microdialysis product will depend 
upon the pH of the perfusate, the pH of the test solution and the recovery of 
hydrogen ions (H^).
8.3.1 Methods.
In order to examine the effect of perfusing the microdialysis probe with a 
pH 7 solution while dialysing acidic solutions on the pH of the microdialysis 
product, a microdialysis probe was placed in a beaker of pH 1.0 HCl and another 
in a beaker of pH 2.0 HCl. The microdialysis probes were perfused at 0.1 mL hr"^  
for 80 minutes with distilled water adjusted to pH 7.0 with NaOH. The H  ^
concentration of the microdialysis product and of the acid in the beaker was 
measured by titration to pH 7 with NaOH.
A further experiment was performed to investigate the reverse situation 
where the microdialysis probe was dialysed with an acidic solution while 
dialysing a pH 7 solution. The microdialysis probe was placed in a beaker 
containing distilled water adjusted to pH 7 at room temperature and perfused with 
pH 2.5 HCl for 18 hours at 0.1 mL hi*'^  to produce a sufficient volume of 
microdialysis product for accurate pH measurement.
8.3.2 Result.
In the former experiment where the microdialysis probe was perftised with 
pH 7 soultion, the recovery of H^ in the microdialysis product was 96 % and 92 % 
in the pH 1 and pH 2 experiments respectively giving a calculated pH of 1.03 and 
2.07 respectively.
In the experiment studying the effect of perfusing the microdialysis probe 
with pH 2.5 HCl, the pH in the test solution fell from 7.0 to 6.09 over the time of
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the experiment. The pH of the microdialysis product was 5.9. Conversion of pH to 
H^ concentration for the dialysis fluid at pH 2.5 and the microdialysis product pH 
of 5.9 indicates 99.96 % equilibration of H^ across the dialysis membrane.
8.3.3 Conclusions.
The above experiments indicated that thr oughout the range of stomach pH 
associated with acid nitrosation (pHl- 4) the pH of the microdialysis product was 
virtually the same as the pH of the solution in which the probe was placed. This 
was the case whether the pH of the solution perfused was 2.5 or 7. This indicates 
very rapid equilibration of the H^ ions across the dialysate membrane due to their 
small molecular size.
8.4 Effect of pH of the test solution on the recovery of various 
chemicals.
These experiments were performed to determine whether the effect of the 
pH of the test solution had any effect on the recovery of the chemicals of interest. 
The experiments were performed in both aqueous solutions and in human gastric 
juice obtained from subjects undergoing gastric acid secretion studies.
8.4.1 Methods.
i) Nitrite and Thiocyanate
The effect of pH on the recoveries of nitrite and thiocyanate was 
investigated using aqueous solutions of 200 pM NaNOz or 500 pM NaSCN at pH
1.5, 2.5, 3.5, 5 and 7. Two experiments using four microdialysis probes were 
performed for each pH value. The pH of the test solutions were adjusted at 37°C 
using HCl or NaOH. The beaker containing the test solutions was immersed in a 
water-bath set at 37°C. The probes were perfused with distilled water at 0.15mL 
hr"\
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The experiments were repeated with gastric juice instead of aqueous 
solutions. Three experiments were performed at pH 1.5 and 7 and single 
experiments at pH 2.5, 3.5 and 5 using four microdialysis probes per experiment. 
Nitrite and thiocyanate were analysed colorimetrically as described previously.
ii) Ascorbic acid and total vitamin C
Two experiments each, using four- microdialysis probes, were performed 
using aqueous solutions of 200 pM ascorbic acid adjusted to pH 1.5, 2.5, 3.5, 5 
and 7 at 37 °C using HCl or NaOH. The microdialysis probes were perfused with 
distilled water at 0.15 mL hr'*. The experiments were repeated with human gastric 
juice, pH adjusted using NaOH.
8.4.2 Data analysis.
All data are presented as mean + S.D. Coefficient of variation is expressed 
as S.D./mean.
8.4.3 Results. 
Aqueous solutions
i) Nitrite and thiocyanate
The mean nitrite recovery was slightly reduced at the lower pH values of 
pHl.5 and 2.5 being 73 % (±2.3) and 83 % (± 3.1) respectively compared with 
8 8  % (± 2,4), 90 % (± 2.7) and 8 8  % (± 3.0) respectively for pH 3.5, 5 and 7 (Fig 
8.2). The intra-probe coefficients of variation were < 6 %, < 5 %,  < 5 %,  < 6 % 
and <4  % at pH 1.5, 2.5, 3.5, 5 and 7 respectively.
Thiocyanate recoveries were relatively unaffected by pH being 93 % (± 1.1), 
91 % (± 2.6), 91 % (± 2.9), 8 8  % (± 3.5) and 89 % (± 1.5) at pH 1.5, 2.5, 3.5, 5 
and 7 respectively (Fig 8.3). The intra-probe coefficients of variation were 
< 2 %, < 6  %, < 5 %, < 6  % and < 3 % at pH 1.5, 2.5, 3.5, 5 and 7 respectively.
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ii) Ascorbic acid and total vitamin C
The ascorbic acid recoveries at pH 1.5, 2.5, 3.5, 5 and 7 were 71 % (± 5.2), 
69 % (± 5.8), 69 % (± 4.2), 70 % (± 2.0) and 6 6  % (± 2.6) respectively (Fig. 8.4); 
for total vitamin C recoveries were 73 % (± 4.4), 74 % (± 4.8), 77 % (± 6 .6 ), 78 % 
(± 4.6) and 69 % (± 2.5) respectively (Fig. 8.5).
The intra-probe coefficients of variation were < 10 %, < 13 %, < 7 %, < 6  %, 
< 4 % for ascorbic acid and < 12 %, < 11 %, < 11 %, < 8  %, < 5 % for total 
vitamin C at pH 1.5, 2.5, 3.5, 5 and 7 respectively.
Gastric Juice
i) Nitrite and thiocyanate
The nitrite recoveries were similar to those of the aqueous solution, showing 
slightly lower recoveries at pH 1.5 with 64 % (± 6 .8 ) and pH 2.5 with 78 % (± 3.8) 
versus the higher pH 3.5, 5 and 7 with recoveries of 90 % (± 2.0), 8 6  % (± 2.0) 
and 85 % (± 4.1) respectively (Fig 8.2). The thiocyanate recoveries in gastric juice 
were lower than the recoveries in the aqueous solutions. The recoveries were 
72 % (± 2.8), 79 % (± 2.4), 77 % (± 2.2), 75 % (± 1.8) and 70 % (± 2.8) at 
increasing pH 1.5,2.5, 3.5, 5 and 7 respectively (Fig 8.3).
ii) Ascorbic acid and total vitamin C
The ascorbic acid recoveries from gastric juice at pH 1.5,2.5, 3.5, 5 and 7 
were 62 % (± 2.8), 67% (± 3.2), 63 % (± 2.4), 62 % (± 4.0) and 64 % (± 2.2) 
respectively; for total vitamin C recoveries were 6 6  % (± 3.8), 6 8  % (± 3.0), 72 % 
(± 4.6), 70 % (± 4.4), 70 % (± 3.6) respectively (Fig 8.4 and 8.5).
8.4.4 Conclusions.
Using a perfusion rate of 0.15 mL hr'* the recovery rate of each compound 
at 37°C was > 60 %. The recovery in aqueous solution was slightly higher than in 
gastric juice, particularly for the thiocyanate with a typical difference of > 1 0  %; 
for nitrite, ascorbic acid and total vitamin C the differences were typically < 10 %.
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The recovery of nitrite from both aqueous solutions and gastric juice at pH 1.5 and
2.5 was slightly reduced compared to that from pH 3.5, 5 and 7.
The microdialysis provided good reproducibility for the recovery of the 
chemicals of nitrosation in aqueous solutions with the intra-probe coefficient of 
variation being < 6  %, < 6  %, < 13 % and < 12 % for nitrite, thiocyanate, ascorbic 
acid and total vitamin C respectively. This indicated that the microdialysis probes 
are reliable tools for the measui'ement of the chemicals of nitrosation in the human 
upper gastrointestinal tract.
8.5 Elucidating the cause for reduced nitrite recovery at pH 1.5 
and 2.5. Part I: permeability of the microdialysis tubing to 
nitric oxide.
The above experiments demonstrated that nitrite recovery in aqueous 
solution and gastric juice was reduced at pH 1.5 and to a lesser extent at pH 2.5 
compared to higher pH values. When nitrite is acidified it produces nitrous acid 
and about 1 % molar equivalent of the nitrous acid exists in the form of nitric 
oxide. Nitric oxide is able to pass through various synthetic polymers. The 
fraction existing as nitric oxide may be able to escape through the collecting tube 
as the dialysate travels its length leading to the lower recovery. The following 
experiments were performed in order to investigate this hypothesis.
8.5.1 Method.
A 20 cm length of the microdialysis collecting tube was immersed in a 
solution of pH 1 HCl containing 5mM ascorbic acid and 100 pM nitrite at 37°C. 
The nitric oxide concentration in this test solution was 91 pM as measured with 
the nitric oxide sensor and meter (ISO-NO Mk.II, World Precision Instruments 
Inc, Sarasota, Florida U.S.A.). The collecting tube of the microdialysis probe was 
placed in this solution and perfused with 0.1 M NaOH at a rate of 0.1 mL hr'*. The 
NaOH was used to perfuse the tube as this will entrap any nitric oxide, which 
diffuses into the tube, as nitrite:
2N0 + O2 ^  2N0z 
NO2 + NO N2O3
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N2O3 + HaO ^  2 iï" + 2 N0 2 ' 2 HNO2 
HNO2 + NaOH —> NaN0 2  + H2O
The experiment was repeated with the beaker solution at pH 7.0, which 
generated no nitric oxide.
8.5.2 Results.
In the experiment performed at pH 1, the microdialysis product was found 
to have a nitrite concentration of 95 pM. In contrast, no nitrite was found in the 
microdialysis product in the second experiment where the beaker pH was 7 where 
no nitric oxide was generated.
8.5.3 Conclusions.
These studies confirmed that the collecting tube was permeable to any 
dissolved nitric oxide present in the dialysate. This would also imply that any 
unreacted H^ ions and nitrite ions which have diffused into the microdialysis 
probe will be able to react to generate nitric oxide and lead to further losses during 
transit through the collecting tube measuring 1 metre in length.
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Fig 8.2: Mean nitrite recoveries in aqueous solution and gastric juice at pH
1.5, 2.5, 3.5, 5.0 and 7.0 at 37‘*C.
For aqueous solutions n = 8  for each pH.
For gastric juice n = 12 at pH 1.5 and 7, n = 4 at pH 2.5, 3.5 and 5. 
Error bars represent + SD. Perfusion rate 0.15 mL hr '.
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Fig 8.3: Mean thiocyanate recoveries in aqueous solution and gastric juice 
at pH 1.5, 2.5, 3.5, 5.0 and 7.0 at 37”C.
For aqueous solutions n = 8  for each pH.
For gastric juice n = 12 at pH 1.5 and 7, n = 4 at pH 2.5, 3.5 and 5. 
Error bars represent + SD. Perfusion rate 0.15 mL hr '.
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Fig 8.4: Mean ascorbic acid recovery in aqueous solution and gastric juice at 
pH 1.5, 2.5, 3.5, 5.0 and 7.0 at 37”C.
For aqueous solutions n = 8 for each pH.
For gastric juice n = 4 at each pH.
Error bars represent + SD. Perfusion rate 0.15 mL hr '.
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Fig 8.5: Mean total vitamin C recovery in aqueous solution and gastric juice 
at pH 1.5, 2.5, 3.5, 5.0 and 7.0 at 37"C.
For aqueous solutions n = 8 for each pH.
For gastric juice n = 4 at each pH.
Error bars represent + SD. Perfusion rate 0.15 mL hr
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8.6 Elucidating the cause for reduced nitrite recovery at pH 1.5 
and 2.5. Part II: formation of nitric oxide and loss of nitrite 
at pH 1.5 and 2.5.
The previous experiment suggested that nitrite is lost as nitric oxide during 
transit through the collecting tube by reacting with ions at pH 1.5 and 2.5. The 
amount lost in this way will depend on the time the dialysed fluid is present 
within the collecting tube, which is determined by the microdialysis perfusion rate. 
The hypothesis was tested in the following experiment.
8.6.1 Method.
The microdialysis probes were placed in aqueous solutions containing 200 
pM NaNOz plus 500 pM NaSCN at pH 1.5 and ?>1^ C and perfused with distilled 
water at 0.1, 0.15, 0.2, and 0.3 mL hr"*. By increasing the perfusion rate it was 
postulated that the recovery of nitrite at pH 1.5 will increase by reducing the 
transit time in the collecting tube thus allowing less time for nitrite and H^ ions to 
react to generate nitric oxide. The improved recovery by reducing the transit and 
therfore the chemical reaction time will eventually be counter-balanced by the 
reduction in the recovery of nitrite consequent to the increased perfusion rate.
Four microdialysis probes were used simultaneously for each aqueous 
solution. The experiment was repeated with pH 7 aqueous solution where nitrite 
was stable. Further experiments were carried out in gastric juice pH 1.5 at 37°C to 
which 200pM NaNOz was added but without adding NaSCN (natural 
concentration of thiocyanate in the gastric juice was used). A single micro-dialysis 
probe was used for the gastric juice experiments.
8.6.2 Data Analysis.
The results are given as mean ± S.D.
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8.6.3 Results.
In contrast to the studies at higher pH, the nitrite recoveries at pH 1.5 
actually increased as expected with increasing flow rate being 61 % (± 1.2 ), 72 % 
(± 2.4), 67 % (± 3.4), 71 % (± 3.7) at 0.1, 0.15, 0 .2 , and 0.3 mL hr* respectively 
(Fig 8 .6 ). The thiocyanate recoveries were 97 % (± 2.4), 92 % (+ 0.6), 95 % (± 
3.3), 83% (±4.1).
The nitrite recoveries in aqueous solution at pH 7 were 94 % (± 2.0), 87 %
(± 2.4), 84 % (± 2.4), 6 6  % (± 3.2) and similar to that of thiocyanates which were, 
96 % (± 1.1), 8 6  % (± 0.8), 8 8  % (± 1.4), 70 % (± 2.3) at 0.1, 0.15, 0.2 and 0.3 mL 
hr * respectively.
The nitrite recoveries in gastric juice again increased with increasing 
microdialysis perfusion rate being 55 %, 75 %, 77 % and 6 8  % at 0.1, 0.15, 0,2 
and 0.3 mL hr * respectively; whereas for thiocyanate the recoveries decreased 
with increasing perfusion rates being 93 %, 84 %, 75 % and 67 % respectively.
8.6.4 Conclusions.
The above studies confirm the low recovery of nitrite at pH 1.5 (and 2.5) 
was due to the loss of nitrite as nitric oxide through the chemical reaction between 
H^ ion and nitrite to form nitrous acid and subsequently nitric oxide. Nitric oxide 
readily diffuses through polymers including that of the efferent tube of the 
microdialysis probe leading to the loss of nitrite as the dialysate travels the length 
of the tubing. The recovery of thiocyanate, ascorbic acid and total vitamin C (see 
previous experiments) all fell with increasing microdialysis perfusion rate 
irrespective of the pH of the solution, whereas the recovery of nitrite at pH 1.5 did 
not decrease and in fact slightly increased. At pH 7 where nitrite is stable, the 
recovery of nitrite showed the typical pattern of decreasing recovery with 
increasing microdialysis perfusion rate. The absence of decreasing recovery with 
increasing microdialysis perfusion rate for nitrite at pH < 2.5 can be explained by 
the higher flow rate reducing the fraction lost as nitric oxide in the collecting tube 
and this offsetting the reduced initial recovery across the dialysis membrane.
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Fig 8.6: Mean nitrite recovery at pH 1.5 at different rates of perfusion in 
aqueous solutions and gastric juice.
For aqueous solutions, n = 4 for each perfusion rate 
For gastric juice, n = I for each perfusion rate.
Error bars represent + SD.
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8.7 Dynamic studies simulating the interaction between salivary
nitrite and gastric juice ascorbic acid in acid stomach.
8.7.1 Introduction.
Nitrite and thiocyanate are delivered in the saliva which is swallowed 
intermittently and interact with the ascorbic acid in acidic gastric juice in the 
human stomach. Acidification of nitrite forms nitrous acid and nitrosating species 
such as N 2 O 3 ,  nitrosonium ion (NO"^ ) or nitrosothiocyanate (NOSCN). These 
nitrosating species are reduced to nitric oxide by ascorbic acid, with the latter 
being oxidized to dehydroascorbic acid. The nitric oxide formed in this way can 
react with dissolved oxygen to reform nitrosating species which can in turn react 
with any remaining ascorbic acid. This recycling of nitrite will continue until the 
entire ascorbic acid is converted to dehydroascorbic acid or the oxygen is used up.
2N0 + O2 -> 2N0z 
NO2 + NO N2O3
Studies were performed in order to ensure that the microdialysis probes 
were reliable under these dynamic conditions and that they were sufficiently 
sensitive to detect the presence of the chemicals under such conditions. 
Experiments were performed to simulate the conditions of both low and high 
gastric juice ascorbic acid concentrations. In the low dose ascorbic acid 
experiments we predicted that the ascorbic acid would not be detectable in the 
stomach sample and the microdialysis product. In the high dose ascorbic acid 
experiment, ascorbic acid should be detectable in both the stomach sample and the 
microdialysis product with no nitrite being detectable in the microdialysis product.
Further experiments were performed at pH 3.5 to test the reliability of the 
microdialysis probes under the condition where acidified nitrite reacts more 
slowly with ascorbic acid, and consequently the reaction between ascorbic acid 
and nitrite is much slower and potentially both these chemicals will co-exist.
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8.7.2 Methods.
A specially constructed glass flask (artificial stomach. Fig 8.7) containing a 
60 mL of 1 mM NaSCN in pH 2.5 HCl was used to simulate the stomach.
Ascorbic acid was infused into the solution at a rate of either 18 pmol hr"* or 150 
pmol hr"* simulating low and high ascorbic acid secretion rate into gastric juice 
respectively. Ten minutes after starting the ascorbic acid infusion, ImL boluses of 
nitrite (1.2 mmol L"*) were injected into the stomach every 3 minutes simulating 
the delivery of nitrite in saliva. A 2 mL sample was taken directly from the 
stomach at the time points corresponding to the start, middle and end of the 
microdialysis collection period and 0.5 mL aliquots were added to each of 0.5mL 
M/S 1:1 solution and 0.5 mL M/S + DTT for ascorbic acid and total vitamin C 
respectively. Another 0.5 mL aliquot was added to 50 pL 1 M NaOH for nitrite 
and thiocyanate analysis (latter only measured in 0.15 mL hr * experiments). The 
microdialysis probes were perfused with distilled water at 0.1 mL hr"*. The 
microdialysis products were collected in 20 pL of IM NaOH for nitrite and 20 pL 
of M/S for ascorbic acid and total vitamin C. The samples were further diluted 1:1 
with distilled water for nitrite (thiocyanate), 1:1 with M/S or 1:1 M/S + DTT for 
ascorbic acid and total vitamin C respectively. A nitric oxide sensor (World 
Precision Instruments Inc., Sarasota, Florida, U.S.A.) and meter (ISO-NO Mark II, 
World Precision Instruments, I.N.C., Sarasota, Florida, U.S.A.) were used to 
monitor the nitric oxide generated during the experiments.
Nitrite was analysed colorimetrically using the Greiss reagent, and ascorbic 
acid and total vitamin C analysed by HPLC as described above. Experiments were 
repeated at 0.15 mL hr * perfusion rate but without monitoring nitric oxide 
production. Thiocyanate concentration was measured in the 0.15 mL hr"* but not 
in the 0.1 mL hi'"* experiments.
Further experiments were performed at pH 3.5, infusing low and high-dose 
ascorbic acid into the artificial stomach in separate experiments. Microdialysis 
probes were perfused with distilled water at 0.15 mL hr"*.
8.7.3 Data analysis.
The results are given as mean (+ S.D).
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8.7.4 Results.
Dynamic experiments at p H  2,5
i) Low-dose ascorbic acid infusion (Nitrite in excess of ascorbic acid)
Prior to commencing the nitrite delivery, infusing ascorbic acid at 18 pmol 
hr"* into the simulated gastric juice resulted in a progressive rise in the ascorbic 
acid concentration in the samples taken directly from the stomach (performed in a 
separate experiment without the addition of nitrite). As soon as the nitrite 
administration commenced, ascorbic acid could not be detected but the 
concentration of the total vitamin C progressively increased indicating that the 
infused ascorbic acid was all oxidized to dehydroascorbic acid. The concentration 
of nitrite progressively increased as more nitrite was administered. There was only 
a small initial rise in nitric oxide reaching 8  pM on adding the first bolus of nitrite 
but no increase thereafter.
In the 3 studies performed at 0.1 mL hi*"*, the mean concentrations of nitrite, 
ascorbic acid and total vitamin C in the samples taken directlv from the stomach 
during the 40min time period corresponding to the microdialysis collection period 
were 135 pM (± 21), 0 pM and 87 pM (± 57) respectively. The recoveries from 
the microdialysis probe compared to the stomach samples were 8 6  % (+ 13.8) for 
nitrite and 92 % (+ 15.4) for total vitamin C. No ascorbic acid was detectable in 
the microdialysis sample.
For the two 0.15 mL hi*"*experiments using two microdialysis probes each 
for nitrite and thiocyanate; two for ascorbic acid and total vitamin C. Ascorbic 
acid was again undetectable from both the stomach samples and four 
microdialysis samples. The mean nitrite, thiocyanate and total vitamin C 
concentrations in the stomach samples were 128 pM, 727 pM and 59 pM 
respectively. The microdialysis recoveries for nitrite, thiocyanate and total 
vitamin C were 94 % (+ 6.4), 93 % (± 4.2) and 94 % (+ 3.5) respectively.
ii) High-dose ascorbic acid infusion (ascorbic acid in excess o f  nitrite)
Ascorbic acid was infused into the stomach at 8 -fold higher rate (150 pmol 
hr'*). Ascorbic acid remained detectable from the samples taken directly from the 
stomach during nitrite administration with only a proportion being converted to
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dehydro-ascorbic acid. The nitric oxide concentration progressively increased 
with each addition of nitrite producing a nitric oxide concentration equivalent to 
the concentration of nitrite added.
Five experiments were performed at 0.1 mL hr *. The mean nitrite, ascorbic 
acid and total vitamin C detected in the samples taken directly from the stomach 
were 27 pM (± 14), 352 pM (± 80) and 619 pM (±213) respectively. The 
microdialysis recoveries for nitrite, ascorbic acid and total vitamin C were 0 % (± 
0.8), 67 % (± 19.6) and 73 % (± 9.8) respectively.
Two experiments using four microdialysis probes (two each for nitrite and 
thiocyanate; two probes for ascorbic acid and total vitamin C) were perfoimed at 
0.15 mL h‘*. The mean concentrations of nitrite, thiocyanate, ascorbic acid and 
total vitamin C in the stomach samples were 20 pM, 752 pM, 619 pM and 828 
pM respectively. The micro dialysis recoveries for nitrite, thiocyanate, ascorbic 
acid and total vitamin C were 0 %, 98 % (± 1.7), 54 % (± 2.9) and 82 % (± 1.0) 
respectively.
Dynamic experiments at pH  3,5
i) Low-dose ascorbic acid
For the three experiments, the mean concentrations of nitrite, thiocyanate, 
ascorbic acid and total vitamin C in the stomach samples were 137 pM (±11),
774 pM (± 15), 10 pM (± 1.4) and 95 pM (± 15) respectively. The microdialysis 
recoveries for nitrite, thiocyanate, ascorbic acid and total vitamin C were 106 (± 
6.8), 95 (± 2.5), 52 (± 4.9) and 78 (± 8.8) respectively.
ii) High-dose ascorbic acid
For the three experiments, the mean concentrations of nitrite, thiocyanate, 
ascorbic acid and total vitamin C in the stomach samples were 77 pM (± 6), 782 
(± 44), 763 pM (± 59), 900 pM (±118) respectively. The microdialysis recoveries 
for nitrite, thiocyanate, ascorbic acid and total vitamin C were 89 (± 11.7), 96 (± 
4.2), 71 (± 2.5) and 85 (± 3.2) respectively.
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Fig 8.7: Artificial stomach used in the dynamic experiments.
The apparatus was placed in a water bath maintained at 37°C. The 
mixture was stirred gently using the magnetic stirrer. Ascorbic acid was 
delivered using a syringe drive and the nitrite bolus administered using a 
syringe.
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8.7.5 Conclusions.
In the experiments conducted at pH 2.5 simulating the dynamic conditions 
of swallowed salivary nitrite interacting with low and high gastric juice ascorbic 
acid concentrations, the microdialysis probes proved to be reliable in measuring 
the chemicals relevant to nitrosation. In the low dose ascorbic acid experiments 
(nitrite in excess of ascorbic acid) the nitrite recovery was in excess of 8 6  % and 
greater than 90 % for both thiocyanate and total vitamin C. Ascorbic acid was 
non-existent in the stomach sample as expected and 0  % in the microdialysis 
samples. In the high dose ascorbic acid experiments (ascorbic acid in excess of 
nitrite) the recoveries were 0 %, > 90 %, > 50 % and > 70 % for nitrite, 
thiocyanate, ascorbic acid and total vitamin C respectively. The small amount of 
nitrite (20 pM) detected in the stomach sample was derived from nitric oxide as 
follows:
2N0 + O2 2 NO2
NO2 + NO N2O3
N2O3 + H2O 2H^ 4- 2 NO2 2 HNO2
HNO2 + NaOH NaN0 2  + H2O
The microdialysis probe reliably distinguishes this nitrite ‘anomaly’ as any nitric 
oxide entering the probe will be rapidly lost tlirough the probe due to its highly 
permeable nature.
At pH 3.5 the reaction between ascorbic acid and nitrite is much slower and 
therefore both ascorbic acid and nitrite co-existed in solution. Both ascorbic acid 
and nitrite were recovered in the microdialysis product indicating that the 
microdialysis probes were reliable under such conditions. The nitrite recovery in 
the low-dose ascorbic acid experiment at pH 3.5 was higher than that in the 
stomach sample and is likely to reflect the loss of nitrite during sampling and 
processing of the stomach solution rather than an artefactual elevation of nitrite in 
the microdialysis sample.
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9.1 Assembly.
The probes were assembled for use in the human upper gastrointestinal tract 
and the recoveries of the assembled probes assessed. Four microdialysis probes 
were secured in exposed recesses of a nasogastric tube 3.3 mm in diameter (Rüsch 
U.K. Ltd., High Wycombe, U.K.) using waterproof taping (Sleek, Johnson & 
Johnson, Newai’k, N.J., U.S.A.). Recesses in the nasogastric tube were created by 
cutting four 4 cm X 3 mm oblong sections, spaced 1 cm apart, along the 
nasogastric tube. Each recess was isolated by injecting silicone into the lumen of 
the nasogastric tube to prevent fluid tracking between the individual microdialysis 
probes, which could interfere with measuring the local environment. Four 
perforations were made in the intact wall of the recesses of the nasogastric tube (it 
was not possible to fully expose the microdialysis probe in order to maintain the 
rigidity of the assembly which would otherwise compromise the fragile 
microdialysis probes). To protect the exposed dialysing section of the 
microdialysis tubes, a fine mesh was secured around the dialysing section of the 
microdialysis probe with 2/0 silk sutures (Bthikon Ltd, Edinbui'gh, U.K.). This 
configuration allowed free contact of the microdialysis probes to the external 
medium without trapping fluid within the lumen of the thin nasogastric tube 
surrounding the microdialysis probes and the probes consequently sampling 
stagnant fluid. The inlet (afferent) and outlet (efferent) tubings of the 
microdialysis probes were for the most part contained inside the lumen of the 
nasogastric tube and sealed with wateiproof taping. The assembled probe was 
attached to a 5-channel pH probe (Synetics Medical Ltd., Enfield, Middlesex, 
U.K.) with each microdialysis probe lying adjacent to a pH sensor (Fig 9.1). The 
cardia probe had two pH sensors spaced 1 cm apart, the additional sensor located 
1cm proximal to the cardia microdialysis probe in order to locate the pH step-up 
point which can accurately localise the gastro-oesophageal junction The 
outputs from the pH sensors were digitalised (DAS 1201 data acquisition board, 
Keithley Instruments Ltd., Reading, Berkshire, U.K.), monitored on a computer 
screen during the procedure and stored on computer for subsequent analysis.
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9.2 Validation of the assembled probes for use in the human
upper gastrointestinal tract.
Before using the assembled probes in humans, it was necessary to 
investigate whether mounting the microdialysis probes had any adverse effect on 
the recovery of the chemicals of interest.
9.2.1 Method.
Aqueous solution of NaSCN 500 pM at pH 1.5, adjusted with HCl, at 37°C 
was prepared in a large shallow glass beaker. It was important to have a shallow 
container as the temperature differential seen between the bottom and the upper 
part of fluid column in a tall thin glass cylinder alters the microdialysis recovery 
rates. The assembled micro dialysis probes were immersed and positioned to avoid 
contact with the beaker sidewall which may reduce the recovery of the chemicals 
by reducing the surface area of the microdialysis probes available for diffusion. A 
magnetic stirrer was placed in the centre of the beaker to stir the solution gently. 
The experiment was conducted at 37°C. To the solution was added NaNOa to 
make a concentration of 200 pM. The microdialysis probes were perfused as 
previously using distilled water at 0.15 mL hr"\ Samples were taken from the 
beaker at 0 and 40 minutes corresponding to the beginning and the end of the 
experiment. Collection of the microdialysis sample commenced at 10 minutes and 
ended at 50 minutes (i.e. a ten-minute delay) to account for the time taken for the 
dialysate to travel from the probe tip to end of the outlet tube. The microdialysis 
products were collected in 20 pL 1 M NaOH in the chi'omatography glass vial as 
previously mentioned. The experiment was repeated at pH 2.5 and then at pH 7 
where pH adjustment was made using NaOH. Nitrite and thiocyanate 
concentrations were determined as mentioned previously.
The experiment was repeated for ascorbic acid and total vitamin C recovery 
at pH 1.5,2.5 and 7 at 37°C. The ascorbic acid concentration in the beaker was 
200pM. The microdialysis product was collected in 20 pL 1:1 M/S, processed for 
ascorbic acid and total vitamin C as described previously and their concentrations 
were determined by HPLC.
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Figure 9.1: Assembled microdialysis probes for human use.
Four microdialysis probes were set in a fine-bore nasogastric tube. 
A multi-channel pH sensor is attached adjacent to the microdialysis 
probes. A fine tenflon tube is also attached to allow intragastric 
instillation of potassium nitrate.
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9.2.2 Data analysis.
Data are presented as mean (± S.D.). Coefficient of variation is expressed as 
S.D./mean.
9.2.3 Results.
The mean recoveries for nitrite, thiocyanate, ascorbic acid and total vitamin 
C for three experiments each at pH 1.5, 2.5, and 7 were 71 % (± 5.5), 81 % (+ 4.1), 
86 % (± 5.9) for nitrite; 93% (+ 2.4), 92 % (+ 3.8), 90 % (+ 4.5) for thiocyanate;
61 % (± 5.5), 62 % (± 9.0), 57 % (± 3.8) for ascorbic acid and 65 % (± 5.7), 65 % 
(+ 5.9), 61 % (± 6,5) for total vitamin C at the respective pH. The recoveries were 
thus slightly reduced in the assembly. The intra-probe coefficient of variation for 
the four microdialysis probes at pH 1.5,2.5 and 7 respectively ranged from 
< 12 %, < 6 %, < 8 % respectively for nitrite recoveries; < 3 %, < 7 %, < 7 % 
respectively for thiocyanate recoveries; < 9 %, < 14 %, < 10 % respectively for 
ascorbic acid recoveries and <11 %, < 12 %, < 19 % respectively for total 
vitamin C recoveries.
9.2.4 Conclusions.
We tested the function of the assembled probes suitable for the simultaneous 
measurement at four positions thi'oughout the human upper gastrointestinal tract 
complete with pH electrodes alongside each microdialysis probes. The recovery 
was slightly reduced probably due to the surface of the microdialysis membrane 
being partially excluded by the surface of the nasogastric tube to which they were 
attached. The microdialysis probes assembled as above proved to be reliable in 
measuring the chemicals of nitrosation. The recovery of each probe in the 
assembled apparatus should be checked each time before it is used in order to 
detect any equipment damage.
For the human studies, we decided to use 0.15 inL lir'  ^ as the perfusion rate 
for the microdialysis probes as this rate produced the best overall balance between 
satisfactory recoveries of the chemicals of interest and sufficient volume of 
microdialysis product for chemical analyses to be performed.
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9.3 Disinfection of the microdialysis probes.
In order to use the microdialysis probes in humans it was necessary to 
disinfect the equipment with suitable disinfectants. The following experiments 
were performed in order to establish whether the disinfecting agents had any 
impact on the function of the probes. Initial experiments involved the use of 
glutaraldehyde (Cidex, Jolinson and Johnson, Newark, N.J., USA) and the 
cleaning procedure was performed in an enclosed fume cupboard. Due to the 
regulations in the department, the cleaning agent was subsequently changed to 
Virkon S®(DAHS, Sudbury, Suffolk, UK).
9.3.1 Method and Results.
The used microdialysis probes were initially soaked for 20 minutes in 
Klerzyme (Shield Medicare Ltd., Famham, UK) to remove proteinaceous material. 
The probes were then rinsed with water. The probes were soaked in Cidex or 
Virkon and perfused with distilled water at 0.6mL hr’* for 30 minutes. The probes 
were rinsed with water. Subsequently the probes were soaked in distilled water 
and perfused with 1 M ethylenediamine tetra acetic acid (EDTA) to remove any 
trace elements which will oxidize any ascorbic acid in subsequent experiments.
The final cleaning stages involved soaking the probes in distilled water and 
perfusing them with distilled water at 0.6 mL hr'* overnight.
The probes were checked for recovery using an aqueous solution at pH 7 
containing 200 pM NaNOz and 500 pM NaSCN and any substandard probes 
manifested by a significantly reduced recovery or significantly reduced product 
volume were discarded and replaced with new probes. Both the Cidex and Virkon 
did not have any detrimental impact on the recoveries of the microdialysis probes.
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10.1 Introduction.
Despite the cardia representing less than 5% of the surface area of the 
stomach, the majority of gastric cancers occur at the gastro-oesophageal junction 
in the absence of H. pylori infection Intestinal metaplasia is a common finding
at the cardia 197-200) ^ significant proportion of patients is associated
with carditis and H. pylori infection In the remainder of the patients
intestinal metaplasia cannot be attributed to H. pylori and is likely to be related to 
the presence of acidic gastric juice / gastro-oesophageal reflux -210) 
mutagen responsible for the high incidence of metaplasia and neoplasia at the 
gastro-oesophageal junction remains unknown. Cancer of the cardia also differs 
from cancer of the more distal stomach with respect to associated gastric 
physiology. The foiiner occurs in patients with normal gastric secretory function 
(320,321,322). contrast, cancer of the more distal stomach usually develops in
subjects with H. pylorUmàucQà atrophic gastritis and hypochlorhydria
Intestinal metaplasia and cancer at the gastro-oesophageal junction are being 
attributed to gastro-oesophageal reflux and the noxious effects of acid, pepsin and 
duodenal contents in the refluxate. However, this hypothesis cannot entirely 
explain cancer at the gastric cardia which has a columnar mucosa well able to 
withstand the physiological constituents of gastric juice. In addition, 
epidemiological studies indicate only a weak association between symptoms of 
reflux and cardia cancer
For many years there has been interest in the potential role of endogenously 
produced V-nitroso compounds in the aetiology of upper gastrointestinal cancer
Acidic conditions present in the stomach protonate nitrite to nitrous acid 
which subsequently gives rise to nitrosating species which are able to react with 
secondary amines and amides foiming potentially carcinogenic A-nitroso 
compounds The major source of nitrite entering the healthy acid-secreting
stomach is saliva and arises from the enterosalivary re-circulation of dietaiy 
nitrate as discussed previously. Bacteria catalyse the reduction of nitrate to nitrite 
in the oral cavity and is inhibited by antibacterial agents The salivary
glands actively take up and secrete thiocyanate which is also found in gastric juice 
(271,272)^  Thiocyanate is a potent catalyst of the nitrosation of secondary amines by 
acidified nitrite This delivery of nitrite and thiocyanate into the acidic
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environment of the stomach has therefore been regarded as a potentially important 
source of endogenous formation of carcinogenic A-nitroso compounds 
Ascorbic acid is an important inliibitor of acid-catalysed nitrosation. The healthy 
human stomach actively secretes ascorbic acid into the gastric juice <^ 74,275) 
Ascorbic acid rapidly reduces the acidified nitrite / nitrosating species to nitric 
oxide, and itself oxidised to dehydroascorbic acid The relative
availability of nitrite compared to ascorbic acid determines whether A-nitrosation 
can proceed within the gastric lumen. When the supply of nitrite exceeds that of 
ascorbic acid nitrosation will occur; and conversely when ascorbic acid supply 
exceeds that of nitrite then nitrosation will be prevented. The removal of 
intragastric nitrite by the ascorbic acid in gastric juice thus prevents the generation 
of A-nitroso compounds within the gastric lumen.
Previous studies have regarded the gastric lumen as a homogeneous 
compartment with respect to acid-catalysed nitrosation. However, the gastric 
cardia is the most proximal region of the stomach where the greatest nitrite load 
will be delivered. Nitric oxide generated from the reaction of acidified nitrite and 
ascorbic acid has been shown to be the greatest at the cardia This suggests 
that the highest intragastric ratio of nitrite to ascorbic acid and thus the condtion 
most suitable for generating A-nitroso compounds should occur in the region of 
the cardia. This chapter examines this hypothesis and provide an insight into the 
potential mechanism for mutagenesis and carcinogenesis at this anatomical site.
10.2 Method.
10.2.1 Subject selection and microdialysis procedure
Subjects who were negative for H. pylori as determined by the *"*C-urea 
breath tests were enrolled in the study. All the subjects undergoing the study were 
endoscoped prior to the experiment to exclude any pathology and to record the 
positions of the gastro-oesophageal junction, the size of hiatal hernia, if any were 
present. A rapid urease test (CLO™, Delta West Pty Ltd., Bentley, Australia) was 
performed using two biopsy specimens: one from the antrum and another from the 
gastric body to confirm that the subjects were not re-infected by H. pylori since
1 1 0
some of the subjects had a negative urea breath test performed several years prior 
to the experiment. All CLO tests were confinned to be negative.
On the day of the study the subjects presented having fasted overnight. They 
were instructed to avoid nitrate-rich foods for 24 hours prior to the procedure. The 
probe assembly was passed per orally and positioned so that one microdialysis 
probe was positioned in each of the following regions: the distal oesophagus 5cm 
above the gastro-oesophageal junction, cardia, 5 cm distal to the gastro- 
oesophageal junction in the proximal stomach and 10 cm distal the to the gastro- 
oesophageal junction in the distal stomach (Fig 10.1). The pH sensor sited 1cm 
proximal to the cardia microdialysis probe recorded esophageal pH (> 4) and the 
pH sensor at the cardia microdialysis probe recorded gastric pH (< 2.5). This 
ensured that the cardia microdialysis probe was located just distal to the gastro- 
oesophageal junction as the pH step-up corresponds to the squamocolumnar 
junction under fasting conditions The position of the assembly was checked 
by an abdominal X-ray, The subjects lay semi-recumbent throughout the study. 
The pH being recorded by each sensor was closely monitored during each study 
and the position of the tube adjusted if required to maintain its correct location 
relative to the gastro-oesophageal junction.
After the confirmation of satisfactory positioning, the microdialysis probes 
were perfused with degassed, distilled water at 0.15 mL hr"*. The first 15 minutes’ 
collections of the microdialysis samples were discarded and the following 40 
minutes collected for analyses. Following this basal collection, 2 mmol of 
potassium nitrate in 25 mL of water was administered intragastrically via a fine 
Teflon feeding tube attached to the nasogastric tube. Forty minutes after 
administering the potassium nitrate further microdialysis collections were 
obtained for 40 minutes.
The microdialysis samples were collected in a 300 pL glass vials 
(Chromacol, Ltd., Herts, U.K.) containing preseiwatives. Ascorbic acid and total 
vitamin C were collected in 20 pL of 2 % metaphosphoric acid containing an 
equal volume of 0.5 % sulfamic acid (M/S). One half of the sample was diluted 
with an equal volume of M/S for ascorbic acid and the other half with an equal 
volume of 12 mg mL'* dithiothreitol in M/S (M/S+DTT) for total vitamin C 
samples. The nitrite and thiocyanate samples were collected into 20 pL of 1 M 
NaOH. Separate collections were necessary as the preservative used for nitrite and
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thiocyanate was incompatible with ascorbic acid / total vitamin C and vice versa.
In order to collect separate specimens for nitrite / thiocyanate and ascorbic acid / 
total vitamin C the collection of microdialysis samples was alternated every 2 
minutes into each collecting tube. The vitamin C samples were frozen at -70°C 
for analysis within four weeks and the nitrite and thiocyanate samples were stored 
at 4°C for analysis on the same day.
Venous blood was obtained from an indwelling intravenous catheter every 
15 minutes from the start of the study. Serum nitrate was collected in a plain 
Vacutainer® tube, plasma ascorbic acid and total vitamin C determinations were 
collected in Vacutainer® tubes containing lithium heparin. Blood samples were 
allowed to stand for 20 minutes at room temperature and were centrifuged at 3000 
r.p.m. at 4°C for 10 minutes and the supernatant for plasma ascorbic acid and total 
vitamin C were diluted with equal volumes of M/S solution or M/S+DTT 
respectively and snap frozen in liquid nitrogen and stored at -70°C until analysis. 
The supernatant for serum nitrate was transferred into a plain test tube and frozen 
at -20°C until analysis.
Samples of saliva were obtained every 15 minutes for nitrite and thiocyanate 
determination. This was done by asking the patient to spit into a sterile container 
and 500 pL was immediately added to 50 pL of 1 M NaOH in a 1.5 mL 
Eppendorf tube and stored at 4°C until analysis on the same day.
Prior to each study the recovery of each microdialysis probe fully assembled 
on the nasogastric tube was assessed for each individual chemical at 37°C at pH 
1.5, 2.5 and 7. Any probe that was damaged was discarded and replaced with a 
new probe. Following each study, the individual probes were then removed from 
the nasogastric tube, cleaned and sterilized with Cidex (Johnson and Johnson, 
Newark, N.J.) and latterly Virkon® (DAHS, Sudbury, Suffolk, UK) before being 
remounted into a fresh nasogastric tube.
1 1 2
MD Probes
5cm
^  pH Probes
5cm
5cm
Fig 10.1: Schematic diagram of the positions of the microdialysis probes
and the pH sensors.
The broken line indicates the gastro-oesophageal junction. The 
microdialysis probes are positioned from proximal to distally: distal 
oesophagus, cardia, proximal stomach and distal stomach. The pH 
sensor 1 lies Just above the gastro-oesophageal junction and sensor 2 
just below at the cardia. The pH of sensor 1 is > 4 and for sensor 2 is 
< 2.5. This enables accurate positioning of the microdialysis probe at 
the cardia.
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10.2.2 Chemical analyses
The chemicals collected in this experiment were serum nitrate; salivary 
nitrite and thiocyanate; microdialysis nitrite, thiocyanate, ascorbic acid and total 
vitamin C. Nitrite, thiocyanate, ascorbic acid and total vitamin C were analysed as 
previously mentioned.
i) Saliva assay
Prior to analysis, the saliva samples were centrifuged at 13000 r.p.m for two 
minutes using a micro centrifuge and the supernatant was analysed. The 
supernatant was diluted 1:4 with distilled water. The samples were analysed for 
nitrite and thiocyanate colorimetrically on a 96-well microplate using the 
modified Greiss reagent for nitrite and the Bowler method for thiocyanate as 
desribed in 7.3.2 and 7.3.3 respectively.
it) Microdialysis assay
The volumes obtained from the microdialysis experiments (approximately 
55 p,l) only allowed for single measurement to be made for each sample therefore 
extreme care was taken to ensure that the samples were processed correctly. The 
microdialysis products for thiocyanate and nitrite were diluted 1:3 with distilled 
water and analysed colorimetrically in a 96-well microplate as above. For 
ascorbic acid and total vitamin C the samples were diluted 1:2 using M/S for 
ascorbic acid and M/S+DTT for total vitamin C and analysed by HPLC coupled to 
an electrochemical detector as described in 7.3.1.
Hi) Serum nitrate assay
After thawing, the serum samples were filtered through a 10-kDalton 
microfilter (Microcon 10, Millipore UK Ltd, Watford, UK) centrifuged at 13000 
r.p.m. for one hour to remove high-molecular-weight substances and an aliquot of 
filtrate was analysed as described in 7.3.4 by reduction of nitrate to nitrite and 
analysing the samples colorimetrically with the Greiss reagent. The original nitrite 
concentration in the serum was also determined. The difference between the total 
nitrite (reduced nitrate + original nitrite) and the original nitrite represented the 
actual serum nitrate concentration.
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10.3 Statistical analyses.
All data are presented as median and interquartile range (IQR) unless 
otherwise stated. Paired data were analysed using 1-sample Wilcoxon test. For the 
comparison of pre- and post-nitrate data of the serum niti*ate, plasma ascorbic acid, 
plasma total vitamin C, saliva nitrite and saliva thiocyanate, individual post-nitrate 
time points (60 to 120 minutes) were compared to the 45 minute sample which 
represented the concentrations of the chemicals of interest just before nitrite was 
administered.
In order to calculate the ascorbic acid to nitrite ratio, any samples with 
undetectable ascorbic acid or nitrite concentrations were allocated a concentration 
of 1 p.M, the approximate lower limit of detection for both ascorbic acid and 
nitrite using our analytic methods. If both ascorbic acid and nitrite were 
undetectable, these samples were excluded from analysis. Statistical testing was 
performed using the 1-sample Wilcoxon test. Bonferroni conection was applied 
for multiple comparisons. A two-tailed p < 0.05 was considered statistically 
significant.
10.4 Ethics.
The study was approved by the North Glasgow University NHS Trust Ethics 
Committee and each subject gave written, informed consent,
10.5 Results.
Twenty one patients were recruited. Four patients were unable to tolerate 
the procedure for the duration of the experiment and were excluded leaving 17 
patients available for analysis. The mean age was 32.1 years (range: 18-52 years) 
and 12 were males.
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10.5.1 Blood.
i) Nitrate
Just prior to nitrate administration (45 min), the fasting serum nitrate 
concentration was 17.3 pM (14.0-22.0). Following the ingestion of 2 mmol 
potassium nitrate, the serum nitrate increased three-fold within 30 min, increasing 
to 59.4 pM (49.5 -  66.2) 40 minutes after nitrate administration at 90 minutes and 
remained at this level for at least the following 45 min (p < 0.01 for all post­
nitrate time points (60 -135 mins.) vs pre-nitrate time point at 45 mins.) (Fig.
10.2).
ii) Ascorbic acid and total vitaminC
The plasma ascorbic acid concentration at the beginning of the experiment 
was 52.9 pM (32.6 -  64.0) and that of TVC was 56.2 pM (39.8 -  67.0). The serum 
concentration of ascorbic acid and TVC were unchanged following the nitrate 
administration.
10.5.2 Saliva.
i) Nitrite
Prior to insertion of the probe assembly (-15 min), the salivary nitrite 
concentration was 53.9 pM (45.7 -  146.1) and fell to 23.1 pM (10.1 -  42.2) at 15 
minutes after the insertion of the microdialysis assembly (p < 0.01). Following the 
administration of potassium nitrate, the saliva nitrite concentration increased 8- 
fold to 201.2 pM (92.7 -  292.6) at 90 minutes {p < 0.01 vs 45 min (pre-nitrate)} 
and remained elevated for at least the following 45 minutes (Fig. 10.3).
ii) Thiocyanate
Prior to passing the probe assembly (-15 min), the salivary thiocyanate 
concentration was 2044 pM (948 - 4380) and this fell to 1238 pM (489 - 1739) 15 
minutes after the placement of the assembly (p < 0.01) and remained at this level 
throughout the remainder of the study.
1 1 6
7 0
60
50
40 
Nitrate 
(mM) 30
20
10
0
Nitrate
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Time (Minutes)
Fig 10.2: Median serum nitrate before and after nitrate administration.
Vertical bars represent IQR. N = 17 for all time points.
2 mmol potassium nitrate given at 50 minutes (indicated by red 
arrow).
*p < 0.01 compared to 45minute sample.
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Figure 10.3: Median salivary nitrite before and after nitrate administration.
Vertical bars represent IQR. N = 17 at ail time points.
-  15 minutes indicates sample before insertion of microdialysis 
assembly. 2 mmol potassium nitrate administered at 50 minutes 
(arrow).
t  p < 0.05 compared to 45 minute sample.
* p < 0.01 compared to 45 minute sample.
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10.5.3 Oesophagus.
i ) p H
The median (range) pH of the distal esophagus was 7 (6.7 -  7.6) before and 
7 (6.6 -  7.6) after nitrate was administered.
ii) Nitrite
The fasting nitrite concentrations in the distal esophagus was 17.6 pM (13.1
-  34.3) which was similar to the median fasting salivary nitrite concentration of
20.7 pM (10.3 -  41.1) during 0 - 4 5  minutes, prior to the nitrate administration 
(Fig. 10.4). Following the nitrate meal, the nitrite concentration in the distal 
esophagus reached 165.5 pM (103.4 -  237.6) (p < 0.01 vs fasting levels) which 
was non-significantly lower than that of the median salivary nitrite 215.8 pM 
(123.3 -  245.0) during 90 -  135 minutes, corresponding to the post-nitrate 
microdialysis collection period (Fig. 10.4). 7 of the 17 patients and 8 of 17 
patients before and after nitrate administration had higher nitrite recovery from 
the distal oesophagus than in the saliva.
Hi) Thiocyanate
The median thiocyanate concentration in the distal oesophagus before 
nitrate administration was 540 pM (398 - 1096) which was significantly lower 
than the thiocyanate concentration of 1123 pM (487 - 1698) in the saliva during 0
-  45 minutes (p < 0.01). Following nitrate administration, there was a non­
significant increase in the thiocyanate concentration in the distal oesophagus to 
629 pM (438 - 1237) and was again lower than the thiocyanate concentration of 
1073 pM (577 - 1971) in saliva during 9 0 -  135 minutes (p < 0.01) (Fig. 10,5).
vi) Ascorbic acid and total vitamin C
Both ascorbic acid and total vitamin C concentrations were low in the 
oesophagus. The median ascorbic acid concentration was 11.6 pM (2.4 -  16.7) 
before the nitrate meal and was non-significantly lower at 6.9 pM (1.5 -  15.5)
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after the nitrate meal. The total vitamin C concentration was 14.2 pM (3.7-17.1) 
before the nitrate meal and 7.8 pM (5.4-16.1) after the nitrate meal (N.S).
v) Ascorbic acid to total vitaminC ratio
This ratio indicates the proportion of ascorbic acid in the reduced form.
The median ratio of aseorbic acid to total vitamin C in the squamous oesophagus 
before and after nitrate administration were 82% (40-100%) (N = 15) and 73% 
(52-100) (N = 15) respectively (N.S.)
10.5.4 Stomach.
i)pH
Prior to nitrate administration, the median pH of the cardia, proximal and 
distal stomach were 2.6 (2.5 -  3.6), 1.9 (1.6 -  2.9) and 1.7 (1.4 -  3.0) respectively 
(Table 10.1). Following the nitrate meal the pH of different regions of the 
stomach were 2.8 (2.5 -  3.7), 1.7 (1.5 -  3.0) and 1.5 (1.4 -  2.2) respectively 
(Table 10.2). The percentage of time the pH was above 4 in the cardia, proximal 
stomach and distal stomach were 18.5, 0 and 0%. Following the nitrate meal, the 
percentage of the time the pH was above 4 were 23, 0 and 0% at the respective 
sites.
ii) Nitrite
The median nitrite concentrations within the stomach were 0 pM (0 -  14.2) 
at the cardia and 0 pM for both proximal and distal stomach before nitrate was 
administered (Fig. 10.6; table 10.1). Following nitrate administration, the nitrite 
concentrations increased significantly at the cardia to 30.9 pM (12.4 -  57.9) (p < 
0.01 vs cardia before nitrate) but remained at 0 pM (0 -  18.7) at the proximal 
stomach (p < 0.01 vs cardia after nitrate) and 0 pM at the distal stomach (p<0.01 
vs cai'dia after nitrate) (Fig. 10.6; table 10.2).
The nitrite concentration at the cardia, 0 pM (0 -  14.2) before the nitrate 
meal and 30.9 pM (12.4 -  57.9) after the nitrate meal were both significantly 
lower than that of the distal oesophagus which were 17.6 pM (13.1 -  34.3) before 
the nitrate meal and 165.5pM (103.4 - 237.6) after the nitrate meal (both p < 0.01 
vs after nitrate).
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Figure 10.4: Individual salivary and oesophageal nitrite concentrations 
before and after nitrate administration.
Horizontal line represents median nitrite. Both saliva and 
oesophageal nitrite increased after the nitrate (*  p < 0.01 vs 
before nitrate).
The salivary and oesophageal nitrite concentrations were not 
significantly different from one another both before and after the 
nitrate.
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Figure 10.5: Individual salivary and oesophageal thiocyanate (SCN ) 
concentrations before and after nitrate administration.
Horizontal line represents the mean SCN'. Outliers are indicated by 
the values next to the symbols.
SCN in saliva was significantly higher than SCN' in the distal 
oesophagus before and after nitrate (* p<0.01 compared to 
oesophagus).
SCN concentrations were similar both before and after nitrate 
for saliva and oesophagus.
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Hi) Thiocyanate
Prior to nitrate administration, the mean thiocyanate concentrations in the 
cardia, proximal stomach and distal stomach were 554 p,M (267 - 833), 697 pM 
(286 - 914) and 486 pM (289 - 933) respectively (N.S.) (Fig. 10.7; table 10.1). 
Following nitrate administration, the respective thiocyanate concentrations were 
469 pM (273 - 1057), 651 pM (381 - 1009) and 650 pM (325 - 1139) (table 10.2).
iv) Ascorbic acid
There was a proximal to distal gradient in intra-gastric ascorbic acid with 
the lowest level occurring at the cardia both before and after the nitrate meal (Fig. 
10.8; tables 10.1 and 10.2). The median concentration was 9.3 pM (4.5 -  13.9) at 
the cardia, 20.8 pM (9.5 -  69.3) at the proximal stomach (p < 0.01 vs cardia) and
27.7 pM (10.3 -  104.2) at the distal stomach (p < 0.01 vs cardia, N.S. vs proximal 
stomach). Following the nitrate meal the median concentration of ascorbic acid at 
the cardia and the proximal stomach were unchanged respectively at 6.9 pM (1.3 - 
12.0), 19.9 pM (5.5 -  50.6) (p = 0.018 vs cardia), and increased non-significantly 
to 40.4 pM (12.3 -  101.0) at the distal stomach (p < 0.01 vs cardia).
v) Total vitamin C
The intra-gastric concentration of total vitamin C also showed an increasing 
concentration gradient moving distally from the cardia both before and after the 
nitrate meal (Fig 10,9; tables 10.1 and 10.2). Before the nitrate meal, the total 
vitamin C concentration was lowest at the cardia 11.9 pM (5.7-18.7) higher at 
the proximal stomach, 29.8 pM (12.4 -  87.8) (p < 0.01 vs cardia) and slightly 
higher at the distal stomach, 35.0 pM (15.0 -  111.2) (p < 0.01 vs cardia, N.S. vs 
proximal stomach). Following the nitrate meal, the total vitamin C levels for the 
cardia, proximal stomach and distal stomach were 14.9 pM (7.1 -  30.1), 35.1 pM 
(13.5 -  79.9) (p = 0.036 vs cardia) and 68.4 pM (22.7 -  128.1) (p < 0.01 vs cardia; 
p = 0.018 vs proximal stomach) respectively.
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vi) Ratio of ascorbic acid to total vitamin C
Before nitrate administration the ascorbic acid to total vitamin C ratios were 
72% (43-94%) in the cardia, 79% (50-91%) in the proximal stomach (N = 16) and 
83% (69-95%) in the distal stomach (N = 16). Following nitrate administration, 
the mean ratio fell to 49% (9-75%) (N = 15), 50% (22-92%) and 60% (50-78%) 
for the oesophagus, cardia, proximal and distal stomach respectively (p < 0.01 for 
cardia pre vs post-nitrate; p < 0.05 distal stomach pre vs post-nitrate).
vii) Ratio of ascorbic acid to nitrite
The ascorbic acid to nitrite ratio is an indicator of nitrosation potential. The 
higher the ratio, the greater the ascorbic acid relative to nitrite and the condition is 
imfavourable for the formation of nitroso compounds; at low ratios when the 
nitrite concentration exceeds that of the ascorbic acid, the condition favours the 
generation of nitroso compounds.
Prior to nitrate administration, there was a marked gradient in the ratio of 
ascorbic acid to nitrite throughout the stomach (Fig. 10.10). The ratio was lowest 
in the cardia, median (range) 1.5 (0.2 -112), higher in the proximal stomach, 20.8 
(3.7 -193) (p < 0.01 vs cardia) and highest in the distal stomach at 27.7 (7 - 351)
(p < 0.01 vs cardia; N.S. vs proximal stomach). Following the nitrate 
administration, the ratio at the cardia fell to 0.3 (0 - 108) (p = 0.018 vs cardia pre­
nitrate), but the ratio in the proximal stomach, 7.8 (0 - 264) (p < 0.01 vs cardia 
post-nitrate) and in the distal stomach, 40 (0.7 - 428) (p < 0.01 vs cardia post­
nitrate) were not significantly different from their values before nitrate.
The proportion of patients showing ascorbic acid to nitrite ratio of less than 
one prior to nitrate was 7/16 (44%), 0/17 (0%) and 0/17 (0%) for the cardia, 
proximal stomach and distal stomach respectively. Following the nitrate meal, the 
proportions were 14/17 (82%), 3/16 (19%) and 1/16 (0.1%) respectively.
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Fig 10.10: Graph showing nitrosation potential in different regions of the 
stomach before and after nitrate administration.
Interrupted line at A A/nitrite ratio of I. Points above this line (O) AA 
is in excess of nitrite and condition does not favour nitrosation;
points below the line ( • )  nitrite is in excess of AA and condition 
favours nitrosation.
p = 0.018 compared to pre-nitrate meal, 
t  p < 0.01 compared to cardia pre-nitrate meal.
(|[ p = 0.001 compared to cardia post-nitrate meal.
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OESOPHAGUS CARDIA PROXIMALSTOMACH
DISTAL
STOMACH
pH 7.0 (6.6 -  7.6) 2.6 (2.5 -  3.6) 1.8 (1.6 -  2.9) 1.7 (1 .4 -3 .0 )
Nitrite (pM) 17.6 (13.1-34.3) 0 (0 -1 4 .2 ) 0 0
Ascorbic acid (pM) 11.6 (2.4-16.7) 9 .3(4 .5-13 .9) 20 .8(9 .5 -69 .3) 27.7 (10.3-104.2)
Total Vitamin C 
(pM) 14.2(3 .7-17.1) 11.9(5.7-16.7) 29.8 (12.4-87.8)
35.0 (15 .0- 
111.2)
Thiocyanate (pM) 540 (398 -1096) 554 (267 -  833) 697 (286-914) 486 (289 -  933)
Table 10.1: Median (IQR) pH, nitrite, ascorbic acid, total vitamin C and
thiocyanate concentrations in the different regions of the upper 
gastrointestinal tract before nitrate administration.
OESOPHAGUS CARDIA PROXIMALSTOMACH
DISTAL
STOMACH
pH 7.0 (6.6 -  7.6) 2.8 (2.5 -  3.7) 1.7 (1 .5 -3 .0 ) 1.5 (1 .4 -2 .2 )
Nitrite (pM) 165.5 (103.4- 237.6) 30.9 (12.4-57.9) 0 (0 -1 8 .7 ) 0
Ascorbic acid (pM) 6.9 (1.5 -15 .5) 6.9 (1 .3-12.0) 19.9 (5 .5 -50 .6) 40.4 (12 .3- 101.0)
Total Vitamin C 
(pM) 7.8 (5.4 -16 .1) 14.9(7.1-30.1) 35.1 (13.5-79.9)
68.4 (22.7 -  
128.1)
Thiocyanate (pM) 629 (438 -1237) 469(273-1057) 651 (381 -  1009) 650 (325-1139)
Table 10.2: Median (IQR) pH, nitrite, ascorbic acid, total vitamin C and
thiocyanate concentrations in the different regions of the upper 
gastrointestinal tract following nitrate administration.
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10.6 Discussion.
Previous studies have regarded the gastric lumen as a homogeneous 
compartment with respect to acid-catalysed nitrosation and examined the 
concentrations of chemicals relevant to luminal nitrosation in saliva and aspirated 
mixed gastric juice We examined the luminal concentrations in different
anatomical regions of the upper gastrointestinal tract. This showed that the most 
proximal cardia region of the stomach has the most favourable chemical 
conditions for luminal generation of Wnitroso compounds. The concentrations of 
both nitrite and thiocyanate were found to be high in the distal oesophagus. 
Thiocyanate concentration in the distal oesophagus was approximately half of the 
concenti'ation in saliva whereas nitrite concentration in the distal oesophagus was 
similar to that in the saliva. Nitrite concentration in the oesophagus increased 
approximately nine-fold following nitrate ingestion consistent with it originating 
from the enterosalivary recirculation of nitrate and its reduction by buccal bacteria 
(286 - 288,325,326) interesting finding was that approximately 50% of the subjects 
had a higher concentration of nitrite in their distal oesophagus than in the salivary 
samples. The high concentrations of nitrite and thiocyanate in the oesophagus are 
largely due to swallowing saliva and difhision distributing these anions produced 
in the mouth thi'oughout the oropharyngeal-oesophageal cavity. However, nitrate 
and thiocyanate are secreted by many exocrine glands which likely
includes oesophageal submucosal glands which are similar to salivary glands 
The fact that the oesophageal thiocyanate concentration was lower than that of the 
saliva whereas approximately 50% of the subjects had oesophageal nitrite 
concentration higher than that of saliva suggests that more nitrite was either being 
secreted in the oesophagus, or more likely, an on-going reduction of nitrate to 
nitrite was occurring within the oesophageal lumen by the bacterial nitrate 
reductase activity present in the saliva. Nitrate reduction has been demonstrated 
outside the oral cavity in expectorated saliva and nitrate reduction is unlikely 
to be confined to the oral cavity. Concentrations of both nitrite and thiocyanate 
measiued in the saliva sample obtained prior to insertion of the orogastric tube 
were approximately two times higher than those measured in saliva when the tube 
was in place. This can be explained by the presence of the tube stimulating buccal 
secretions. Stimulation of salivary secretion has been shown to reduce the
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concentration of nitrate and nitrite in saliva However, the output of nitrate
increases on stimulation and more nitrate may be reduced to nitrite during 
mechanical stimulation
Our studies have also demonstrated that there are marked differences in the 
concentrations of nitrite and ascorbic acid in the different anatomical regions of 
the stomach. Under fasting conditions, little nitrite was detected in the stomach. 
However, following nitrate ingestion, the nitrite concentration increased in the 
most proximal cardia region of the stomach but showed no significant rise in the 
more distal regions of the stomach. Consequently, the nitrite concentration after 
nitrate ingestion was highest in the gastric cardia. The observation that the nitrite 
concentration was highest in the cai’dia region of the stomach is consistent with 
the fact that nitrite enters the acid secreting stomach via the oesophagus which 
opens into the gastric cardia. When this nitrite enters the stomach the acidic 
gastric juice containing ascorbic acid, rapidly converts nitrite to nitrous acid and 
subsequently to nitric oxide, the latter will rapidly diffuse into the surrounding 
epithelium ^^ ^^ .333)
The total vitamin C concentration, and to some degree the ascorbic acid 
concentration in the distal stomach, increased non-significantly following the 
administration of nitrate. In 6 out of the 17 subjects the total vitamin C 
concentrations were lower at all gastric sites, including the cardia, during the pre­
nitrate period compared to the post-nitrate period. A possible explanation is that 
immediately after inserting the microdialysis assembly, the salivary flow may 
have been greater compared to the post-nitrate period of the study when the 
subjects were accustomed to the presence of a foreign object in the upper gastro­
intestinal tract and therefore may have been producing less saliva and hence less 
dilution of gastric juice vitamin C. The concentrations of ascorbic acid and total 
vitamin C also showed marked intragastric regional variations both being lower in 
the cardia region than in the proximal or distal stomach.This pattern was apparent 
both before and following nitrate ingestion. The reason for the concentration of 
ascorbic acid and total vitamin C being lowest in the most proximal cardia region 
of the stomach is also uncleai’. Vitamin C present in fasting gastric juice is 
believed to be due to its active secretion by the gastric mucosa (274,275) cePs 
responsible for secreting the vitamin into gastric juice are not known but biopsies 
from dilTerent regions of the stomach have shown that the mucosa levels of
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vitamin C are highest in the antrimi In contrast with nitrite and ascorbic acid, 
there was no gradient in the intragastric concentration of thiocyanate with 
substantial concentrations being present throughout the stomach. The 
concentration of thiocyanate in the stomach was similar to that in the oesophagus 
and 50% of that in saliva.
The fact that the cardia region of the stomach had both the highest nitrite 
concentration and lowest ascorbic acid concentration meant that the ratio of 
ascorbic acid to nitrite was markedly lower in the cai'dia than in the more distal 
stomach. Before nitrate administration, the median ascorbic acid to nitrite ratio at 
the cardia was 1.5 versus 20.8 in the proximal and 27.7 in the distal stomach.
After nitrate, the ratio in the cardia was only 0.3 compared with 7,8 in the 
proximal and 40 in the distal stomach. The ratio of ascorbic acid to nitrite is a 
critical determinant of acid nitrosation (^ >7,259.334)^  When ascorbic acid is in excess 
of nitrite, acid nitrosation is prevented (257,259)^  These observations indicate that 
the potential for intragastric acid catalysed luminal nitrosation will not be uniform 
throughout the length of the stomach but will be maximal in the most proximal 
cardia region. At this location, intragastric nitrite is maximal, intragastric ascorbic 
acid minimal, and thiocyanate is available to catalyse the nitrosation process. The 
clinical significance of om' obseiwations is that the anatomical location of 
maximal potential for acid catalysed luminal nitrosation corresponds with the 
location of the highest incidence of epithelial mutagenesis within the healthy acid 
secreting stomach It is tempting to propose that luminally generated N-
nitroso compounds may be contributing to the high incidence of metaplasia and 
neoplasia at the gastric cardia. V-nitroso compounds can rapidly diffuse into the 
adjacent epithelium and therein be metabolically activated to powerful DNA 
alkylating agents In addition, many JV-nitroso compounds are unstable
and therefore their epithelial effects will be maximal nearest their site of 
formation. The findings of our current study are consistent with our previous 
observation that nitric oxide levels are maximal at the gastric cardia In the 
present study, the concentration of nitrite was similar in buccal saliva and down as 
far as the distal oesophagus but then fell substantially on entering the gastric 
cardia. The fall in nitrite concentration between the distal oesophagus and cardia 
can be explained by the acidic gastric juice and its ascorbic acid content 
converting nitrite to nitric oxide
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Observations in oui' earlier study together with those of our present study 
indicate that two distinct luminal mechanisms both potentially leading to 
epithelial DNA damage are occurring maximally at the most proximal cardia 
region of the acid secreting stomach. (Fig 6.2). The first involves generation of 
high luminal concentrations of nitric oxide arising from the reaction between 
salivary nitrite and gastric juice ascorbic acid This nitric oxide will diffuse 
into the adjacent epithelium and within the cells form nitrosating species which 
can directly and indirectly damage DNA The second mechanism which is 
reported in the present study involves the generation of nitrosating species within 
the lumen due to the acidification of nitrite in the absence of adequate ascorbic 
acid. These nitrosating species formed in the lumen may react with nitrogenous 
compounds present in the lumen to form A-nitroso compounds which may then 
diffuse into the epithelial cells to damage DNA. The first mechanism is promoted 
by the presence of ascorbic acid whereas the second is promoted by the lack of 
ascorbic acid. Both mechanisms may operate maximally at this site although not 
simultaneously. When a bolus of nitrite laden saliva enters the cardia the ascorbic 
acid will convert much of it to nitric oxide. In the process, ascorbic acid will be 
consumed leading to the second mechanism now occurring at that same site. A 
common factor driving both processes is the delivery of nitrate derived nitrite into 
the acidic cai'dia region of the stomach. Further studies are required to determine 
whether this nitrate derived nitrosative chemistry focused at the most proximal 
cardia region of the acid secreting stomach is contributing to the high incidence of 
mutagenesis at this anatomical site.
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CHAPTER ELEVEN
NITRITE CONCENTRATIONS 
IN THE UPPER 
AERO-DIGESTIVE TRACT 
IN HEALTHY VOLUNTEERS
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11.1 Introduction.
The major source of nitrate found in the human saliva is derived from the 
diet with approximately 1 mmol per day of nitrate being derived endogenously 
279,284)^ Y iig  nitrate is taken up by the salivary gland where it is concentrated and is 
then secreted in the saliva into the oral cavity where nitrate is reduced to nitrite 
(286,287) reduction of nitrate to nitrite in the oral cavity is enzymic as boiled or 
filtered saliva is devoid of such activity and it also follows the classic 
Michaelis Menton kinetics The enzyme nitrate reductase is derived from the 
bacteria found in the oral cavity and ingestion of antibiotics or the use of 
chlohexidine antibacterial mouthwash greatly reduces/ abolishes the conversion of 
nitrate to nitrite The nitrate reductase activity is located on the dorsum of
the tongue and the other mucosal surfaces are apparently devoid of such activity 
However, nitrate reduction to nitrite does not necessarily have to take place 
on the surface of the tongue as studies of expectorated saliva have shown nitrate 
reducing capability
Our preceding study revealed a high concentration of nitrite in the distal 
oesophageal lumen. The concentrations of the chemicals relevant to nitrosation, 
which include nitrite, nitrate and thiocyanate in the other regions of the upper 
aero-digestive tract including the nasal cavity and the pharynx are presently 
unknovm and maybe important in the pathogenesis of neoplasia in this region.
Our previous study has shown that microdialysis probes are a suitable method for 
sampling chemicals from multiple sites simultaneously and with slight 
modifications in assembly of the probes we were able to measure the chemicals 
within the upper aero-digestive tract.
11.2 Aim.
The aim of this part of the study was to investigate the concentrations of the 
chemicals relevant to nitrosation in the pharynx, the upper and lower oesophagus 
as well as the nasal cavity. In addition the study was conducted to elucidate 
whether there was any concentration gradient for these chemicals in the upper 
aero-digestive tract.
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11.3 Methods.
i) Microdialysis Assembly
Four microdialysis probes were mounted onto a thin nasogastric tube and 
secured as before. They were spaced such that a microdialysis probe was 
positioned in the nasal cavity, phaiynx (7.5cm distal to the nasal probe), upper and 
lower oesophagus (10 and 20cm distal to the pharyngeal probe respectively)
(Figl 1.1). The positions of the microdialysis probes could be estimated 
beforehand as the endoscopic measurements were available prior to the study. A 
fine Teflon feeding catheter was secured to the assembly to allow administration 
of nitrate solution into the distal oesophagus. The microdialysis probes were 
tested for their recoveries of nitrite and thiocyante at pH 7 at 37°C prior to human 
experiments.
ii) Subjects and experimental procedure
Seven asymptomatic, healthy volunteers were studied. The subjects 
consumed a low nitrate diet for 24 horns and attended having fasted overnight.
The probes were passed intra-nasally and the pharyngeal microdialysis probe was 
observed to be in the correct position by observing the oral cavity during 
placement of the probe assembly.
The microdialysis probes were perfused with distilled water at 0.15 mL h"^  
and allowed to run for 15 minutes to reach equilibrium. The microdialysis 
products were collected in 20 pL of 1 M NaOH. Collection of the microdialysis 
samples was performed for 40 minutes under fasting conditions and 40 minutes 
after 50 ml of 2 mmol potassium nitrate solution administration. A 10-minute time 
lag was included for starting and ending the collection of microdialysis products 
to allow for the time the dialysate to travel the length of the microdialysis 
collecting tube. One half of the product was removed and transferred to another 
vial and stored at -80°C for later analysis of nitrate by HPLC. Semm nitrate and 
salivary samples were collected every 15 minutes as described in the previous 
experiments for microdialysis. The microdialysis probes were decontaminated and 
their function checked prior to reassembly as mentioned previously.
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ni) Chemical analyses
Serum nitrate was analysed using bacterial nitrate reductase to reduce the 
nitrate to nitrite and then analysed colorimetrically using the Greiss reagent as 
previously described. Measurement of serum nitrate by HPLC after filtration 
through a micofilter was attempted but the separ ating column became rapidly 
contaminated and hence the samples were analysed colorimetrically.
Salivary nitrite was analysed colorimetrically using the Greiss reagent as 
described previously. A small number of salivary specimens (4 patients) were also 
analysed for nitrate and nitrite using high performance liquid chromatography as 
described below.
Microdialysis sample for nitrite was analysed both colorimetrically using 
the Greiss reagent and by HPLC as described above. Microdialysis samples of 
nitrate were analysed using HPLC since collection in NaOH and the small 
volumes involved (50 pL) made it impossible to use the bacterial nitrate reductase 
method without ‘risking’ the loss of the samples during the neutralisation of alkali 
with acid. Thiocyanate samples were analysed colorimetrically using the Bowler 
method as described previously.
iv) Nitrate analysis by high performance liquid chromatography
Nitrate concentrations in the microdialysis samples were determined by 
HPLC using an ultraviolet detector employing the method described by Blanco 
(342) instruments comprised of an automated sample injector (Shimadzu SIL- 
10AD) with a 50 pL loop, a pump (Shimadzu LC-IOAT VP), an ultraviolet 
detector (Shimadzu SPD-6A), a precolumn (Phenomenex Security guard SAX 
strong anion exchanger 4 x 3  mm (i.d.)) and an analytical column (Paitisil SAX 
10 pm, 25 cm x 4.6 cm (i.d.)) respectively. The mobile phase consisted of 20 mM 
NaCl with 1 mM sodium dihydrogen orthophosphate adjusted to pH 7 using 1 
mM NaOH. A mixture of 85 % mobile phase and 15 % acetonitrile was used. The 
mixture was filtered through a 0.45 micron filter and degassed with helium.
Analysis was performed at room temperature. The flow rate was 1.5 mL 
min'^ and the retention time of nitrate was approximately 6 minutes. A stock 
nitrate solution of 10 mM was prepared every 2 weeks and stored at 4®C. Working 
standards of 1000, 500, 250,125, 62.5, 31.25,15.6 and 7.8 pM were prepared by
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diluting appropriate volumes of the stock solution on the day of analysis. The 
autosampler was programmed to inject 20 pL of standards, quality control and 
samples. Saliva samples were centrifuged at 13000 r.p.m for 2 minutes and 
diluted with distilled water to a ratio of 1:2 to 1:5 depending on the nitrite 
concentration as determined colorimetrically. The variable dilution was to ensure 
that the nitrate in the samples was diluted sufficiently to lie within the ‘standard 
curve’. It was assumed that approximately 30% of the nitrate will be converted to 
nitrite and hence we derived the approximate nitrate concentration and diluted the 
samples accordingly so that the samples were neither too concentrated nor too 
dilute. Microdialysis samples were injected undiluted, unless the microdialysis 
sample analysed for nitrite suggested further dilution was necessary. Subsequent 
standards and samples were procesessed with standards and quality controls 
occuring every tenth sample. The coefficient of variation for this method was
10.7 % for 15.6 pM and < 5 % for nitrate concentrations >31.25 pM.
11.4 Data Analyses.
The microdialysis nitrite concentrations are presented using the 
colorimetrically derived data. The results obtained using the HPLC and the 
colorimetric methods were very similar in most instances but the HPLC appeared 
to significantly overestimate the nitrite concentrations on a number of samples 
where the data was clearly incorrect both in relation to the nitrite as determined 
colorimetrically and the nitrate concentration as determined simultaneously by 
HPLC. Since we have found the colorimetric method for nitrite determination to 
be accurate and reproducible in our experience with the lowest detection limit 
being 1 pM, and that the higher nitrite concentrations as determined by the 
colorimetric method was in good agreement with the HPLC method, the nitrite 
data is presented from the colorimetric analysis. The nitrate data was derived 
using HPLC as the method of collection for the microdialysis and saliva 
specimens entailed collecting the samples In NaOH which rendered the nitrate 
reductase method unsuitable.
The data are presented as median and inter-quartile range unless otherwise 
stated. Serum nitrate, salivary nitrite, salivary thiocyanate and saliva nitrate 
concentrations were grouped into pre-nitrate (0 -  45 minutes) and post-nitrate
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periods (90 -  135 minutes) and the two periods were compared using the 1- 
sample Wilcoxon test. Comparisons of salivary nitrite, nitrate and thiocyanate 
before (-15 minutes) and after (0 -  45 minutes) insertion of the microdialysis 
probes were performed using the Mann-Whitney U test. For the microdialysis 
samples, Kruskall-Wallis test was used to analyse the chemicals of interest at the 
different anatomical regions for both the pre and post-nitrate data. Comparison 
between pre and post-nitrate microdialysis data was analysed using the 1 -sample 
Wilcoxon test. A two-tailed p<0.05 was considered statistically significant.
The concentrations of thiocyanate, nitrite and nitrate in the pharynx, upper 
oesophagus and lower oesophagus relative to the concentrations of these 
chemicals in the saliva were examined. The results are expressed as a percentage 
and calculated using the equation shown below. Where either the nitrite or the 
nitrate was undetectable, the data for the ratio was excluded. We did not compare 
the concentrations of the chemicals in the nasal cavity as the site was not exposed 
to saliva.
Concentration o f chemical in the microdialysis sample 
---------------------------------------------------------------------------------------------------------XlOO %
Mean concentration o f  the chemical in saliva over the 40 minute collection period
Nitrite to nitrate ratio was also examined in the different anatomical sites and was 
expressed as a percentage.
11.5 Results.
Seven subjects were included in the study, six were male. The mean age was
29.1 years (range: 19 - 42).
11.5.1 Serum Nitrate.
The serum nitrate concentration increased from 11.0 pM (9.2 -  13.4) before 
the administration of nitrate to 34.6 pM (26.7 -  42.3) after the administration of 
nitrate
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(p < 0.001) with a peak of 38.3 pM (28.7 -  45.5) at 75 minutes, 25 minutes after 
nitrate administration (Fig 11.2).
In the four patients who had salivary nitrate measured, the serum nitrate 
concentration was 10.6 pM (9.3-12.3) before the administration of nitrate and 
32.6 pM (22.2 -  38.3) after the administration of nitrate (p = 0.001).
11.5.2 Saliva.
i) NitritCf nitrate and nitrite to nitrate ratio
The salivary nitrite concentration in the seven subjects before inserting the 
microdialysis assembly (-15 minutes) was 89.1 pM (38 -  149.3). Following 
insertion of the microdialysis probes salivary nitrite concentration fell to 29.7 pM 
(16 -  41.5) before the administration of nitrate (0 -  45 minutes) (p = 0.003 vs 
before inserting microdialysis probes) and increased to 259 pM (123 -  329) 
following the administration of nitrate (90 -  135 minutes) (p < 0.001 vs pre­
nitrate) with a peak concentration of 331 pM (139 - 371) at 75 minutes, 25 
minutes after nitrate administration. The nitrite concentration decreased to 121.2 
pM (115 -  170) at the end of the experiment at 135 minutes (Fig 11.3).
In the four subjects that had salivary nitrate measured, the salivary nitrate 
concentration before the insertion of the microdialysis probes (-15 minutes) was 
178.7pM (100.1 -  246.5). Following the insertion of the microdialysis probes the 
nitrate concentration fell slightly to 137 pM (101 -184) (N.S. vs before 
micro dialysis insertion) before the administration of nitrate (0 -  45 minutes) and 
increased to 1237 pM (471 -  1769) after the administration of nitrate (90-135 
minutes) (p < 0.001 vs pre-nitrate). In these four subjects the salivary nitrite 
concentrations were similar to the salivary nitrite concentrations of the whole 
group. The salivary nitrite concentration for the four subjects was 119.2pM (50.8 
-  202.3) before the insertion of the microdialysis probes (-15minutes) which fell 
after the insertion of the microdialysis assembly to 30.4 pM (7.9 -  66.5) before 
the administration of nitrate (p = 0.04 vs before microdialysis insertion) and 
increased to 175.3 pM (121.4 - 360.9) following the administration of nitrate (p < 
0.001 vs pre-nitrate). The peak nitrite concentration was 268 pM (77 - 619) at 90
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minutes, 40 minutes after nitrate, and this slowly declined to 121.6 pM (115.3 -  
195.3) at the end of the experiment at 135 minutes.
The median salivary nitrite to nitrate ratio for the four patients before 
insertion of the microdialysis assembly (-15 minutes) was 0.87 (0.22 -  1.19). 
Following the insertion of the assembly the ratios were significantly lower, the 
ratio was 0.21 (0 -  0.66) before the administration of nitrate (p < 0.05 vs before 
insetion of microdialysis assembly) and 0.23 (0.1 -  0.42) following the 
administration of nitrate (N.S. vs pre-nitrate).
ii) Thiocyanate
Before the insertion of the microdialysis assembly (-15 minutes) the salivary 
thiocyanate concentration in the seven subjects was 1833 pM (372 - 3429). The 
salivary thiocyanate concentration fell to 796 pM (330 -  1602) after microdialysis 
insertion and before the administration of nitrate (0 -  45 minutes) (N.S. vs before 
microdialysis insertion). Following the administration of nitrate (90 -135 
minutes) the thiocyanate concentration remained at a similar concentration of 821 
pM (312 -  1407) (N.S. before nitrate).
11.5.3 Microdialysis samples.
i) Nitrate, nitrite and thiocyanate in the upper aerodigestive tract
The nitrate concentrations in the nasal cavity, pharynx, upper and lower 
oesophagus before the administration of niti'ate for the seven subjects were 8.9 
pM (0 -  13.1), 58.9 pM (25.3 -  64.7), 93.9 pM (78.4 - 113) and 89.2 pM (72.7 - 
125) respectively (p = 0.001 for trend, Kruskall-Wallis). The concentrations 
following the administration of nitrate were 41.6 pM (34.1 -  51.7), 383 pM (132 - 
493), 795 pM (566 - 1221) and 814 pM (365 - 1386) for the nasal cavity, pharynx, 
upper and lower oesophagus respectively (p = 0.002 for trend, Kruskall-Wallis; p
< 0.05 vs pre-nitrate for all 4 sites) (Fig. 11.4).
The nitrite concentrations for the seven subjects before the administration of 
nitrate were 0 pM, 6.8 pM (1 .6 - 15.8), 21.0 pM (11.5 -  49.7) and 19.9 pM (17.2 
-  37.8) for the nasal cavity, pharynx, upper and lower oesophagus respectively (p
< 0.001 for trend, Kiuskall Wallis). Following the administration of nitrate no
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nitrite was detected in the nasal cavity whereas nitrite eoneentrations increased to 
93 pM (23.8 -  213), 243 pM (134 - 271) and 196pM (142 - 289) in the pharynx, 
upper and lower oesophagus respectively (p = 0.001 for trend, Kruskall-Wallis; p 
< 0.05 vs pre-nitrate for pharynx, upper and lower oesophagus) (Fig. 11.4).
The thiocyanate concentrations in the nasal cavity, pharynx, upper and 
lower oesophagus for the seven subjects before the nitrate administration were 90 
pM (72 - 128), 262 pM (110 - 985), 638 pM (223 - 1142) and 725 pM (181 - 
1146) respectively (p = 0.003 for trend, Kruskall-Wallis). Following the 
administration of nitrate, concentrations of thiocyanate in the nasal cavity, 
pharynx, upper and lower oesophagus remained unchaged at 100 pM (42.0 - 109), 
326 pM (128 - 845), 633 pM (240 - 1361) and 594 pM (219 - 1432)
(p = 0.003 for trend, Kruskall-Wallis) respectively (Fig. 11.4).
ii) Nitrite to nitrate ratio in the upper aerodigestive tract
The median (range) nitrite to nitrate ratios, expressed as percentage were 
0% (N = 5), 9% (1 - 67) (N = 7), 26% (11 - 97) (N = 7) and 32% (13 - 100) (N = 
6) before the nitrate meal in the nasal cavity, pharynx, upper and lower 
oesophagus respectively (p = 0.002, Kruskall-Wallis); the ratios after the nitrate 
meal were 0%, 19% (5 - 110), 22% (15 - 92) and 28% (14 - 93) for the respective 
anatomical regions (p = 0.002, Kruskall-Wallis; p == N.S. vs pre-nitrate). In 
comparison the corresponding salivary nitrite to nitrate ratios, in the 4 subjects 
where salivary nitrate was available, were 0.21 (0 -  0.66) before nitrate 
administration and 0.23 (0.1 -  0.42) following nitrate administration.
11.5.4 Thiocyanate, nitrite and nitrate concentrations in the 
pharynx and the oesophageal lumen relative to salivary 
concentrations.
i) Thiocyanate
The median (range) ratio of thiocyanate concentration in the phai ynx, upper 
and lower oesophagus relative to the thiocyanate concentration in the saliva 
expressed as a percentage for the seven subjects before the administration of
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nitrate were 43 % (11 -  60), 76 % (46 -  104) and 72 % (31 -  109) (p = 0.013 for 
trend, Ki’uskall-Wallis) respectively. After nitrate administration they were 44 % 
(9 -70), 88 % (45 -  102) and 79 % (29 -  103) in the pharynx, upper and lower 
oesophagus respectively (p = 0.012 for trend, Ki'uskall-Wallis; p = N.S. pre vs 
post-nitrate).
ii) Nitrite
The median (range) ratios of the nitrite concentration in the pharynx, upper 
and lower oesophagus relative to the nitrite concentration in the saliva expressed 
as a percentage for the seven subjects were 31 % (3 -  49), 81 % (47 -  160) and 
92 % (59 -  103) (p = 0.01 for trend, Kruskall-Wallis) before nitrate 
administration; 38 % (3 -  93), 82 % (44 -  160) and 59 % (49 -  190) after nitrate 
administration in the pharynx, upper and lower oesophagus respectively (N.S. for 
trend, p = 0.035 for pharynx pre vs post-nitrate).
In one of the 7 subjects before nitrate administration and 3 of the 7 subjects 
after nitrate administration, nitrite concentrations in the oesophagus were greater 
than that of the saliva. The concentrations of nitrite detected in the upper 
oesophagus for one subject before nitrate administration was 160% of the salivary 
nitrite concentrations. The concentrations of nitrite detected from the lower 
oesophagus for the 3 subjects after nitrate administration were 130%, 160% and 
190% of the salivary nitrite concentrations.
Hi) Nitrate
The results presented are for the 4 subjects with salivary nitrate data. The 
median (range) ratios of the nitrite concentration in the pharynx, upper and lower 
oesophagus relative to the nitrite concentration in the saliva expressed as a 
percentage were 33% (29- 42), 69 % (36 -  110) and 93 % (36 -  119) (N=3) 
before nitrate administration; 33 % (22 -  59), 53 % (45 -  104) and 56 % (36 -  
118) after nitrate administration in the pharynx, upper and lower oesophagus 
respectively. No statistical analysis was performed in view of the small sample 
sizes.
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Fig 11.1; Positions of the microdialysis probes.
Red dots indicate the positions of the microdialysis probes in the 
nasal cavity, pharynx, upper and lower oesophagus.
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administration.
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Fig 11.3: Median salivary nitrite concentrations before and after nitrate
administration.
Error bars represent IQR. Two mmol potassium nitrate administered 
at SOmins (red arrow). MD indicates periods of micro dial y sis 
sampling (black arrows); 0 to 45 minute collection period is before 
nitrate administration and 90 to 135 minute collection period is after 
nitrate administration. Before insertion of the microdialysis probes, 
the nitrite concentration was 89 pM (38 -149). 
t  p < 0.001 comparing 90 - 135 minutes (after nitrate) vs 0 - 45 
minutes (before nitrate),
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Fig 11.4: Concentrations of nitrate, nitrite and thiocyanate in the upper
aerodigestive tract before and after nitrate administration.
The horizontal bars indicate medians. NC, nasal cavity; PHX, 
pharynx; UOE, upper oesophagus; LOE, lower oesophagus.
N O ] , nitrite; N O /, nitrate; SCN", thiocyanate.
*  p = 0.001 for comparing different anatomical regions for pre-nitrate, 
Kruskall-Wallis.
* * p  = 0.002 for comparing different anatomical regions post-nitrate, 
Kruskall-Wallis; p < 0.05 for all sites vs pre-nitrate, 
t p < 0.001 for comparing different anatomical regions pre-nitrate, 
tt p = 0.001 for comparing different anatomical regions post-nitrate;
p < 0.05 for pharynx, upper and lower oesophagus vs pre-nitrate, 
t  p < 0.05 for comparing different anatomical regions pre and post­
nitrate.
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11.6 Discussion.
We have previously studied the concentrations of the chemicals relevant to 
nitrosation in the saliva and the lumen of the upper gastrointestinal tract of healthy 
subjects without gastro-oesophagel reflux (chapter 10). The previous study 
indicated that significant concentrations of nitrite and thiocyanate were present in 
the saliva and the distal oesophagus. In the current study, the fasting salivary 
nitrite concentration of 30 pM increased by over 10-fold to a peak of 331 pM 
following nitrate administration. The nitrite concentration in the distal oesophagus 
increased from 20 pM before nitrate administration to 180 pM after nitrate 
administration. Both the saliva and oesophageal nitrite results were similar to the 
previous study in subjects without gastro-oesophageal reflux.
In the four patients in whom salivary nitrate was measured, the median 
nitrate concentration was 137 pM before nitrate administration and increased 
almost 10-fold to 1237 pM following nitrate administration. This is in comparison 
to the serum nitrate concentrations of 11 pM and 33 pM respectively. The serum 
nitrate concentrations following nitrate administration was somewhat lower than 
in the previous study (17pM before nitrate administration and 59pM after nitrate). 
The substantially higher nitrate concentration in the saliva compared to the serum 
is due to the active uptake and concentration of the anion by the salivary gland 
(282) Yhe disproportionately higher salivary nitrate concentration compared to the 
serum nitrate concentration after nitrate administration in this study is likely to be 
due to the nitrate reductase method employed for nitrate reduction in the serum 
may have potentially underestimated the nitrate concentration in the serum 
There appears to be a non-proteinaceous chemical (serum filtered through a 10 
micron microfilter) in the serum which inhibits the bacterial nitrate reductase. We 
were also unable to utilise the HPLC for serum nitrate measurement due to the 
contamination of the analytical column by filtered serum which interfered with 
the assay. These problems however do not detract from our findings as the main 
aim was to measure the concentrations of the chemicals in the lumen of the upper 
aero-digestive tract and measurement of the serum nitrate was merely to confiiTn 
the increase in serum nitrate following its administration.
Approximately 20 to 30 % of the nitrate is converted to nitrite in the saliva 
as indicated by the salivary nitrite to nitrate ratio. The ratios ranged from 0 to
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100 %. Despite such a wide range, the ratios in an individual patient were 
consistent throughout the experimental period. Such individual variability has 
been noted previously The variability between patients can be
explained by variability in the salivary flow rate and the capacity to reduce 
nitrate to nitrite Salivary secretions are devoid of nitrite
Salivary nitrite is derived from the bacterial reduction of salivary nitrate within 
the oral cavity. Where the saliva flow rate is lower, the time available for nitrate 
reduction to nitrite by bacterial enzymes is greater and hence nitrite concentration 
will be greater as a result. The insertion of the microdialysis assembly stimulates 
the flow of saliva and in so doing reduces the concentration of both nitrate and 
nitrite. The reduction in the salivary nitrite to nitrate ratio in our study following 
stimulation is in contrast to the study by Granli where mechanical stimulation 
increased the nitrite to nitrate ratio in some individuals Granli's study 
involved chewing to stimulate salivary production whereas in our patients 
stimulation was effected by the presence of a foreign material. Chewing is likely 
to mix the bacteria on the dorsum of the tongue more thoroughly with saliva and 
therefore make nitrate reduction more efficient and likely account for the 
difference observed.
Our study is the first to describe the concentrations of nitrate, nitrite and 
thiocyanate in the nasal cavity, the phaiynx and the upper and lower oesophagus 
by utilising the microdialysis probes which enabled simultaneous measurement of 
these chemicals at the different sites. Before the nitrate meal, the concentration of 
nitrate was lowest in the nasal cavity followed by the pharynx and then the 
proximal and the lower oesophagus (both of the latter had similar concentrations 
of the chemicals). Due to the design of the microdialysis assembly the secretions 
in the nasal cavity may not have been in constant contact with the mucosa in the 
nasal cavity which resulted in the lower concentrations of the various chemicals 
sampled. What is clear from the data, however, is that there appears to be no 
nitrate reduction to nitrite within the nasal cavity even after nitrate administration 
when nitrate concentrations in the nasal cavity increased by 5-fold. The bacterial 
nitrate reductase catalyses the nitrate reduction to nitrite in the oral cavity. In man 
the dorsal surface of the tongue appears to be the site of nitrate-reducing activity 
whereas the inferior surface of the tongue, the buccal surface, the hard and soft 
palates are devoid of such activity Bacterial nitrate reductase is induced
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during anaerobic respiration Previously published studies examined the 
partial pressure of oxygen within the different regions within the oral cavity 
Eskow noted pO] to be 117 mm Hg and 86 mm Hg in the air above the 
anterior and posterior regions of the tongue whereas pO] was noted to be between 
2 to 3 mm Hg in the buccal pouch Globerman noted the pO] was below 10 
mm Hg when the oxygen tension was measured directly at the surface of the 
tongue The deep pits which are present in the dorsal surface of the tongue 
may provide the anaerobic condition necessary for inducing anaerobic respiration 
in the nitrate-reducing bacteria The oxygen tension within the nasal cavity 
has not been studied as far as we are aware but it is unlikely to have a low oxygen 
tension in the healthy state and may not be suitable for the induction of the 
bacterial nitrate-reductase since nitrate-reducing bacteria are present within the 
nasal cavity Other potential factors for the difference observed for nitrate
reduction to nitrite include differences in the micro-organisms found in the nasal 
cavity and the oral cavity/tongue and the possible differences in the
density of the nitrate-reducing bacteria at the two sites since there appears to be a 
positive correlation between nitrite production and the density of the nitrate- 
reducing bacteria
Compared to the two oesophageal sites the concentrations of the chemicals 
were lower in the pharynx. One explanation for such finding may be because the 
act of swallowing saliva is inteimittent and therefore the microdialysis probe in 
the pharynx may be sampling intermittently within the pharyngeal cavity whereas 
the probes in the oesopahgus lies in a more confined space where the lumen is 
virtually collapsed The viscous saliva swallowed is likely to remain adherent 
on the oesopahgeal mucosa which will be sampled constantly by the microdialysis 
probe which would produce a higher concentrations of chemicals compared to the 
pharynx. This theory is supported by the findings of a lower thiocyanate 
concentration in the pharynx compared to that of the oesophagus. The thiocyanate 
concentrations relative to that of the saliva in percentage terms were 43 %, 76 % 
and 72 % in the pharynx, upper oesophagus and lower oesophagus before nitrate 
administration. A similar trend was seen for thiocyanate concentrations after the 
nitrate meal. In the validation study, at pH > 4 (Chapter 8), nitrite recovery was 
similar to the thiocyanate recovery at approximately 80 - 90 % therefore the low 
concentrations of thiocyanate, nitrite and nitrate in the pharynx compared to the
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oesophageal samples is in keeping with intermittent nature of the microdialysis 
sampling in the pharynx.
In the current experiment, one of the seven subjects before nitrate 
administration and three of the seven subjects after the nitrate administration had 
nitrite recoveries fr om the oesophagus greater than that of the salivary nitrite 
concentrations, one patient by as much as 190 % of the nitrite concentration in the 
saliva. This is likely to be explained by the nitrate being converted to nitrite by the 
action of the bacterial nitrate reductase while the saliva was adherent to the 
oesophageal mucosa since the concentration of nitrite in the oesophagus should 
not exceed that of the saliva as none of the chemicals studied had 100 % recovery 
in the validation studies. Local secretion of nitrite is an alternative explanation 
which may account for the higher nitrite recovery in the oesophagus in some 
individuals. This is unlikely for a number of reasons. Firstly, the submucosal 
glands in the oesophagus are similar to salivary glands and salivary glands do 
not secrete nitrite Secondly, nitrate secreted by the salivary glands is
derived from the nitrate in the blood and nitrite concentrations are extremely low 
in the circulation of healthy individuals as it is rapidly oxidized to nitrate by 
haemoglobin therefore there is no source of nitrite unless it is generated
within the submucosal glands. Another potential explanation could be due to 
mechanical stimulation by the presence of the microdialysis tube. A previous 
study has shown that mechanical stimulation by chewing increased nitrate output 
and increased the nitrite to nitrate ratio in the saliva However, our study 
showed the opposite and the mechanical stimulation of saliva secretion by the 
presence of a foreign body does not appear to explain the above finding.
The significance of such high concentrations of nitrate and nitrite in the 
upper digestive tract is thiee-fold. Firstly, in subjects without gastro-oesophageal 
reflux and a noimal acid-secreting stomach, acid-catalysed nitrosation reaction 
may occur at the gastro-oesophageal junction, where acidic gastric juice first 
meets salivary nitrite. Secondly, bacterial nitrosation which has been proposed as 
a potential mechanism in the development of gastric cancer in the achlohydric 
stomach occur at neutral pH This mechanism may be potentially important 
for the development of neoplasia within the length of the oesophagus since some 
of the bacteria found in the oral cavity are capable of catalysing the formation of 
A-nitroso compounds in the presence of nitrate and nitrite (241,357,358)^  Thirdly,
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nitric oxide, a highly reactive radical is generated at the gastro-oesophageal 
junction where salivary nitrite at neutral pH meets acidic gastric juice containing 
ascorbic acid The nitrite becomes acidified and is rapidly reduced to nitric 
oxide by the ascorbic acid in gastric juice. The nitric oxide thus produced can 
diffuse into the sunounding tissues and may lead to detrimental intracellular 
effects such as deamination of DNA or the formation of A-nitroso
compounds within the cells (202,303) could cause mutagenesis. The first and 
the third mechanisms are acid-dependent and therefore require acid gastric juice 
and are more relevant for cardia and oesophageal adenocarcinoma. Bacterial 
nitrosation, on the other hand, occurs in the absence of acidic gastric juice at 
neutral pH and potentially relevant for squamous oesophageal carcinoma and non- 
cardia gastric cancer. Thus it can be concluded that high concentrations of nitrate 
and nitrite in the upper gastrointestinal tract have the potential of generating 
mutagenic chemicals which may be important in the aetiopathogenesis of cancer 
in the upper gastrointestinal tract.
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CHAPTER TWELVE
STUDY OF NITROSATION POTENTIAL
IN BARRETT’S OESOPAHGUS
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12.1 Introduction.
The incidences of adenocarcinoma of the oesophagus and cardia in the 
western nations have increased dramatically over the past 25 years The 
cause for the marked increase in these cancers is yet to be identified.
An important factor is gastro-oesophgeal reflux, which increases the risk of 
developing esophageal adenocai’cinoma almost 8 -fold compared to those 
individuals without reflux The increased risk appears to be specific for 
Barrett’s oesophagus which markedly increases the risk for developing 
esophageal adenocarcinoma compared to uncomplicated reflux Barrett’s 
oesophagus develops in those with duodeno-gastroesophageal reflux and
the presence of Banett’s oesophagus increases the risk for developing 
oesophageal adenocarcinoma 40-fold over the general population with more 
recent risk estimates suggesting a cancer incidence among patients with Barrett’s 
oesophagus of approximately 1 per 200 patient-years It is assumed
that the reflux of gastric acid, pepsin and bile acids causes mucosal damage 
leading to the development of intestinal metaplasia, dysplasia and subsequently 
adenocarcinoma of the oesophagus. However it is unclear whether the mucosal 
damage induced by the refluxate is sufficient to induce cancer or whether it 
merely sensitizes the epithelium to luminal carcinogens.
In the previous chapters we have discussed the mechanism of acid-catalysed 
nitrosation which involves the acidification of salivaiy nitrite. Acidification of 
nitrite produces the nitrosating species such as N2O3 and NO^ which react with 
nitrosatable substrates to generate carcinogenic A-nitroso compounds. The major 
inliibitor of A-nitroso compound formation within the gastric lumen is ascorbic 
acid which is actively secreted into the gastric juice Ascorbic acid reacts
with the nitrosating species to generate nitric oxide and is itself oxidised to 
dehydroascrorbic acid Although this action of ascorbic acid
inhibits the luminal generation of A-nitroso compounds, the nitric oxide produced 
in the process can readily diffuse into the adjacent epithelium and within it induce 
nitrosative stress as high concentrations of nitric oxide reacts with oxygen
to form the nitrosating species N2O3 The latter can directly deaminate DNA
or indirectly damage DNA via the formation of A-nitroso compounds 
Nitric oxide has also been shown to inhibit a number of DNA repair enzymes '
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306) oxide in high concentrations is known to be mutagenic and is
implicated in neoplasia associated with chronic inflammation In chapter
1 0  we examined the luminal nitrite chemistry following nitrate ingestion in 
subjects with healthy, acid secreting stomachs and without reflux disease. We 
found that this chemistry was focused at the gastric cardia where nitrite in saliva 
first encounters acidic gastric juice. This anatomical location had the chemical 
conditions most favoring luminal A-nitroso compound formation in being the 
acidic environment with the highest nitrite and lowest vitamin C concentration. 
Also, in a previous study we found that the peak nitric oxide concentration 
generated from dietary nitrate occurred at the gastric cardia These 
observations raise the possibility that the active luminal nitrosating chemistry 
occurring at the gastric cardia may contribute to the high incidence of mutagenesis 
occurring at the cardia. In subjects with gastro-oesophageal reflux, the anatomical 
location where saliva nitrite first encounters acidic gastric juice moves proximally 
to within the distal oesophagus rather than at the gastric cardia.
In the present chapter, we have examined the anatomical location of luminal 
nitrosative stress following nitrate ingestion in patients with Barrett’s oesophagus. 
This chapter examines the nitrosation potential within the BaiTett’s oesophagus 
using the microdialysis probes and the following chapter examines nitric oxide 
generation within the Barrett’s segment during periods of acid reflux.
12.2 Methods.
12,2.1 Design of the microdialysis probes
CMA flexible mierodialysis probes employed in the previous experiments 
were used to measure the local luminal concentrations of the chemicals relevant to 
nitrosation (ie nitrite, thiocyanate, ascorbic acid and total vitamin C). Five such 
probes were attached to a 3.3mm diameter nasogastric tube (Rüsch Manufacturing, 
Lurgen, UK) as previously described. The probes were located on the tube so that 
one of the probes would be at each of the following anatomical sites: squamous 
oesophagus, Barrett’s segment, hiatus hernia, proximal stomach and distal 
stomach (Fig 12.1). The hiatal hernia microdialysis probe was positioned 1cm 
below the gastro-oesophageal junction (defined by the position of the proximal
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gastric fold) and the Barrett’s probe 2.5cm above the gastro-oesophageal junction. 
The gastric microdialysis probes were positioned 5 and 10 cm distal to the hiatal 
hernia probe. The probe in the squamous oesophagus was positioned 5 to 10cm 
proximal to the Barrett’s probe. These allowed us to simultaneously measure and 
thus compare the nitrosative chemistry at each of these anatomical locations. 
Individual tubes were prepared for each subject with the location of the 
microdialysis probes located at sites coiTesponding to the patient’s individual 
anatomy. A multi-channel pH catheter (Synectics Medical Ltd., Enfield, U.K.) 
was mounted alongside the nasogastric tube so that we could monitor the luminal 
pH at the site of each microdialysis probe. The outputs from the pH sensors were 
digitalized (DAS 1201 data acquisition board, Keithley Instruments Ltd., Reading, 
Berkshire, U.K.), monitored on a computer screen during the procedure and stored 
on computer for subsequent analysis. A frne-bore Teflon tube with its opening at 
the tip of the nasogastric tube was attached to the assembly for intragastric 
delivery of the nitrate solution.
Each microdialysis probe was perfused with degassed distilled water by 
means of a mierodialysis pump (Univentor 864 microdialysis syringe pump. 
Biotech Instruments Ltd., U.K.) at a rate of 150 pL hi*’\  The mierodialysis product 
was collected from each probe for analysis of the various chemicals. The samples 
for ascorbic acid and total vitamin C were collected into a glass vial (no. 1) 
containing 20 pL of a solution of 2 % metaphosphoric acid and 0.5 % sulphamic 
acid (M/S) and were further diluted with equal volumes of metaphosphoric / 
sulphamic acid solution for ascorbic acid and with 12 mg mL'^ dithiothreitol in 
metaphosphoric/sulphamic acid solution (M/S + DTT) for total vitamin C 
determination. The nitrite and thiocyanate samples were collected into a glass vial 
(no. 2) containing 20 pL 1 M NaOH. The two different collections fr om each tube 
were achieved by alternating the mierodialysis collecting tube between vials 1 and 
2 every two minutes. The vitamin C samples were frozen at -70°C for analysis 
within four weeks and the nitrite and thiocyanate samples were stored at 4®C for 
analysis on the same day. Prior to each study, the fully assembled apparatus was 
calibrated for recovery of each chemical by individual mierodialysis probes as 
previously described.
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12.2.2 Subjects and Methods
Patients with endoscopic evidence of BaiTett’s oesophagus were examined. 
In each subject, the columnar-lined oesophagus extended at least 3 cm proximal to 
the upper border of the gastric folds as determined by previous endocopy. The 
size of the hiatal hernia was measured from the proximal gastric fold to the point 
at which the diaphi agmatic constriction of the gastric lumen occurred. Biopsies of 
the columnar-lined oesophagus confirmed intestinal metaplasia in all patients. 
Each patient was confirmed to be H, pylori -  negative by histology and rapid 
urease test of both antral and hody mucosal biopsies.
The subjects stopped all anti-secretory medications for at least five days and 
were instructed to avoid nitrate-rich foods for 24 hours prior to the procedure. 
They attended in the morning having fasted since the previous evening and 
underwent an endoscopic examination to confirm anatomic locations and to apply 
radio-opaque clips (Haemoclips, Olympus HX-600-090, KeyMed, Southend-on- 
Sea, UK) at the squamo-columnar junction and the gastro-oesophageal junction to 
delineate the Barrett’s segment. Following this the mierodialysis probe assembly 
was passed per orally such that the mierodialysis probes were located 
appropriately using the distance from the incisors as the reference point. The 
position of the assembly was checked by an abdominal X-ray and final adjustment 
performed using the Hemoclips as reference points.
The purpose of this study was to examine the nitrosation chemistry during 
gastro-oesophageal reflux. In order to ensure that reflux occured throughout the 
duration of the experiment, the subjects lay in the right-lateral decubitus position 
(365) without the head-down position to provoke gastro-oesophageal reflux.
A low dose (0.06 pg kg" )^ of pentagastrin (Cambridge Laboratories, Wallsend, 
England, U.K.) was infused intravenously to stimulate physiological levels of 
gastric secretion and acid reflux throughout the study.
The first 15 minute collections of the mierodialysis samples were discarded 
and the following 40 minutes collected for analyses. Following this basal 
collection, 2 mmol potassium nitrate in 25mL of water was administered intra- 
gastrically via the fine Teflon feeding tube attached to the nasogastric tube. Forty 
minutes after administering the potassium nitrate further mierodialysis collections 
were obtained for 40 minutes. The delay between administration of nitrate and
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commencing collections is to allow time for the nitrate to be absorbed, secreted in 
saliva and converted in the mouth to nitrite. Venous blood was obtained from an 
indwelling intravenous catheter every 15 minutes for determination of serum 
nitrate. The samples were centrifuged at 3000 r.p.m. at 4°C for 10 minutes and the 
supernatant for serum nitrate was transferred into a plain test tube and frozen at 
-20®C until analysis within 4 weeks. Samples of saliva were obtained every 15 
minutes for nitrite and thiocyanate determination. This was done by asking the 
patient to spit into a sterile container and 500pL was immediately added to 50pL 
of 1 M NaOH in a 1.5 mL Eppendorf tube for nitrite and thiocyanate analysis and 
stored at 4°C until analysis on the same day. Prior to analysis, the saliva samples 
were centrifuged at 13000 r.p.m. for two minutes using a microcentrifuge and the 
supernatant was analysed.
12.2.3 Chemical Analyses
The chemicals of interest, nitrite, thiocyanate, ascorbic acid and total 
vitamin C were determined as previously. Semm nitrate and salivary nitrite were 
also determined as previously described.
12.3 Statistical Analyses.
Data are presented as medians and inter quartile range (IQR) unless 
otherwise stated. Kmskall-Wallis test was used to analyse the concentrations of 
the chemicals of nitrosation in the different regions of the upper GI tract for both 
pre and post-nitrate data. Comparison between the pre and post-nitrate 
mierodialysis data was analysed using 1-sample Wilcoxon test.
Serum nitrate, salivary nitrite and thiocyanate data and pH of the different 
regions of the upper GI tract were analysed using 1-sample Wilcoxon test using 
the Bonferroni’s correction.
For the analysis of ascorbic acid to total vitamin C ratio, if both ascorbic 
acid and total vitamin C were undetectable from the single sample, the sample 
was excluded from statistical analysis.
In order to calculate the ascorbic acid to nitrite ratio, any samples with 
undetectable levels of ascorbic acid or nitrite concentrations were allocated a
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concentration of 1 pM, the approximate lower limit of detection for both ascorbic 
acid and nitrite using our analytical methods. If both ascorbic acid and nitrite were 
undetectable, these samples were excluded from analysis. Kruskall-Wallis test 
was used to analyse the ascorbic acid to nitrite ratio in the different regions before 
and after nitrate ingestion. A two-tailed p < 0.05 was considered statistically 
significant.
12.4 Results
Fourteen subjects with Barrett’s oesophagus consented to the study. Four 
could not tolerate the procedure and therefore results are available for ten subjects. 
The mean age of the subjects was 65 years (range: 48 - 70) and 4 were females. 
The median length of Barrett’s segment was 5 cm (range: 3-12 cm) for the ten 
patients in the mierodialysis experiment.
12.4.1 Serum
The nitrate concentration in the blood just prior to administration of the 
nitrate solution at 45 minutes was 13.0 pM (12.3-19.8) and the peak nitrate level
50.5 pM (30.5 -  69,6) (p< 0.01 vs 45 min) was seen 55 minutes after the nitrate 
was administered and remained at this level throughout the remainder of the 
experiment (Fig 12.2).
12.4.2 Saliva
i) Nitrite and thiocyanate
The saliva nitrite concentration before the insertion of the probe assembly 
was 73.1 pM (61.8 -  216.4) (n = 9) and fell to 35.0 pM (26.3 -  78.9) at 15 
minutes (n = 9) after the insertion of the mierodialysis assembly (N.S.). Following 
the administration of nitrate, the saliva nitrite concentration increased from 56.3 
pM (23.2 -  82.6) (n = 10) at 45 minutes, just prior to nitrate administration, to a 
peak of 351.4 pM (107.8 -  405.4) at 135 minutes, 85 minutes after nitrate 
administration (p < 0.01) (n = 8) (Fig 12.3).
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The saliva thiocyanate concentration just before passing the probe assembly 
was 794 pM (682 - 1339) (n = 9) similar to 770 pM (459 - 1446) (n = 9) (N.S.) 15 
minutes after the placement of the assembly. The thiocyanate concentrations 
remained at a similar concentration after the administration of nitrate and fell non- 
significantly to 491 pM (333-656) (n = 8) at 135 minutes.
ii) pH  of the individual regions of the upper GI tract
The pH in the squamous esophagus, Baii'ett’s oesophagus, hiatal hernia, 
proximal and distal stomach were 6.2 (5.8 - 7.0) (p < 0.05 vs all other sites), 2.7 
(1.6 -3.3) (p <0.05 vs hiatal hernia, proximal and distal stomach), 1.4 (1.2 -1.9), 
1.4 (1.3 -  1.8) and 1.4 (1.2 - 1.7) respectively before nitrate administration (table
12.1). The respective pH after nitrate administration were 5.7 (4.5 -  6.5) (p < 0.05 
vs all other sites), 2.7 (1.7 -  3.8) (p < 0.05 vs hiatal hernia, proximal and distal 
stomach), 1.6 (1.1 -  1.9), 1.5 (1.2 - 1.6) and 1.4 (1.2 - 1.6) (table 12.1).
The pH was greater than 4 for 94 % (61.9 -  100), 18.7 % (0.9 -  42.3), 0 %
(0 -  0.2), 0 % and 0 % in the squamous esophagus, Barrett’s segment, hiatus 
hernia, proximal and distal stomach respectively before nitrate administration. 
After nitrate administration the respective percent pH > 4 were 92 % (56.3 -
98.2), 3.6 % (1.2 -  15.3), 0 %, 0 %, 0 % (all N.S. vs pre-nitrate).
12.4,3 Mierodialysis Samples
i) Nitrite
The nitrite concentration in the squamous oesophagus before the nitrate 
meal was 40.1 pM (12.7 -  63.4). In the Barrett’s segment, nitrite concentration 
fell to 0 pM (0 -  5.9); for hiatal hernia, proximal and distal stomach the nitrite 
concentrations were 0 pM (0 -  0.3), 0 pM and 0 pM respectively (p < 0.001 for 
trend) (Fig 12.4, table 12.1). Following nitrate administration, the squamous 
oesophageal nitrite concentration was 106.2 pM (75.7 -  141.6) and fell by 98 % 
to 1.9 pM (0 -  7.4) in the Barrett’s segment; the nitrite concentrations in the hiatal 
hernia, proximal stomach and distal stomach were 0 pM (0 -  1.1), 0 pM and
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0 pM respectively (p < 0.001 for trend) (Fig 12.4, table 12.1). The nitrite 
concentrations in the upper GI tract was significantly different before nitrate 
ingestion compared to after nitrate ingestion only for the squamous oesophagus 
(p = 0.03).
ii) Thiocyanate
The thiocyanate concentration in the squamaous oesophagus was the highest 
at 409 pM (319 - 673) before nitrate administration, and in the Barretf s segment, 
hiatal hernia, proximal stomach and distal stomach thiocyanate concentrations 
were 317 pM (192 - 511), 265 pM (239 - 422), 270 pM (231 - 434) and 279 pM 
(223 - 505) respectively (N.S. for trend) (Fig 12.5, table 12.1). Following nitrate 
administration, thiocyanate concentrations in the squamaous oesophagus,
Barrett’s segment, hiatal hernia, proximal stomach and distal stomach were 390 
pM (262 - 622), 260 pM (171 - 679), 235 pM (207 - 486), 229 pM (151 - 440) 
and 249 pM (184 - 494) respectively (N.S. for trend; N.S. vs pre-nitrate) (Fig 
12.5, table 12.1).
Hi) Ascorbic acid and total vitamin C
Increasing ascorbic acid and total vitamin C concentrations were seen 
moving distally from the squamous oesophagus to the distal stomach. The 
ascorbic acid concentrations for the squamous oesophagus, Barrett’s segment, 
hiatal hernia, proximal and distal stomach were 3.5 pM (0 -  11.7), 9.9 pM (3.4 -  
16.8), 27.7 pM (6.7 -  42.5), 38.4 pM (20.6 -  66.6) and 43.4 pM (24.1 -  68.5) 
respectively before nitrate administration (p < 0.001 for trend) (Fig 12.6, table
12.1). Following nitrate administration, the ascorbic acid concentrations for the 
squamous oesophagus, Ban'ett’s segment, hiatal hernia, proximal and distal 
stomach were 1.2 pM (0 -  12.4), 2.9 pM (0.2 -  32.4), 14.7 pM (0-42.7), 28.4 
pM (9.1 -  45.4) and 48,6 pM (17.0 -  73.6) respectively (p = 0.009 for trend)
(N.S. vs pre-nitrate) (Fig 12.6, table 12.1).
Total vitamin C concentrations for the respective regions before nitrate 
administration were 3.8 pM (0 -  14.7), 19.1 pM (5.1 -  32.2), 34.1 pM (10.2 -  
47.5), 41.1 pM (24.9 -  77.0) and 58.9 pM (22.6 -  72.8) (p = 0.001 for trend) (Fig
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12.7, table 12.1). After nitrate administration concentrations of total vitamin C for 
the respective regions were 5.6 pM (0.4 -  34.3), 23.4 pM (13.4 — 28.4), 33.4 pM 
(21.5 -  44.9), 35.6 pM (18.3 -  71.2) and 46.5 pM (20.0 -  78.7) (p < 0.05 for 
trend) (N.S. vs pre-nitrate) (Fig 12.7, table 12.1).
The median ascorbic acid to total vitamin C ratios before nitrate 
administration for squamous oesophagus (n = 7), Barrett’s segment (n = 8), hiatal 
hernia, proximal and distal stomach were 0.70 (0.4 -  0.78), 0.64 (0.55 -  0.70),
0.78 (0.49 -  0.89), 0.93 (0.86 -  0.97) and 0.85 (0.82 -  0.98) respectively (p =
0.028 for trend) (Fig 12.8). After nitrate administration the median ascorbic acid 
to total vitamin C ratios were 0.27 (0 -  0.4) (n = 9), 0.16 (0.02 -  0.63), 0.42 (0.03
-  0.86), 0.67 (0.47 -  0.82) and 0.83 (0.69 -  0.91) (p -  0.048 for trend) (p = 0.018 
for proximal stomach pre-nitrate vs post-nitrate) (Fig 12.8).
iv) Ascorbic acid to nitrite ratio
The ascorbic acid to nitrite ratio provides an indication of the potential to 
generate carcinogenic A-nitroso compounds by luminal acid-catalysed nitrosation. 
The median (IQR) ascorbic acid to nitrite ratios for the squamous oesophagus, 
Barrett’s segment, hiatal hernia, proximal and distal stomach were 0.1 (0.02 - 
0.47), 7.4 (1.6 - 16.8), 26.2 (6.7 - 42.5), 32.3 (15.1 -  65.2) and 32.7 (18.9 - 68.5) 
respectively before nitrate administration (p < 0.001 for trend) (Fig 12.9, table
12.1). The ascorbic acid to nitrite ratios after nitrate administration for the 
respective regions were 0.02 (0.01 -0.13) (p = 0.032 vs squamous oesophagus 
pre-nitrate), 3.4 (0.14 -  12.4) (n = 9), 29.2 (1.5 -  47.9) (n = 8), 25,0 (8.5 -  48.5) (n
-  9) and 34.2 (13.8 -  64.3) (p < 0.001 for trend) (Fig 12.9, table 12.1).
Although the squamous oesophagus had the lowest ascorbic acid to nitrite 
ratio both before and after nitrate administration, acid-catalysed nitrosation does 
not normally occur due to the high pH at this anatomical site. The only anatomical 
sites favouring luminal acid-catalysed nitrosation were in the Barrett’s segment 
where 2 of the 10 subjects before nitrate and 4 of 9 after nitrate had acidic nitrite 
in excess of ascorbic acid and within the hiatus hernia in 1 of the 10 before nitrate 
and 2 of the 8 studied after nitrate. In the proximal and distal stomach, all subjects 
had ascorbic acid in excess of nitrite.
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#  MD probe / pH probe
Qips
G O J
Fig 12.1: Positions of the mierodialysis and pH probes in subjects with
Barrett’s oesophagus.
From proximal to distally: squamous oesophagus, Barrett’s 
oesophagus, hiatal hernia, proximal and distal stomach. Metallic clips 
were attached to the squamo-columnar junction (SCJ) and gastro- 
oesophageal Junction (GOJ) to delineate the Barrett’s segment.
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105 120 135
Fig 12.2: Median serum nitrate concentrations before and after nitrate
administration.
The error bars represent the IQR, Potassium nitrate (2 mmol) was 
administered at 50 minutes, indicated by the red arrow, 
t  p < 0.01 vs 45 minutes, just prior to nitriate administration.
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600
Saliva
(mM)
500 N=8
400
300 Nitrate
N=9
200
N=9100
0
60 90 105 120 13515 0 15 30 45 75
Time (minute)
Fig 12.3: Median salivary nitrite before and after nitrate administration.
The error bars represent the IQR. N=IO  for all time points unless 
indicated otherwise. Potassium nitriate (2 mmol) was administered at 
50 minutes, indicated by the red arrow. -15 minutes indicates 15 
minutes before insertion of mierodialysis probe assembly.
* p<0.05 vs 45 minutes (just prior to nitrate administration).
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0.8 -
AATTVC
Ratio
0.4 -
= 9
P R E *
P O S T ’0.2 -
0.0
BOSQ DGHH PG
Fig 12.8: Median (IQR) ascorbic acid to total vitamin C ratio before and a
after nitrate.
N = 10 unless otherwise indicated.
PRE: before nitrate, POST: after nitrate.
SQ: squamous esophagus, BO: Barrett’s oesopahgus, HH: hiatus 
hernia, PG: proximal stomach, DG: distal stomach.
* p = 0.028 for trend. ** p = 0.048 for trend, ^p = 0.018 pre vs post­
nitrate at proximal stomach.
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Fig 12.9: Ascorbic acid to nitrite ratio before and after nitrate
administration.
SQ: squamous oesophagus; BO: Barrett’s oesophagus; HH: hiatal 
hernia; PS: proximal stomach; DS: distal stomach, 
o condition unfavourable for acid-catalysed nitrosation.
•  condition favourable for acid-catalysed nitrosation.
Note that acid-catalysed nitrosation does not occur in the squamous 
oesophagus where pH is high despite demonstarting the lowest 
ascorbic acid to nitrite ratio.
p < 0.01 for trend both before and after nitrate administration, 
t  p = 0.032 vs pre-nitrate administration.
* p<0.001, Kruskall-Wallis test comparing different regions before 
and after nitrate.
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12.5 Discussion.
In the current study examining the nitrosation chemistry in Barrett’s 
oesophagus during periods of gastro-oesophageal reflux, the most notable finding 
was the fall in luminal nitrite concentration on passing from the more proximal 
squamous oesophagus into the Barrett’s segment exposed to acidic gastric 
refluxate (Fig 12.4, table 12.1). In chapter 10 we examined the nitrite 
concentration in the oesophagus and stomach of normal volunteers without gastro- 
oesophageal reflux. In such subjects, high concentrations of nitrite were found 
throughout the length of the oesophagus and the marked fall in concentration 
occurred on entering the acidic environment of the gastric cardia. Previous work 
indicated that the nitrite concentration in the gastric lumen was similar to that of 
saliva where high intragastric pH was achieved in subjects treated with 
omeprazole Thus the nitrite concentration seems to fall at the point where 
neutral luminal pH first drops to acidic luminal pH. During periods of gastro- 
oesophageal reflux in subjects with Barrett’s oesophagus, the transition from 
neutral to acid pH was occurring more proximally within the Barrett’s segment 
and consequently the nitrite was disappearing more proximally at this site. This 
suggests that nitrite is either being absorbed by the surrounding Barrett’s 
epithelium or being converted to another chemical. When the nitrite passes from 
the neutral pH of the proximal oesophagus into the acidic environment of 
refluxing gastric juice in the Barrett’s oesophagus, it will be converted 
immediately to nitrous acid. However, this in itself cannot explain the marked fall 
in measured nitrite within the Ban'ett’s oesophagus as the mierodialysis probes do 
not distinguish between nitrous acid and nitrite (both measured as nitrite). Nitrous 
acid is less polar than the nitrite anion and the former may be more readily 
absorbed. However, the ability to absorb substances depends upon their polarity at 
the mucosal surface. Columnar mucosa has a mucus layer and this, along with its 
bicarbonate secretion, maintains a neutial surface pH Consequently, nitrous 
acid would be in the form of the nitrite anion at the epithelial surface and 
therefore not fully absorbed. Therefore it seems unlikely that the disappearance of 
nitrite within the Barrett’s segment can be attributed to any significant extent to its 
absorption of nitrite or nitrous acid. A more plausible explanation for the 
disappearance of the nitrite on entering the acidic lumen of the Bai'rett’s segment 
is its conversion to nitric oxide and the absorption of the dissolved gas into the
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Barrett’s epithelium. The mierodialysis probes do not detect nitric oxide (see 
chapter 8). At pH less than 3.5, approximately 1% of nitrous acid exists as nitric 
oxide However, in the presence of acid and reducing agents such as ascorbic 
acid, most of the nitrous acid is rapidly reduced to nitric oxide. Stoichemically, 1 
mole of ascorbic acid reacts with 2 moles of nitrous acid forming 2 moles of nitric 
oxide and 1 mole of dehydroascorbic acid The changes in the ascorbic acid to 
total vitamin C ratio within the Barrett’s segment are consistent with nitrous acid 
reacting with ascorbic acid to form nitric oxide. Prior to nitrate administration, the 
majority of the vitamin C was ascorbic acid at all the sites examined (Fig 12.8).
The Barrett’s segment had the lowest ascorbic acid to total vitamin C ratio both 
before and after nitrate administration. Following the nitrate administration and 
consequently increased delivery of salivary nitrite, there was a marked fall in the 
ratio of ascorbic acid to total vitamin C affecting all regions of the upper 
gastrointestinal tract except the distal stomach where the ratio remained relatively 
constant above 82 % (Fig 12.8). The lowest ratio of ascorbic acid to total vitamin 
C was noted in the Barrett’s segment which is consistent with nitrite in swallowed 
saliva reacting with ascorbic acid within the acidic Barrett’s segment resulting in 
the nitrite being reduced to nitric oxide and the ascorbic acid to dehydroascorbic 
acid. The fall in ascorbic acid to total vitamin C ratio in the regions distal to the 
Barrett’s oesophagus can be explained by the increased nitrite delivery to these 
regions. The acidified nitrite is incompletely reduced in the Barrett’s segment as a 
result of ascorbic acid depletion and / or due to the rapid transit of unreacted 
salivary nitrite and passes to more distal locations until it is reduced to nitric oxide. 
The fall in the ratio of ascorbic acid to total vitamin C in the squamous 
oesophagus after nitrate despite the median pH of 5.2 was unexpected. A possible 
explanation for such finding is that ascorbic acid is unstable at the higher luminal 
pH of the squamous oesophagus and oxidizes to dehydroascorbic acid. However, 
if this was the explanation, then the ascorbic acid to total vitamin C ratio should 
remain constant both before and after the nitrate meal since nitrite does not 
oxidise ascorbic acid at neutral pH. The most likely explanation for the increased 
ascorbic acid oxidation in the squamous oesophagus following the nitrate meal is 
that the ascorbic acid originating from the stomach is being oxidized by the 
acidified nitrite as it refluxes past the Barrett’s segment to reach the proximal 
squamous mucosa. This explanation is supported by the observation in the
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squamous oesophagus of some individuals maintaining pH > 4 virtually 100% of 
the time, whilst in others there were clear increases in the percentage of time pH < 
4 in the squamous oesophagus. In the latter group of subjects, greater ascorbic 
acid and total vitamin C concentrations were noted in the post-nitrate period than 
in the pre-nitrate period indicating that the gastric juice ascorbic acid refluxed 
proximally into the squamous oesophagus.
We also examined the ascorbic acid to nitrite ratio which indicates the 
potential to generate the carcinogenic W-nitroso compounds. The conditions 
required for generating iV-nitroso compounds by acid nitrosation are pH of less 
than 4, nitrite in excess of ascorbic acid (low ascorbic acid to nitrite ratio) and 
thiocyanate which catalyse the reaction A  ratio of ascorbic
acid to nitrite greater than 1 indicates that the concentration of ascorbic acid is 
greater than the concentration of nitrite and the conditions m e unfavourable for 
the generation of W-nitroso compounds; a ratio less than 1 indicates that nitrite is 
in excess of ascorbic acid and conditions favour the generation of A-nitroso 
compounds. Before nitrate administration the ascorbic acid to nitrite ratios were 
0.1, 7.4, 26.2, 32.3 and 32.7 in the squamous oesophagus, Barrett’s segment, 
hiatal hernia, proximal and distal stomach respectively (Fig 12.9); the respective 
ratios after nitrate administration were 0.02, 3.4,29.2, 25 and 34.2 (Fig 12.9). On 
closer inspection of the individual data we found that the conditions favouring the 
generation of A-nitroso compounds are confined to the Barrett’s segment and to a 
lesser extent within the hiatus hernia during acid reflux. Within the Barrett’s 
segment, 2  of the 1 0  subjects had acidified nitrite in excess of ascorbic acid before 
nitrate and 4 of 9 after nitrate administration (Fig 12.9). Within the hiatus hernia 1 
of 1 0  had acidified nitrite in excess of ascorbic acid before nitrate and 2  of 8  after 
nitrate. In the proximal and distal stomach, ascorbic acid was always in excess of 
nitrite. In the more proximal squamous oesophagus nitrite was present in 
considerable excess of ascorbic acid but nitrosation does not normally occur in 
this region as the pH is too high for such reaction to occur. However, there may be 
conditions suitable for generating A-nitroso compounds during periods of acid 
reflux where acidified nitrite exists in excess of ascorbic acid particularly in the 
distal regions of the squamous oesophagus. In contrast to the study in subjects 
without gastro-oesophageal reflux, we did not specifically study the transitional 
region where the neutral pH of the squamous oesophagus became acid in patients
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with Barrett’s oesophagus. We provoked gastro-oesophageal reflux in patients 
with Barrett’s oesophagus which is a dynamic event and it would have been 
impossible to position the probes accurately with each reflux episode compared to 
subjects without reflux where this transition zone of the pH was fixed at the 
gastro-oesophageal junction.
In summary, the cmrent studies demonstrated high nitrite concentrations in 
the squamous oesophagus in subjects with Barrett’s oesophagus which fell 
considerably within the Barrett’s segment during periods of gastro-oesophageal 
reflux. This can be explained by the reduction of acidified nitrite by the ascorbic 
acid, present in the gastric refluxate, to nitric oxide. The Barrett’s segment 
demonstrated the lowest ascorbic acid to total vitamin C ratio which indicates the 
high oxidative stress in this region. This was due to the acidifed Barrett’s segment 
being the most proximal region encountering the high nitrite load delivered. We 
also demonstrated that the BaiTett’s segment had the conditions most favourable 
for the formation of A-nitroso compounds, that is, the lowest ascorbic acid to 
nitrite ratio in the acidic environment within the upper gastrointestinal tract which 
became less favourable in the more distal anatomical regions. Throughout the 
upper gastrointestinal tract examined the thiocyanate ion, a catalyst for acid- 
nitrosation, was in abundance. These findings indicate that during periods of acid 
reflux into the Barrett’s oesophagus, carcinogenic nitrosamines may by generated 
due to the presence of conditions which favours the formation of such chemicals.
We chose to study subjects with Barrett’s oesophagus, a group of people 
with the most severe form of gastro-oesophageal reflux as they form the group of 
people most at risk of developing adenocarcinoma of the oesophagus and 
therefore from the present studies we cannot say whether the luminal chemistiy 
observed during reflux in the Barrett’s patients differs from that in non-Barrett’s 
patients with an equivalent degree of reflux.
In the next chapter we studied the generation of nitric oxide in the BaiTett’s 
segment during gastro-oesophageal reflux.
177
CHAPTER THIRTEEN
NITRIC OXIDE GENERATION
IN
BARRETT’S OESOPHAGUS
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13.1 Introduction.
Nitric oxide is generated in the lumen of the upper gastrointestinal tract by 
the reaction of acidified nitrite and ascorbic acid secreted in gastric juice.
Nitrite is derived from dietary nitrate which undergoes enterosalivary circulation. 
Nitrate secreted into the oral cavity by the salivary glands is reduced by the 
enzyme nitrate reductase derived from the bacteria on the dorsum of the tongue. 
The nitrite in saliva meets acidic gastric juice and becomes protonated to form 
nitrous acid which generates the nitrosating species such as N2O3 and NO"^ . The 
NO^ can also combine with thiocyanate which is also secreted in saliva to form 
another nitrosating species nitrosothiocyanate (NOSCN) and effectively catalyse 
the nitrosation reaction. The nitrosating species reacts with ascorbic acid in the 
gastric juice which is secreted by the gastric mucosa to form nitric oxide. In the 
process ascorbic acid is oxidised to dehydroascorbic acid. In the absence of 
ascorbic acid, the nitrosating species react with nitrosatable substrates such as 
secondary amines and amides to generate the carcinogenic A-nitroso compounds. 
Ascorbic acid has a higher affinity for the nitrosating species and reacts to form 
nitric oxide thereby preventing the formation of A-nitroso compounds. Although 
this action of ascorbic acid inliibits the luminal generation of A-nitroso 
compounds, the nitric oxide produced in the process can readily diffuse into the 
adjacent epithelium where it can combine with oxygen to form N2O3 and thereby 
induce nitrosative stress intracellularly
The previous chapter investigated the nitrosative chemistry in patients with 
Barretf s oesophagus and the results indicated that during periods of acid reflux 
lai’ge amounts of nitrite disappeared within the Barrett’s segment. Previous study 
in healthy volunteers without gastro-oesophageal reflux indicated that nitric oxide 
was generated at the interface where salivary nitrite at neutral pH entered the 
acidic gastric juice at the gastro-oesophageal junction which was also the site 
where condition for the generation of A-nitroso compounds was optimal. These 
studies suggested that nitric oxide is likely to be generated within the Barrett’s 
oesophagus dui'ing periods of acid reflux.
We measured nitric oxide within the Barrett’s segment using a miniturised 
nitric oxide probe and found that substantial concentration of nitric oxide was 
generated during periods of gastro-oesophageal reflux. Attempt was made to
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measure nitric oxide generation in five patients since the pH probe was 
refurbished prior to use and subsequently malfunctioned after five subjects were 
studied.
13.2 Aims.
We sought to establish whether nitric oxide was being generated within the 
Ban'etf s segment during periods of gastro-oesophageal reflux to explain the 
disappearance of nitrite in the Barretf s segment during acid reflux.
13.3 Subjects.
The subjects consisted of 5 patients with Barrett’s oesophagus who 
underwent the microdialysis procedure previously. All were H. pylori negative on 
histological examination and rapid urease test of both gastric antral and body 
mucosal biopsies.
13.4 Methods.
13.4.1 Nitric Oxide Sensor.
We employed a miniaturized custom-made nitric oxide sensor (World 
Precision Instruments Inc., Sarasota, Florida, U.S.A.) to allow measurement of 
luminal nitric oxide concentrations throughout the upper gastrointestinal tract as 
previously described (Fig 13.1). An antimony pH sensor (Synetics Medical 
Ltd., Enfield, England) was attached to the nitric oxide sensor using waterproof 
taping (Sleek, Smith and Nephew, Hull, England) with the pH sensor positioned 
adjacent to the tip of the nitric oxide probe. A fine-bore Teflon feeding tube was 
also attached to the assembly to allow intra-gastric instillation of the nitrate 
solution. The nitric oxide sensor was connected to a dissolved nitric oxide meter 
(ISO-NO Mark II, World Precision Instruments, I.N.C., Sarasota, Florida, U.S.A.) 
which displays the reading as a redox current (pA). The output from the pH sensor 
was attached to a pre-amplifier. Both the outputs from the nitric oxide sensor and 
the pH sensor were digitalized (DAS 1201 data acquisition keyboard, Keithley
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Instruments Ltd., Reading, England) and displayed and stored on computer for 
subsequent analysis. The position of the sensors was recorded digitally. All 
electrical equipments used for the study were attached to the mains electrical 
supply via an isolation unit to comply with standard clinical safety procedures.
The nitric oxide probe and pH sensor were calibrated at 37°C prior to each 
study as per manufacturer’s instructions (see above). During transfer of the 
patients to the radiology department for confirming the position of the sensors 
with an abdominal X-ray, the nitric oxide sensor was attached to a portable unit to 
maintain their polarization (ISO-NO Activator, World Precision Instruments, 
Sarasota, Florida, U.S.A.). After use, the nitric oxide sensors and pH probe were 
detached and cleaned using Sterilox ®.
13.4.2 Calibration of nitric oxide probe in-vitro.
Stock KNO2 solutions of the following concentrations were made: 2.02,
4.04, 6,06, 8.08 and 12.12 mM. The solutions were used for calibrating the nitric 
oxide (NO) probe to 20, 40, 60, 80 and 120 pM respectively. Reaction solution 
was made up of concentrated sulphuric acid 800 pL added to 120 mL distilled 
water. To this solution 2.2 g potassium iodide was added just before calibration of 
the NO probe. The reaction solution was synthesised in a fume cupboard and the 
calibration process described below was also performed in the fume cupboard.
Five scintillation glass vials each containing 5 mL of the reaction solution 
were placed in a waterbath set at 37°C and stirred continuously with a small 
magnetic stiiTcr. The tip of the NO probe was lowered carefully into a vial 
containing the reaction solution so as to avoid contact with the magnetic stirrer. 
Care was also taken to avoid dropping the NO probe on its tip as this may lead to 
the rupture of the membrane covering the tip of the probe. The nitric oxide sensor 
was connected to the dissolved nitric oxide meter (ISO-NO Mark II, World 
Precision Instruments, I.N.C., Sarasota, Florida, U.S.A.). The baseline current 
(pA) in the reaction solution was recorded.
Two hundred microlitres of the stock 2.02 mM KNO2 solution was added to 
the reaction solution and the peak current recorded was noted. The NO probe was 
then removed, washed and placed in distilled water. The process was repeated 
using 200pL of the 4.04, 6.06, 8.08 and 12.12 mM KNO2 solutions. These
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solutions represented the 20, 40, 60, 80 and 120 pM standards of NO respectively. 
A‘standard curve’ was obtained from which the NO concentration was obtained. 
The NO probe was ready for use. The chemical reactions which lead to the 
generation of nitric oxide is summarised as follows:
2KN02 + 2KI + 2 H2SO4 2N0 + 12 + 2 H2O + 2 K2SO4
13.4.3 Clinical procedure using the nitric oxide probe.
The experimental conditions were similar to that for microdialysis 
experiments. The patient avoided nitrate-rich food for 24 hours and fasted 
overnight. The nitric oxide sensor assembly was inserted per orally to a point 10 
cm distal to the gastro-esophageal jimction predetermined endoscopically. A plain 
abdominal X-ray was taken to check the sensor position. The subjects were 
positioned in the right-lateral decubitus position with or without the head-down 
position to provoke gastroesophageal reflux throughout the study. Pentagastrin 
0.06 pg kg'  ^was administered intravenously to stimulate acid secretion 
throughout the study. The sensor was withdrawn 1cm every 2 minutes until it was 
in the squamous esophagus. We have previously noted that the NO production 
was maximal where saliva first meets acidic gastric juice. In subjects without 
gastro-oesophageal reflux this was at the cardia In subjects with Barrett’s 
oesophagus NO generation was anticipated to occur at the point where salivary 
nitrite first came into contact with refluxed gastric juice in the distal oesophagus. 
To study the NO generation within the Barrett’s esophagus, the NO sensor was 
positioned where gastro-oesophageal reflux occurred as indicated by a fall in pH 
< 4 on the pH meter adjacent to the NO probe. The NO sensor was maitained in 
this position for several minutes to study NO generation within the Barrett’s 
segment. Following insertion of the sensor, salivary nitiite and serum nitrate were 
collected every 15 minutes and processed as previously described. Once the 
recordings were complete in the squamous oesophagus, the sensor was re-inserted 
to 10cm distal to the gastroesophageal junction and 2 mmol of potassium nitrate 
in SOmL sterile water was administered intra-gastrically. Previous experiments 
with healthy volunteers have shown that administering the same total amount of 
nitrate in 50mL or 25mL produced comparable serum nitrate levels (See chpater
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10 and ref, 278). Twenty minutes after nitrate was administered, the NO probe 
was withdrawn 1cm every 2 minutes as before. The probe was again maintained 
in the Barrett’s segment for several minutes at a point where reflux occurred as 
described above. The procedure was terminated when recording was completed 
from the squamous esophagus.
Serum nitrate and salivary nitrite was treated and analysed as previously 
described and will not be detailed further.
13.5 Statistical Analyses.
All data are presented as medians and interquartile range (ÏQR).
Serum nitrate and salivary nitrite concentrations were grouped into pre and post­
nitrate periods and analysed by the 1-sample Wilcoxon test.
Since only a small number of patients completed the investigation for NO 
measurement, statistical testing was not performed. The descriptive data are 
presented before and after nitrate administration for individual patients.
13.6 Results.
The median (range) length of Barrett’s segment was 5cm (4 -10). 3 subjects 
were females.
13.6.1 Serum
The median serum nitrate concentration during the 4 5-minute interval 
before nitrate administration was 16.2 pM (14.6 -  21.1). The median serum nitrate 
after nitrate administration was significantly higher at 57.3 pM (41.2 -  63.4) (p < 
0.001) (Fig 13.2).
13.6.2 Saliva
The median salivary nitrite increased almost 7-fold from 43.5 pM (28.4 -  
101) during the 45-minute inteival before nitrate administration to 287 pM (104 -
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419) during the 45-minute interval, 15 minutes after nitrate administration (p -  
0.001) (Fig 13.3).
13.6.3 Nitric oxide
In two individuals no nitric oxide was detected in the stomach or within the 
Barrett’s segment before or after nitrate administration despite evidence of clear 
gastro-oesophageal reflux into the Barrett’s segment. We suspect this occurred 
due to technical problems. The data for the three remaining patients are thus 
presented. The peak nitric oxide concentrations (range) in the Barrett’s segment 
were 7.6 pM (2.6 -  13.4) before nitrate administration and 20.5 pM (3.4 -  56.5) 
after nitrate administation.
The first patient was a 69 year old male with a 5 cm Barrett’s mucosa. 
Before nitrate administration 24.5pM of nitric oxide was detected in the proximal 
stomach which coincided with a slight rise in pH due to swallowed saliva. In the 
Barrett’s segment nitric oxide attained concentrations of 7.9 pM as pH rose from
1.3 to 2.1 at 39 cm (from the incisors) due to swallowed saliva and 7.4 pM as pH 
fell from 6.5 to 1.4 coinciding with a reflux episode at 35 cm (Fig 13.4a). After 
nitrate administration 7.1 pM and 7.2 pM of nitric oxide was generated at 49 cm 
in the proximal stomach and at 41 cm, just distal to the gastroesophageal junction 
(Fig 13.4b). Within the Barrett’s segment, 4.6 pM and 3.5 pM of nitric oxide were 
generated at 39 cm and 37 cm respectively and a small pH increment can be noted 
which indicated swallowed saliva. At 35 cm, pH baseline was 7 inteiTupted by 
repeated acid reflux episodes and small concetrations of 1.5 pM of nitric oxide 
was generated at this site. With the nitric oxide probe placed again more distally 
at 39 cm, 7.5 pM of nitric oxide is detected as pH falls from 4.2 to 1.8, coinciding 
with gastroesophageal reflux, and 13.5 pM of nitric oxide is detected as pH rises 
from 1.5 to 3 (Fig 13.4b).
The second patient was a 65 year-old female with a 3cm Barrett’s segment. 
Before nitrate administration, virtually no nitric oxide was generated in the 
stomach or the Barrett’s segment despite an episode of reflux with the pH falling 
from 6 to 3.5 (Fig 13.5a). This particular patient initially found some difficulty 
producing sufficient amount of saliva and it is likely that nitrite was not available 
in the Barrett’s segment to react with the gastric juice ascorbic acid at the time of
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gastro-oesophageal reflux. After nitrate administration, up to 8.2 pM of nitric 
oxide was generated in the proximal stomach between 44 cm and 38 cm. At 33 cm 
pH reached 6.6 and as the pH fell to below 4 with each reflux episode, up to 56.5 
pM of nitric oxide was generated instantaneously. Further generation of nitric 
oxide up to 53 pM was seen during episodes of gastro-oesophageal reflux at this 
level.
In the third patient, the Barrett’s segment extended from 40 cm to 36 cm. 
Before nitrate administration between 3.4 pM to 7.7 pM of nitric oxide was 
generated between 46 cm in the proximal stomach and 41 cm, just distal to the 
gastro-oesophageal junction (Fig 13.6a). When pH was above 5 within the 
Barrett’s segment, no nitric oxide was generated. Gastro-oesophageal reflux into 
the Barrett’s segment was accompanied by a simultaneous generation of 13 pM of 
nitric oxide. In the squamous oesophagus at 35 cm to 33 cm reflux episodes were 
not accompanied by nitric oxide generation. Following nitrate administration, 
higher concentrations of nitric oxide was generated both in the proximal stomach 
and the Barrett’s segment (Fig 13.6b). Within the gastric lumen, 5 pM of nitric 
oxide was generated at 46 cm. Just distal to the gastroeophgeal junction, indicated 
by a step-up in pH at 41 to 42 cm, 11.5 pM of nitric oxide was genrated. Within 
the Barrett’s segment no nitric oxide was generated while pH remained above 4. 
Two reflux episodes were followed simultaneously by the generation of 
approximately 20 pM of nitric oxide.
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Fig 13.1: Nitric oxide probe and nitric oxide meter (ISO-NO Mark II).
The insert shows the NO probe attached to a pH sensor and a Teflon 
feeding catheter as used in the human subjects.
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Fig 13.2: Serum nitrate before and after nitrate.
Data presented as medians. Box represents IQR and whiskers 
represent range.
* p < 0.001 pre vs post-nitrate.
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Fig 13.3: Saliva nitrite concentrations before and after nitrate.
Data presented as medians. Box represents median and IQR. 
Whiskers represent range.
* p = 0.001 pre vs post-nitrate.
1 8 8
pH
5 -
4 -
3 -
30
25
20
N i t r i c
O x i d e 15( p M )
10
5
0 xu*^ <rMY>vyv V vvJ\1— I— T - “  I ‘  I r  • r  ' T  ~ T — r — T - “ i r
B A R R E T T ’S
V
1— I— I— I— I I I ' 1— ^
49  49  48  47  46  45  44  44  43  42  41 40  39  39 38  37  36  35  35  35  35  35  35  35 35 35 35 35
D i s t a n c e  ( c m )
Fig 13.4a: Simultaneous recording of pH and nitric oxide before nitrate 
in patient one.
Distance indicates distance (cm) from incisors to NO probe tip. 
Barrett’s segment extends from 35 -  40 cm (shaded grey). Nitric 
oxide generation is seen in proximal stomach at 45 -  46 cm (solid 
arrowhead) coinciding with a slight rise in pH due to swallowed 
saliva. Smaller concentrations of nitric oxide generated in Barrett’s 
segment, one coinciding with slight rise in pH due to swallowed saliva 
(open arrowhead) and another during acid reflux in a segment with a 
neutral pH (broken arrow).
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Fig 13.4b: Simultaneous measurement of pH and nitric oxide concentration 
after nitrate in patient one.
Distance indicates distance (cm) from incisors to NO probe tip.
Nitric oxide generation is seen in the stomach from 49 cm to 41 cm 
(arrowheads). Small amount of nitric oxide is generated within the 
Barrett’s segment (shaded grey) at 35 cm coinciding with reflux 
episodes (solid arrows) as well as at 39 cm to 37 cm coinciding with 
slight rise in pH due to swallowed saliva (open arrowheads). A reflux 
episode at 39 cm generates 7.5 pM  of nitric oxide (broken arrow). 
Swallowed saliva at 39cm generates 13.5pM nitric oxide (red arrow).
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Fig 13.5a: Simultneous recording of pH and nitric oxide before nitrate in 
patient two.
Distance indicates distance (cm) from incisors to NO probe tip. 
Barrett’s segment (shaded grey) extended from 36 cm to 30 cm (36 -  
33 cm shown). The background ‘noise’ producing nitric oxide 
concentration of 5pM  was not corrected. No nitric oxide production 
seen in stomach or in the Barrett’s segment. A brief episode of reflux 
did not generate nitric oxide in the Barrett’s segment.
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Fig 13.5b: Simultaneous measurement of pH and nitric oxide after nitrate in 
patient two.
Distance indicates distance (cm) from incisors to NO probe tip.
Small amount of nitric oxide is generated in the proximal stomach 
(arrowheads). At 33 cm, within the Barrett’s segment (shaded grey), 
up to 56.5 |iM  of nitric oxide is generated when acid reflux occurs 
(arrows).
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Fig 13.6a: Simultaneous recording of pH and nitric oxide before nitrate 
in patient three.
Distance indicates distance (cm) from incisors to NO probe tip.
The shaded area indicates recordings within Barrett’s segment (40 - 36 
cm). SQ = squamous oesophagus. There is a small amount of nitric 
oxide generated in the proximal stomach at 46 cm (open arrowhead). 
Nitric oxide is generated just distal to the gastro-oesophageal junction 
(solid arrowheads) indicated by the step-up in pH. A reflux event in 
the Barrett’s segment generates 13 [xM of nitric oxide as pH falls from 
6.5 to 1.5. No nitric oxide is generated in the squamous oesophagus 
during the three reflux episodes.
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Fig 13.6b: Simultaneous recording of pH and nitric oxide after nitrate 
in patient three.
Distance indicates distance (cm) from incisors to NO probe tip.
The shaded area indicates recordings within Barrett’s segment. (Nitric 
oxide is generated just distal to the gastroesophageal Junction (42 cm 
-  41 cm) and in the proximal stomach (46 cm -  44 cm) (arrowheads). 
No nitric oxide is produced in the Barrett’s segment (shaded gray) 
between pH 6 to 7. Two acid reflux episodes into the Barrett’s at 36 
cm generate 20 pM  of nitric oxide (broken arrows).
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13.7 Discussion.
The previous chapter examined the concentrations of nitrite in Barrett’s 
oesophagus and we found that in most subjects the nitrite delivered in the saliva 
disappeared as nitrite entered the Barrett’s segment under conditions of acid 
reflux. Our previous study examining nitric oxide production in the lumen of the 
upper gastrointestinal tract in healthy subjects without gastro-oesophageal reflux 
demonstrated that nitric oxide is generated at or just distal to the gastro- 
oesophageal junction as the transition from gastric pH to the neutral pH of the 
oesophagus occurred We have already discussed the potential mechanisms to 
explain the loss of nitrite in the Barrett’s segment in the previous chapter. These 
included the absorption of nitrite ion, the absorption of nitrous acid (a less polar 
molecule formed by the protonation of nitrite by gastric acid) and the reduction of 
nitrous acid / nitrosating species to nitric oxide by ascorbic acid in the gastric 
juice. The first two mechanisms were thought unlikely and that the most plausible 
explanation for the loss of nitrite in the Barrett’s segment during acid reflux was 
likely to be due to the latter mechanism in which nitric oxide was generated from 
the reduction of nitrous acid / nitrosating species by gastric juice ascorbic acid.
We were able to confirm the generation of nitric oxide in Barrett’s oesophagus 
during periods of acid reflux using a real-time miniturised nitric oxide probe.
In the absence of gastro-oesophageal reflux, nitric oxide was not detected in 
the Barrett’s oesophagus. However, as gastric acid refluxed into the Barrett’s 
segment, immediate generation of very high concentrations of nitric oxide 
occured within the Barrett’s segment in some patients (Figs. 13.4-13.6). This is 
consistent with the ascorbic acid in acidic gastric juice converting the nitrite in the 
saliva within the oesophageal lumen to nitric oxide. In a proportion of the acid 
reflux episode, very little or no nitric oxide was detected in the Barrett’s segment. 
A number of reasons may explain the variation in intra-oesophageal nitric oxide 
generated with acid reflux. The nitric oxide probe only detects the concentration 
of nitric oxide at its tip and thus within a very localized region. Also the probe 
only detects nitric oxide in solution and as such, if the probe tip is not immersed 
in the refluxed gastric acid, it may not detect nitric oxide even if it formed within 
the vicinity of the probe. This is probably the reason why no nitric oxide was 
detected in the two subjects who participated in the study. Thirdly, the site of
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nitric oxide generation within the oesophagus will be maximal where the 
refluxing acid meets the saliva and this is likely to vary depending upon the extent 
of the reflux episode and the amount and site of saliva within the oesophageal 
lumen. In addition, preceding reflux episodes may deplete local concentration of 
ascorbic acid and or nitrite and thus prevent nitric oxide generation at that site.
Following its generation in the oesophageal lumen, nitric oxide, unlike 
nitrite or nitrous acid, would rapidly diffuse across the lipid membranes into the 
Barrett’s epithelium and oesophageal mucosa. A study in rats demonstrated the 
luminal generation of nitric oxide at the gastro-oesophageal junction (where 
neutral pH of the oesophagus changed to acidic pH of the stomach) when nitrite 
and thiocyanate were administered into the oesophagus and ascorbic acid at pH 2 
was administered intragastrically. Entrapment of nitric oxide was seen in the 
epithelium at the gastro-oesophageal junction with a reduction in the antioxidant 
glutathione indicating an increased nitrosative stress intracellularly at this 
anatomical site A previous study in Barrett’s oesophagus has also 
demonstrated a reduced concentration of glutathione and glutathione S-transferase 
activity compared to the squamous mucosa in the same subjects within the 
metaplastic epithelium These studies indicate that the Barrett’s epithelium is 
exposed to substantial concentrations of nitric oxide despite having lower 
concentrations of glutathione and is therefore exposed to greater nitrosative and 
oxidative stress.
Nitric oxide has diverse physiological roles in the mammalian physiology 
however, prolonged mucosal exposure to nitric oxide has been implicated in 
the development of cancer in chronically inflamed tissues In rats
administered morpholine, the oral co-administration of nitrite plus ascorbic acid 
significantly enhanced tumour development in the forestomach, an effect which 
did not occur when nitrite was administered with morpholine or nitroso- 
morpholine alone was administered In another study, rats pre-treated with 
A-nitroso compound followed by co-administration of nitrite and ascorbate 
increased the yield of malignant forestomach tumors. Even without the pre­
treatment with the nitroso compound, the co-administration of ascorbic acid and 
nitrite produced papillomas in the forestomach whereas nitrite or ascorbic acid 
alone did not The combined administration of nitrite plus anti-oxidant will 
produce high concentrations of nitric oxide and may be responsible for the
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findings noted in such studies. More recent studies in mice have observed that the 
intragastric administration of single large doses of nitrite plus ascorbic acid 
produces DNA damage within the cells of the gastric epithelium and this effect 
was again attributed to the generation of nitric oxide within the gastric lumen
Nitric oxide is known to be mutagenic by several mechanisms (Fig 13.7). A 
number of genetic alterations seen in Barrett’s oesophagus with or without 
dysplasia and adenocarcinoma may be explained by the direct or indirect effect of 
nitric oxide. Nitric oxide can directly deaminate primary amines, such as those of 
DNA which can lead to base substitutions and affect subsequent base-pairing 
360,373)^  Exposure of Salmonella typhimurium and human lymphoblastoid TK6 
cells to nitric oxide produced G:C —^ A:T transition mutations that can be 
explained by nitrosative deamination effected by nitric oxide under aerobic 
conditions In patients with oesophageal adenocarcinoma mutational
analysis at exon 5 - 8 of the p53 tumor suppressor gene showed that the majority 
of the mutations involved a single base substitution, G:C A:T base transition at 
CpG dinucleotides This is consistent with deamination of 5 ’ -methylcytosine, 
found at CpG sites of exon 5 - 8 of the p53 gene to thymine resulting in C —^ 
T replacement, changes which may be produced by base deamination by nitric 
oxide in the presence of oxygen
Once inside the cells, nitric oxide can also reform nitrosating species in the 
presence of oxygen and form A-nitroso compounds intracellularly. An in vitro 
study suggested that physiological concentrations of the ascorbic acid, nitrite, and 
thiocyanate in acid pH found in the human upper gastrointestinal tract prevents 
lumenal generation of A-nitroso compound but the nitric oxide formed by 
ascorbic acid and acidified nitrite rapidly diffuses across the cell membranes and 
generates A-nitroso compounds at concentrations 20-foId greater than that 
generated in the lumen in the absence of ascorbic acid A-nitroso compounds 
thus formed intracellularly may lead to DNA alkylation. The main premutagenic 
adduct generated by methylating A-nitroso compounds, such as nitroso- 
dimethylamine and methylnitrosourea, is O^-methylguanine. The characteristic 
mutation produced by (9^-methylguanine is G:C —» A:T base transition which 
may be an alternative mechanism by which such mutations arise in p53 gene 
mutation in some patients with oesophageal adenocarcinoma. More recent studies 
have revealed that transcriptional silencing of tumor suppressor gene pi 6 involves
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hypeiTnethylation of the CpG island promoter in patients with Barrett’s 
oesophagus with or without dysplasia and oesophageal adenocarcinoma 
A rat model of hepatocellular carcinoma utilising A-nitrosonornicotine 
showed that animals exposed to A-nitrosonomicotine developing hepatocellulai’ 
carcinoma had hypermethylation of pi 6 gene at CpG sites whereas control rats 
did not have such findings suggesting that A-nitroso compounds are capable of 
methylating DNA bases at these critical sites It is tempting to speculate that 
the hypermethylation at the CpG sites of the pi 6 gene in patients with Barrett’s 
oesophagus and oesophageal adenocarcinoma may perhaps be a result of exposure 
to A-nitroso compounds derived fi’om the nitric oxide generated in the 
oesophageal lumen. In addition, nitric oxide can lead to oxidative damage via the 
reaction of nitric oxide and superoxide anion to produce peroxynitrite In- 
vitro studies have shown that nitric oxide produce DNA strand breaks as a result 
of oxidative DNA damage in the presence of superoxide anion The DNA
defects described above are normally repaired by enzymes and nitric oxide, in 
addition to the DNA damage, inhibits key DNA repair enzymes such as O^- 
alkylguanine-DNA alkyl transferase formamidopyrimidine-DNA glycolyase 
and DNA ligase The consequence of the nitric oxide’s actions, therefore, 
not only damages DNA but also prevents DNA repair and genetic defects 
accumulate leading to mutagenesis and carcinogenesis.
In the past, consideration of the aetiology of oesophageal mutagenesis related to 
gastro-oesophageal reflux has focused on the potentially noxious effects of acid, pepsin 
and bile. In this thesis we have demonstrated a couple of potential mechanisms which 
may cause mutagenesis in patients with Barrett’s oesophagus. The generation of 
carcinogenic A-nitroso compounds within the lumen of the Barrett’s segment dui'ing 
gastro-oesophageal reflux was discussed in the previous chapter. The current study 
suggests that potentially mutagenic concentrations of nitric oxide derived from dietary 
nitrate is formed within the Barrett’s segment during periods of acid reflux. From the 
current studies it is unclear whether similar nitrosative chemistry occurs in the 
squamous oesophagus. However, nitric oxide generation in the distal oesophagus as a 
result of acid reflux is unlikely to be confined to Barrett’s oesophagus and is likely to 
occur in other subjects who have gastro-oesophageal reflux. The increased risk for 
developing oesophageal adenocarcinoma in subjects with acid reflux appears to be 
confined to those with Barrettt’s oesophagus and likely to be due to the increased
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cellular turnover present in the intestinal metaplastic mucosa present in Barrett’s 
oesophagus 385,386) the mucosa more susceptible to the mutagenic
effects of intra luminal carcinogens such as nitric oxide and A-nitrosamines.
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Fig 13.7; Intracellular effects of nitric oxide generated in the lumen of the upper 
gastrointestinal tract.
Nitrite in the saliva is swallowed and enters the gastric juice where it forms nitrous 
acid and other nitrosating species (*). Thiocyanate in the saliva and the gastric juice 
catalyse the acid nitrosation. Ascorbic acid (AA) in gastric juice reduces the
nitrosating species to nitric oxide (NO ) and the A A is oxidised to dehydroascorbic
acid. When AA is depleted, the nitrosating species react with secondaiy amines to 
form iV-nitrosamines. The nitrosamines can diffuse into the cell and alkylate DNA. 
The NO formed intra-luminally may diffuse into the surrounding epithelium and 
can cause DNA damage through DNA deamination, DNA alkylation and oxidation 
as well as inhibiting DNA repair enzymes.
2 0 0
CHAPTER FOURTEEN
GENERAL DISCUSSIONS
2 0 1
14.1 Summary.
The work presented in this thesis describes the novel use of microdialysis 
probes in the lumen of the human upper gastrointestinal tract to measure 
chemicals relevant to nitrosation chemistry.
The initial work involved the validation of the microdialysis probes for 
measuring the relevant chemicals. The major obstacle of the microdialysis 
experiment was in obtaining sufficient volume of samples for analysis during the 
stipulated time period of the experiment and utilising a suitable method to analyse 
the microlitre volumes of the samples produced by the microdialysis probes. The 
earlier part of the study, not described in the thesis, involved finding the ideal rate 
of perfusing the microdialysis probes to produce sufficient quantités of 
microdialysis product (dialysate) without severely reducing the recovery of the 
chemicals, hence its concentration, which is a consequence of increasing the 
perfusion rate in order to increase the volume of the dialysate produced. The rate 
of 0.3 mL hr'^ was initially selected for the human study which produced 
satisfactory recovery and ample volumes to allow duplicate sampling. However, 
just prior to human study, using fresh microdialysis probes we noted that the 
recovery became highly variable between each microdialysis probe at 0.3 mL hr'  ^
and that this could be corrected by reducing the perfusion rate to 0.15 mL h r'\ 
Further validation studies were therefore performed using this rate.
We noted that in pH < 2.5 nitrite recovery was much lower than when pH >
3.5. The recovery of nitrite under highly acidic conditions could be increased by 
increasing the perfusion rate up to a point when the recovery fell once more. This 
was explained by the acidified nitrite being converted to nitric oxide which was 
lost through the microdialysis probe and the collecting tubes which are permeable 
to nitric oxide thereby reducing the measured nitrite concentrations in the 
dialysate. Increasing the perfusion rate reduced the transit time and the chemical 
rection time in the microdialysis probes and therefore the loss of nitrite as nitric 
oxide was reduced.
We also studied the recovery of the chemicals under dynamic conditions 
simulating the reaction of salivary nitrite with gastric juice containing ascorbic 
acid and the microdialysis probe again proved that it was reliable in detecting the
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chemicals under the conditions in which ascorbic acid was in excess of nitrite and 
the reverse condition of nitrite in excess of ascrobic acid.
The human studies involved using multiple microdialysis probes mounted 
on a nasogastric tube in defined positions to study the chemicals of nitrosation 
(nitrite, thiocyanate, ascorbic acid and total vitamin C). The initial study examined 
the nitrosation potential in healthy subjects without gastro-oesophageal reflux. We 
found that following an overnight fast, there was an increasing concentration 
gradient of ascorbic acid and total vitamin C at increasingly distal sites. The 
concentration of nitrite in the distal oesophagus was similar to the nitrite 
concentration in the saliva and a decreasing concentration gradient was seen at 
more distal sites with no nitrite detectable in the stomach distal to the cardia. The 
thiocyanate concentration was relatively constant throughout the upper 
gastrointestinal tract. Following nitrate ingestion, serum nitrate and salivary nitrite 
increased indicating that the main source of the nitrite in saliva was dietary.
Nitrite in the distal oesophagus and cardia increased following the nitrate load but 
the reducing concentration gradient more distally was maintained with virtually 
no nitrite detectable distal to the cardia. The ascorbic acid to total vitamin C ratio, 
an indication of proportion of ascorbic acid in its reduced and hence its active 
form was lowest at the cardia and fell further following nitrate ingestion. This 
indicated that ascorbic acid oxidation was greatest at the cardia and oxidation 
increased significantly at this site following increased nitrite load. The ascorbic 
acid to nitrite ratio indicated the potential to generate the carcinogenic W-nitroso 
compounds (the lower the ratio, the greater the nitrosation potential). Whilst this 
ratio was lowest in the distal oesophagus, the neutral pH at this site made it 
unlikely for acid-catalysed nitrosation reaction to occur although the condition 
may be suitable for bacterial nitrosation to occur. The cardia with a pH of 
approximately 2.5 had the lowest ascorbic acid to nitrite ratio with 44 % of the 
fasting subjects having nitrite in excess of ascorbic acid, conditions which favour 
acid-catalysed nitrosation. The proportion of subjects with low ascorbic acid to 
nitrite ratio increased to 82 % following nitrate ingestion indicating that increased 
nitrite load following nitrate ingestion made the condition even more favourable 
for generating W-nitroso compounds at the cardia. The ascorbic acid to nitrite ratio 
also fell at the proximal stomach in 19 % of the subjects following nitrate
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ingestion whereas the distal stomach was hostile for acid-catalysed nitrosation to 
occur even after nitrate ingestion.
Our previous study in subjects without gastro-oesophageal reflux indicated 
that lumenal nitric oxide generation from acidified nitrite and ascorbic acid was 
maximal at the cardia therefore we can conclude that in subjects without reflux, 
nitric oxide is generated from acidified nitrite at this anatomical location in the 
presence of ascorbic acid whereas acid-catalysed nitrosation occurs when ascorbic 
acid is depleted, both of which produce mutagenic chemicals at the cardia which 
may provide a potential explanation for mutagenesis and carcinogensis at this 
location in subjects without reflux.
The subsequent study in asymptomatic volunteers involved examining the 
chemicals relevant to nitrosation in the nasal cavity, the pharynx and the proximal 
and distal oesophagus. We also set up a HPLC method for determining nitrate 
concentrations. Nitrate was not investigated in the earlier studies as the volume of 
the microdialysis product was insufficient to allow separate analysis for nitrate 
without HPLC and even if adequate volumes were available, collection of the 
dialysate for nitrite analysis in NaOH made it impossible to analyse nitrate using 
the bacterial nitrate reductase method and HPLC was not set up for measuring 
nitrate at the time.
We found that the nitrate concentration was lowest in the nose followed by 
the pharynx and the oesophagus had the highest nitrate concentration. Nitrite 
concentrations in the saliva, pharynx and oesophagus were approximately 20 to 
30 % of the nitrate concentration during mechanical stimulation of saliva which 
was similar to the nitrite / nitrate ratio in the saliva reported in the literature.
Nitrite was not detected in the nasal cavity even if nitrate was readily detectable. 
This would suggest that nitrate reduction by bacteria did not appear to occur in the 
nasal cavity which may possibly be related to difference in the partial pressure of 
oxygen or a different resident microbial flora in the nasal cavity compared to that 
of the tongue. The study also suggested that there was ongoing nitrate reduction to 
nitrite in the oesophagus as recovery of nitrite from the oesophageal lumen was 
higher than the concentration of nitrite in the saliva in some individuals and since 
the concentration of a chemical recovered using the microdialysis is always lower 
than that of the sample, recovery rate of nitrite > 100 % would suggest that more 
nitrite was available at distal sites as nitrate was being reduced to nitrite as saliva
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was travelling more distally. The significance of the high nitrite concentrations in 
the oesophageal lumen is three-fold. Firstly, when salivary nitrite encounters 
acidic gastric juice, nitric oxide is produced in significant quantities. Secondly, 
when the ascorbic acid becomes depleted at the gastro-oesophageal junction N~ 
nitroso compounds can be generated from acidified nitrite. Thirdly, in the absence 
of acid for example in the oesophagus and in the achlorhydric stomach, bacterial 
nitrosation may generate 7V-nitroso compounds. All of these mechanisms may 
potentially be mutagenic to the surrounding epithelium resulting in carcinogenesis 
with repeated exposure.
In the third study, patients with BaiTetf s oesophagus were examined using 
the microdialysis probes. The increasing ascorbic acid and total vitamin C 
gradient with increasing distal location seen in healthy individuals without reflux 
was also seen in subjects with Barretf s oesophagus. The most significant finding 
was that during gastro-oesophageal reflux into the Barrett’s oesophagus, nitrite 
concentrations fell significantly at this anatomical location despite the increased 
nitrite load. Recovey of thiocyanate both before and after nitrate ingestion 
remained unchanged within the Barrett’s segment which suggested that the loss of 
nitrite in the Barrett’s oesophagus was indeed correct and that nitrite was being 
‘consumed’ at this site during acid reflux. The ascorbic acid to total vitamin C 
ratio was lowest in the Barrett’s segment both before and after nitrate ingestion 
suggesting that the oxidation of ascorbic acid due to salivary nitrite was maximal 
at this location. However, the squamous oesophagus, hiatal hernia and the 
proximal stomach all had reduced ascorbic acid to total vitamin C ratio following 
nitrate administration compared to before the nitrate was administered. In the 
squamous oesophagus this was attributed to the oxidation of ascorbic acid 
delivered to the oesophagus during gastro-oesophageal reflux. Distal to the 
Barrett’s oesophagus ascorbic acid oxidation was due to the delivery of salivary 
nitrite which did not react with ascorbic acid at more proximal sites.
Before nitrate ingestion 20% of Barrett’s subjects had nitrite in excess of 
ascorbic acid in the Barrett’s segment during acid reflux whereas after nitrate 
ingestion, 44 % of the patients had nitrite in excess of ascorbic acid. This 
proportion was higher than the other sites suggesting that the nitrosation potential 
was greatest in the Barrett’s segment during acid reflux, although the numbers did 
not reach statistical significance. Together, the results of this study and the
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previous study in subjects without reflux which showed that nitric oxide was 
generated at the point where salivary nitrite first encountered gastric juice 
suggested that in Barrett’s oesophagus, the salivary nitrite was being reduced to 
nitric oxide by the gastric juice ascorbic acid during periods of acid reflux in the 
Barrett’s segment.
The last study in this thesis directly examined nitric oxide generation within 
the Barrett’s oesophagus in order to confirm the hypothesis that the loss of nitrite 
in the Barrett’s oesophagus during acid reflux was due to the generation of nitric 
oxide. The number of patients examined was limited due to the break down of the 
nitric oxide probe after examining five patients. The study clearly showed that 
during periods of gastro-oesophageal reflux into the BaiTett’s oesophagus, some 
individuals generated in excess of 50 pM of nitric oxide instantaneously. When 
reflux did not occur nitric oxide was generated where salivary nitrite first 
encountered gastric juice just distal to the gastro-oesophageal junction as noted in 
the previous study in healthy volunteers. Prolonged exposure to nitric oxide is 
mutagenic and has been implicated in carcinogenesis in inflammatory conditions 
such as ulcerative colitis. The level of nitric oxide recorded in the Barrett’s 
segment is very much higher than the concentrations of nitric oxide generated 
enzymatically by intracellular nitric oxide synthetase and provided the substrates 
for its generation ar e not depleted, this level of nitric oxide can be repeatedly 
generated within the Barrett’s oesophagus exposing the mucosa to a considerable 
amount of this highly reactive chemical over a long period of time. The nitric 
oxide generated in the lumen may diffuse into the surrounding mucosa and can 
affect the DNA directly or indirectly by reforming nitrosating species which can 
generate A-nitroso compounds thereby exposing the DNA to mutagenic agents. 
Some of the genetic aberrations seen in patients with adenocarcinoma of the 
oesophagus and cardia ai e consistent with the known effects of nitric oxide and N~ 
nitroso compounds.
The nitric oxide generation within the oesophageal lumen is unlikely to be 
unique to subjects with Ban*ett’s oesophagus and is likely to occur in those who 
have gastro-oesophageal reflux into a normal squamous mucosa but the risk of 
malignant degeneration is confined to those with the metaplastic mucosa of 
Barrett’s oesophagus and is likely to be related to the higher cellular proliferation
206
rate in the intestinal mucosa of the Barrett’s oesophagus compared to the 
surrounding squamous mucosa.
14.2 Conclusions.
The work presented in this thesis examined the nitrosating potential in 
subjects without reflux and those with Barrett’s oesophagus who are a subgroup 
of patients with the most severe gastro-oesophageal reflux. We examined nitrite 
concentrations in the nasal cavity, pharynx and oesophagus in healthy individuals. 
Finally we examined nitric oxide generation within Barrett’s oesophagus during 
gastro-oesophageal reflux.
Within the nasal cavity there appeared to be no nitrate reduction to nitrite 
whereas the pharynx and the oesophagus approximately 30 % of the nitrate was 
reduced to nitrite. Significant concentration of nitrite was found in the saliva and 
distal oesophagus at neutral pH in subjects without gastro-oesophageal reflux and 
in subjects with Barrett’s oesophagus before and after nitrate ingestion. Nitrite 
was converted to nitric oxide on contact with acidic gastric juice in and occured at 
the cardia in individuals without reflux and in the distal oesophagus in subjects 
with Barrett’s oesophagus duiing reflux. Similarly the nitrosating potential was 
maximal, hence the generation of A-nitroso compounds, at the cardia in subjects 
without reflux and in the Barrett’s segment in subjects with Barrett’s oesophagus 
during acid reflux. We therefore conclude that in those with gastro-oesophageal 
reflux, including those with Barrett’s oesophagus, the chemical reactions leading 
to the generation of nitric oxide and the nitrosation reaction moves more 
proximally to the distal oesophagus.
There has been a worldwide increase in the use of nitrogenous fertilisers 
since the Second World War which may have subsequently increased the human 
exposure to nitrates. The increase in incidence of both oesophageal and cardia 
adenocarcinoma in the western world has occurred 2 0 -3 0  years following the 
increased use of nitrogenous fertilisers, consistent with the latent period for the 
development of cancer following the exposure to a carcinogen / precarcinogen. 
The chemistry described in this thesis may provide some insight into the 
pathogenesis of these two cancers.
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